Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(N-glycolylneuraminic acid)(alpha2,3)Galbeta-p-nitrophenol + H2O
(N-glycolylneuraminic acid)(alpha2,3)Gal + p-nitrophenol
(N-glycolylneuraminic acid)(alpha2,3)Galbeta-p-nitrophenol + H2O
N-glycolylneuraminic acid + 4-nitrophenol + ?
-
-
-
-
?
(N-glycolylneuraminic acid)(alpha2,6)Galbeta-p-nitrophenol + H2O
(N-glycolylneuraminic acid)(alpha2,6)Gal + p-nitrophenol
(N-glycolylneuraminic acid)(alpha2,6)Galbeta-p-nitrophenol + H2O
N-glycolylneuraminic acid + 4-nitrophenol + ?
-
-
-
-
?
(N-glycolylneuraminic acid)(alpha2,6)GalNAcbeta-p-nitrophenol + H2O
(N-glycolylneuraminic acid)(alpha2,6)GalNAc + p-nitrophenol
(trifluoromethyl)umbelliferyl alpha-sialoside + H2O
(trifluoromethyl)umbelliferone + sialic acid
-
-
-
-
?
(trifluoromethyl)umbelliferyl alpha-sialoside + lactose
(trifluoromethyl)umbelliferone + sialyllactose
-
-
-
-
?
2'-(4-methyl-umbelliferyl) alpha-D-N-acetylneuraminic acid + H2O
4-methyl-umbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2'-(4-methyl-umbelliferyl) alpha-D-N-acetylneuraminic acid + H2O
4-methyl-umbelliferone + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2'-(4-methylumbelliferyl) 9-O-acetyl-alpha-D-N-acetylneuraminic acid + H2O
4-methyl-umbelliferone + 9-O-acetyl-alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2'-(4-methylumbelliferyl) alpha-D-N-acetylneuraminic acid + H2O
4-methyl-umbelliferone + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2'-(4-methylumbelliferyl) alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
2'-(4-methylumbelliferyl) alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methyl-umbelliferone + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
?
-
-
-
-
?
2-(3-methoxyphenyl)-N-acetylneuraminic acid + H2O
3-methoxyphenol + N-acetylneuraminic acid
2-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
2-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetyl-alpha-D-neuraminic acid
2-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
2-(4-nitrophenyl)-alpha-D-N-acetylneuraminic acid + H2O
4-nitrophenol + alpha-D-N-acetylneuraminic acid
2-chloro-5-(4-methoxyspiro(1,2-dioxetane-3,29-(5-chloro)tricyclo[3.3.1.13,7]decan)-4-yl-phenyl-5-acetamido-3,5-dideoxy-alpha-D-glycero-D-galacto-2-nonulopyranoside)onate + H2O
?
2-deoxy-2,3-dehydro-N-acetylneuraminic acid + H2O
N-acetylneuraminic acid
-
reaction deduced from crystal structures and confirmed by NMR study
-
?
2-O-(3-methoxyphenyl)neuraminic acid + H2O
?
-
-
-
-
?
3'-siallyllactose + H2O
sialic acid + lactose
3'-sialyllactose + Galp(beta1,2)Galf(beta1,4)GlcNAc
?
-
-
-
-
?
3'-sialyllactose + Galp(beta1,2)Galf(beta1,4)GlcNAcOBn
?
-
-
-
-
?
3'-sialyllactose + Galp(beta1,2)Galf(beta1,4)GlcNAcol
?
-
-
-
-
?
3'-sialyllactose + Galp(beta1,2)[Galp(beta1,3)]Gal
?
-
-
-
-
?
3'-sialyllactose + Galp(beta1,2)[Galp(beta1,3)]GalOBn
?
-
-
-
-
?
3'-sialyllactose + Galp(beta1,2)[Galp(beta1,3)]Galol
?
-
-
-
-
?
3'-sialyllactose + Galp(beta1,2)[Galp(beta1,3)]Galp(beta1,6)[Galf(beta1,4)]GlcNAc
lactose + Neu5Ac(alpha2,3)[Galp(beta1,2)]Galp(beta1,6)[Galf(beta1,4)]GlcNAc
-
-
-
-
?
3'-sialyllactose + Galp(beta1,2)[Galp(beta1,3)]Galp(beta1,6)[Galf(beta1,4)]GlcNAcOBn
lactose + Neu5Ac(alpha2,3)[Galp(beta1,2)]Galp(beta1,6)[Galf(beta1,4)]GlcNAcOBn
-
-
-
-
?
3'-sialyllactose + Galp(beta1,2)[Galp(beta1,3)]Galp(beta1,6)[Galf(beta1,4)]GlcNAcol
lactose + Neu5Ac(alpha2,3)[Galp(beta1,2)]Galp(beta1,6)[Galf(beta1,4)]GlcNAcol
-
-
-
-
?
3'-sialyllactose + Galp(beta1,3)Galp(beta1,6)[Galf(beta1,4)]GlcNAc
?
-
-
-
-
?
3'-sialyllactose + Galp(beta1,3)Galp(beta1,6)[Galf(beta1,4)]GlcNAcOBn
?
-
-
-
-
?
3'-sialyllactose + Galp(beta1,3)Galp(beta1,6)[Galf(beta1,4)]GlcNAcol
?
-
-
-
-
?
3'-sialyllactose + Galp(beta1,6)GlcNAc
?
-
-
-
-
?
3'-sialyllactose + Galp(beta1,6)GlcNAcOBn
?
-
-
-
-
?
3'-sialyllactose + Galp(beta1,6)GlcNAcol
?
-
-
-
-
?
3'-sialyllactose + Galp(beta1,6)[Galf(beta1,4)]GlcNA
?
-
-
-
-
?
3'-sialyllactose + Galp(beta1,6)[Galf(beta1,4)]GlcNAc
?
-
-
-
-
?
3'-sialyllactose + Galp(beta1,6)[Galf(beta1,4)]GlcNAcol
?
-
-
-
-
?
3'-sialyllactose + H2O
sialic acid + ?
L0N7M7
-
-
-
?
3'-sialyllactose + H2O
sialic acid + lactose
3'-sialyllactose + mucin oligosaccharide
?
-
-
-
-
?
4-methylumbelliferyl alpha-2-oxo-3-deoxynononic acid + H2O
?
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + alpha-D-N-acetylneuraminic acid
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid + H2O
?
4-methylumbelliferyl alpha-N-acetylneuraminic acid + H2O
4-methylumbelliferone + alpha-N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl alpha-NeuAc + H2O
4-methylumbelliferone + alpha-neuAc
-
-
-
-
?
4-methylumbelliferyl alpha-sialoside + H2O
?
4-methylumbelliferyl D-N-acetylneuraminyl-alpha-(2->3)-D-galactopyranoside + H2O
4-methylumbelliferol + N-acetylneuraminate + 4-methylumbelliferyl alpha-D-galactopyranoside
4-methylumbelliferyl N-acetyl-alpha-D-neuraminic acid + H2O
?
Q5L868
highest activity
-
-
?
4-methylumbelliferyl N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
4-methylumbelliferyl-3-deoxy-D-glycero-D-galacto-2-nonulosonic acid + H2O
?
-
-
-
-
?
4-methylumbelliferyl-3-deoxy-D-glycero-D-galactononulosonic acid + H2O
4-methylumbelliferone + 3-deoxy-D-glycero-D-galactononulosonic acid
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + alpha-D-N-acetylneuraminic acid
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
4-nitrophenyl acetate + H2O
4-nitrophenol + acetate
4-nitrophenyl alpha-D-N-acetylneuraminic acid + H2O
4-nitrophenol + N-acetylneuraminic acid
-
-
-
?
4-nitrophenyl alpha-D-N-acetylneuraminic acid + H2O
?
-
-
-
-
?
4-nitrophenyl alpha-sialoside + H2O
4-nitrophenol + sialic acid
-
-
-
-
?
4-nitrophenyl alpha-sialoside + H2O
?
4-nitrophenyl alpha-sialoside + lactose
4-nitrophenol + sialyllactose
-
-
-
-
?
4-nitrophenyl O-(3,5-dideoxy-5-fluoro-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-3)-O-beta-D-galactopyranoside + H2O
?
4-nitrophenyl O-(3,5-dideoxy-5-fluoro-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-6)-O-beta-D-galactopyranoside + H2O
?
4-nitrophenyl O-(3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-3)-O-beta-D-galactopyranoside + H2O
?
4-nitrophenyl O-(3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-6)-O-beta-D-galactopyranoside + H2O
?
4-nitrophenyl O-(3-deoxy-5-O-methyl-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-3)-O-beta-D-galactopyranoside + H2O
?
4-nitrophenyl O-(3-deoxy-5-O-methyl-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-6)-O-beta-D-galactopyranoside + H2O
?
4-nitrophenyl O-(5-azido-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-3)-O-beta-D-galactopyranoside + H2O
?
4-nitrophenyl O-(5-azido-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-6)-O-beta-D-galactopyranoside + H2O
?
4-nitrophenyl O-[5-(2-azidoacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-3)-O-beta-D-galactopyranoside + H2O
?
4-nitrophenyl O-[5-(2-azidoacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-6)-O-beta-D-galactopyranoside + H2O
?
4-nitrophenyl O-[5-(2-fluoroacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-3)-O-beta-D-galactopyranoside + H2O
?
4-nitrophenyl O-[5-(2-fluoroacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-6)-O-beta-D-galactopyranoside + H2O
?
4-nitrophenyl O-[5-(2-methoxyacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-3)-O-beta-D-galactopyranoside + H2O
?
4-nitrophenyl O-[5-(2-methoxyacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-6)-O-beta-D-galactopyranoside + H2O
?
5-acetylneuraminic acid-(alpha2,3)Galbeta-4-nitrophenol + H2O
N-acetylneuraminic acid + 4-nitrophenol + ?
-
-
-
-
?
5-acetylneuraminic acid-(alpha2,6)Galbeta-4-nitrophenol + H2O
N-acetylneuraminic acid + 4-nitrophenol + ?
-
-
-
-
?
5-azidoacetylneuraminic acid-(alpha2,3)Galbeta-4-nitrophenol + H2O
N-azidoacetylneuraminic acid + 4-nitrophenol + ?
-
-
-
-
?
5-azidoacetylneuraminic acid-(alpha2,6)Galbeta-4-nitrophenol + H2O
N-azidoacetylneuraminic acid + 4-nitrophenol + ?
-
-
-
-
?
5-bromo-4-chloro-3-indolyl-alpha-D-N-acetylneuraminic acid + H2O
5-bromo-4-chloro-3-hydroxyindole + N-acetylneuraminic acid
5-bromo-4-chloro-3-indolyl-alpha-D-N-acetylneuraminic acid + H2O
?
5-bromo-4-chloro-indolyl beta-D-galactopyranosyl-alpha-2,6-N-acetyl-neuraminic acid + H2O
?
5-fluoroacetylneuraminic acid-(alpha2,3)Galbeta-4-nitrophenol + H2O
N-fluoroacetylneuraminic acid + 4-nitrophenol + ?
-
-
-
-
?
5-fluoroacetylneuraminic acid-(alpha2,6)Galbeta-4-nitrophenol + H2O
N-fluoroacetylneuraminic acid + 4-nitrophenol + ?
-
-
-
-
?
5-N-acetyl-2-O-(3-methoxyphenyl)-alpha-D-neuraminic acid + H2O
?
6'-sialyllactose + H2O
sialic acid + lactose
8-fluoromethylumbelliferyl alpha-2-oxo-3-deoxy-D-glycero-D-galacto-nononylgalactopyranoside + H2O
8-fluoromethylumbelliferyl alpha-D-galactopyranoside + 3-deoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosonate
alpha(2-3')-sialyllactose + H2O
sialic acid + lactose
alpha(2-3)-sialyllactose + H2O
sialic acid + lactose
alpha(2-3)sialyl-lactose + H2O
?
-
-
-
?
alpha(2-3)sialyllactose + H2O
sialic acid + lactose
-
-
-
-
?
alpha(2-3)sialylparagloboside + H2O
?
-
-
-
-
?
alpha(2-6')-sialyllactose + H2O
sialic acid + lactose
the nanB encoded enzyme hydrolyzes both (2-3')- and (2-6')-sialyllactose, the latter substrate is preferred
-
-
?
alpha(2-6)-sialyllactose + H2O
sialic acid + lactose
alpha-acid glycoprotein + H2O
?
-
-
-
-
?
alpha-acid glycoprotein + H2O
sialic acid + ?
-
-
-
?
alpha-N-acetylneuraminyl-(2->3)-beta-D-galactosyl-R
?
-
the enzyme is selective for alpha(2-3)-linked sialic acid
-
-
?
alpha-phenyl-N-acetylneuraminoside + H2O
?
-
-
-
-
?
alpha-sialyllactose + H2O
?
-
-
-
-
?
alpha-sialyllactose + H2O
sialic acid + lactose
alpha1-acid glycoprotein + H2O
?
alpha2,3-sialyllactose + H2O
sialic acid + lactose
-
-
-
-
?
apotransferrin + H2O
sialic acid + ?
-
-
-
?
bovine brain gangliosides + H2O
sialic acid + ?
-
-
-
-
?
bovine gland submaxillary gland mucin + H2O
?
-
-
-
-
?
bovine submaxillary gland mucin + H2O
sialic acid + ?
bovine submaxillary mucin + H2O
sialic acid + ?
-
-
-
-
?
Candida albicans cells + H2O
desialylated Candida albicans cells + sialic acid
-
-
-
-
?
casein glycomacropeptide + H2O
sialic acid + ?
-
-
-
-
?
casein glycomacropeptide + lactose
3'-sialyllactose + ?
-
-
-
-
?
Collocalia mucoid + H2O
sialic acid + ?
-
substrate contains a large number of terminal sialic acids
-
-
?
colomic acid + H2O
sialic acid + lactose
-
low activity
-
-
?
colominic acid + H2O
sialic acid + ?
-
-
-
-
?
colominic acid + H2O
sialic acid + lactose
envelope glycoprotein + H2O
sialic acid + ?
-
-
-
-
?
fetuin + H2O
sialic acid + ?
ganglioside GD1a + H2O
ganglioside GM1 + sialic acid
ganglioside GD1a + H2O
sialic acid + ?
ganglioside GD1a + H2O
sialic acid + ganglioside GM1
-
-
-
?
ganglioside GD1b + H2O
sialic acid + ?
-
-
-
-
?
ganglioside GD3 + H2O
N-acetylneuraminate + ganglioside GM3
-
100% activity
-
-
?
ganglioside GM2 + H2O
?
-
-
-
-
?
ganglioside GM2 + H2O
sialic acid + ?
-
-
-
-
?
ganglioside GM3 + H2O
N-acetylneuraminate + beta-D-galactosyl-(1->4)-beta-D-glucosylceramide
ganglioside GM3 + H2O
sialic acid + ?
ganglioside GM3(Neu5Ac) + H2O
desialylated ganglioside GM3 + sialic acid
-
i.e. Neu5Acalpha(2-3)-Galbeta(1-4)-Glcbeta(1-1)-Cer
-
-
?
ganglioside GM3(Neu5Gc) + H2O
desialylated ganglioside GM3 + sialic acid
-
i.e. Neu5Gcalpha(2-3)-Galbeta(1-4)-Glcbeta(1-1)-Cer
-
-
?
ganglioside GQ1 + H2O
?
-
-
-
-
?
ganglioside GQ1b + H2O
?
-
-
-
-
?
ganglioside GT1 + H2O
?
-
-
-
-
?
ganglioside GT1b + H2O
sialic acid + ?
-
-
-
?
ganglioside IV3-alpha-Neu5Ac-nLc4Cer + H2O
desialylated ganglioside nLc4Cer + sialic acid
-
i.e. Neu5Acalpha(2-3)-Galbeta(1-4)GcNAcbeta(1-3)-Galbeta(1-4)-Glcbeta(1-1)-Cer
-
-
?
ganglioside VI3-alpha-Neu5Ac-nLc6Cer + H2O
desialylated ganglioside nLc6Cer + sialic acid
-
i.e. Neu5Acalpha(2-3)-Galbeta(1-4)GcNAcbeta(1-3)-Galbeta(1-4)-GlcNAcbeta(1-3)-Galbeta(1-4)-Glcbeta(1-1)-Cer
-
-
?
glucomacropeptide + H2O
?
lactosyl-ceramide + H2O
?
-
-
-
?
methyl beta-lactoside + p-nitrophenyl-5,9-diacetyl neuraminic acid
?
-
-
-
-
?
methyl beta-lactoside + p-nitrophenyl-N-acetyl heptulosonic acid
?
-
-
-
-
?
methyl beta-lactoside + p-nitrophenyl-N-acetyl neuraminic acid
?
-
-
-
-
?
methyl beta-lactoside + p-nitrophenyl-N-acetyl octulosonic acid
?
-
-
-
-
?
monosialoganglioside GM3 + H2O
?
-
-
-
?
mucin + H2O
sialic acid + ?
mucin of bovine submaxillary gland + H2O
sialic acid + ?
N-(2,4,7,8,9-penta-O-acetyl-N-acetyl-beta-D-neuraminoyl)phenylalanine methylester + H2O
?
-
-
-
-
?
N-(4,7,8,9-tetra-O-acetyl-N-acetyl-2-O-benzyl-alpha-D-neuraminoyl)phenylalanine methylester + H2O
?
-
-
-
-
?
N-acetylneuraminic acid-alpha-2,3-lactose + H2O
?
-
-
-
-
?
N-acetylneuraminic acid-alpha-2,3-lactose + H2O
N-acetylneuraminic acid + lactose
N-acetylneuraminic acid-alpha-2,6-D-galactose + H2O
N-acetylneuraminic acid + D-galactose
-
-
-
-
?
N-acetylneuraminic acid-alpha-2,6-lactose + H2O
?
-
-
-
-
?
N-acetylneuraminic acid-alpha-2,6-lactose + H2O
N-acetylneuraminic acid + lactose
N-acetylneuraminyllactose + H2O
N-acetylneuraminic acid + lactose
N-glycoloylneuraminic acid-alpha-2,3-lactose + H2O
?
-
-
-
-
?
Neu5(4-[(2,4-dinitrophenoxy)methyl]-1H-1,2,3-triazol-1-yl)Ac-alpha-(2->3)-Gal-beta--(1->4)-Glc-beta-n-octyl + H2O
?
-
-
-
-
?
Neu5(azido)Ac-alpha-(2->3)-Gal-beta--(1->4)-Glc-beta-n-octyl + H2O
?
-
-
-
-
?
Neu5,9-diAc(2-3)-alpha-lactose + H2O
?
-
low activity
-
-
?
Neu5,9Ac2(alpha2,3)Galbeta-p-nitrophenol + H2O
Neu5,9Ac2(alpha2,3)Gal + p-nitrophenol
Neu5,9Ac2(alpha2,6)Galbeta-p-nitrophenol + H2O
Neu5,9Ac2(alpha2,6)Gal + p-nitrophenol
Neu5,9Ac2(alpha2,6)GalNAcbeta-p-nitrophenol + H2O
Neu5,9Ac2(alpha2,6)GalNAc + p-nitrophenol
Neu5,9Ac2alpha2,6Galbeta-p-nitrophenol + H2O
Neu5,9Ac2alpha2,6Gal + p-nitrophenol
-
low activity
-
-
?
Neu5Ac(2-3)-alpha-lactose + H2O
Neu5Ac + lactose
Neu5Ac(2-6)-alpha-lactose + H2O
Neu5Ac + lactose
Neu5Ac(alpha2,3)Galbeta-p-nitrophenol + H2O
Neu5Ac(alpha2,3)Gal + 4-nitrophenol
Neu5Ac(alpha2,3)Galbeta-p-nitrophenol + H2O
Neu5Ac(alpha2,3)Gal + p-nitrophenol
Neu5Ac(alpha2,3)Galbeta-p-nitrophenol + H2O
Neu5Acalpha2,3Gal + p-nitrophenol
-
-
-
-
?
Neu5Ac(alpha2,3)lactose + H2O
Neu5Ac + lactose
-
-
-
-
?
Neu5Ac(alpha2,6)-lactose + H2O
?
-
-
-
-
?
Neu5Ac(alpha2,6)Galbeta-p-nitrophenol + H2O
Neu5Ac(alpha2,6)Gal + p-nitrophenol
Neu5Ac(alpha2,6)GalNAcbeta-p-nitrophenol + H2O
Neu5Ac(alpha2,6)GalNAc + p-nitrophenol
Neu5Ac-alpha-(2->3)-Gal-beta--(1->4)-Glc-beta-(CH2)8COOCH3 + H2O
?
-
-
-
-
?
Neu5Ac-alpha-(2->3)-Gal-beta--(1->4)-Glc-beta-CH2(CH3)CH2CH2CH3 + H2O
?
-
-
-
-
?
Neu5Ac-alpha-(2->3)-Gal-beta--(1->4)-Glc-beta-CH2Ph + H2O
?
-
-
-
-
?
Neu5Ac-alpha-(2->3)-Gal-beta--(1->4)-Glc-beta-n-butyl + H2O
?
-
-
-
-
?
Neu5Ac-alpha-(2->3)-Gal-beta--(1->4)-Glc-beta-n-octyl + H2O
?
-
-
-
-
?
Neu5Ac-alpha-(2->3)-Gal-beta--(1->4)-Glc-beta-N3 + H2O
?
-
-
-
-
?
Neu5Ac-alpha-(2->3)-Gal-beta-4-nitrophenol + H2O
Neu5Ac + 4-nitrophenyl beta-D-galactopyranoside
-
-
-
-
?
Neu5Ac-alpha-(2->6)-Gal-beta-4-nitrophenol + H2O
Neu5Ac + 4-nitrophenyl beta-D-galactopyranoside
-
-
-
-
?
Neu5Ac9(2,4-dinitrobenzoyl)N-alpha-(2->3)-Gal-beta--(1->4)-Glc-beta-n-octyl + H2O
?
-
-
-
-
?
Neu5Ac9N-alpha-(2->3)-Gal-beta--(1->4)-Glc-beta-n-octyl + H2O
?
-
-
-
-
?
Neu5Ac9N3-alpha-(2->3)-Gal-beta--(1->4)-Glc-beta-n-octyl + H2O
?
-
-
-
-
?
Neu5Acalpha(2->3)Galbeta(1->)4GlcNAc + H2O
sialic acid + Galbeta(1->)4GlcNAc
Neu5Acalpha(2->3)Galbeta(1->4)GlcNAc + H2O
?
Neu5Acalpha(2->3)Galbeta-4-nitrophenyl + H2O
?
Neu5Acalpha(2->3)LacNAcbeta-4-aminophenyl + H2O
?
-
best substrate
-
-
?
Neu5Acalpha(2->6)Galbeta4-nitrophenyl + H2O
?
Neu5Acalpha(2->6)LacNAcbeta-4-aminophenyl + H2O
?
-
-
-
-
?
Neu5Acalpha2,6Galbeta-p-nitrophenol + H2O
Neu5Acalpha2,6Galbeta + p-nitrophenol
-
-
-
-
?
Neu5AcF-alpha-(2->3)-Gal-beta-4-nitrophenol + H2O
Neu5AcF + 4-nitrophenyl beta-D-galactopyranoside
-
-
-
-
?
Neu5Gcalpha-(2-5)-O-glycolylNeu5Gc + H2O
2 Neu5Gcalpha
Neu5Gcalpha-(2-8)-Neu5Ac + H2O
Neu5Gc + Neu5Ac
Neu5Gcalpha-(2-8)-Neu5Gc + H2O
Neu5Gc + Neu5Gc
Neu5glycolyl-alpha-(2->3)-Gal-beta-4-nitrophenol + H2O
N-glycolylneuraminic acid + 4-nitrophenyl beta-D-galactopyranoside
-
-
-
-
?
N[(5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosyl)onate]-3,4-dimethylpyridinium + H2O
sialic acid + 3,4-dimethylpyridine
-
-
-
-
?
N[(5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosyl)onate]-3-methylpyridinium + H2O
sialic acid + 3-methylpyridine
-
-
-
-
?
N[(5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosyl)onate]-4-methylpyridinium + H2O
sialic acid + 4-methylpyridine
-
-
-
-
?
N[(5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosyl)onate]pyridinium + H2O
sialic acid + pyridine
-
-
-
-
?
O-(5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galactonon-2-ulopyranosylonic acid)-(2->3)-O-(beta-D-galactopyranosyl)-(1->4)-O-(beta-D-glucopyranosyl)-octanol + H2O
?
-
-
-
-
?
O-(5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galactonon-2-ulopyranosylonic acid)-(2->6)-O-(beta-D-galactopyranosyl)-(1->4)-O-(beta-D-glucopyranosyl)-octanol + H2O
?
-
-
-
-
?
O-(5-acetamido-9-O-acetyl-3,5-dideoxy-D-glycero-alpha-D-galactonon-2-ulopyranosylonic acid)-(2->3)-O-(beta-D-galactopyranosyl)-(1->4)-O-(beta-D-glucopyranosyl)-octanol + H2O
?
-
-
-
-
?
O-(5-acetamido-9-O-acetyl-3,5-dideoxy-D-glycero-alpha-D-galactonon-2-ulopyranosylonic acid)-(2->6)-O-(beta-D-galactopyranosyl)-(1->4)-O-(beta-D-glucopyranosyl)-octanol + H2O
?
-
-
-
-
?
O-(5-glycolylamido-3,5,-dideoxy-D-glycero-alpha-D-galactonon-2-ulopyranosylonic acid)-(2->3)-O-(beta-D-galactopyranosyl)-(1->4)-O-(beta-D-glucopyranosyl)-octanol + H2O
?
-
-
-
-
?
O-(5-glycolylamido-3,5,-dideoxy-D-glycero-alpha-D-galactonon-2-ulopyranosylonic acid)-(2->6)-O-(beta-D-galactopyranosyl)-(1-> 4)-O-(beta-D-glucopyranosyl)-octanol + H2O
?
-
-
-
-
?
octyl-ganglioside GM3 + H2O
?
-
-
-
?
octyl-lactoside + H2O
?
-
-
-
?
orosomucoid + H2O
sialic acid + ?
-
-
-
-
?
ovomucin + H2O
?
-
-
-
-
?
p-nitrophenyl-5,9-diacetyl neuraminic acid + H2O
?
-
-
-
-
?
p-nitrophenyl-N-acetyl heptulosonic acid + H2O
?
-
-
-
-
?
p-nitrophenyl-N-acetyl neuraminic acid + H2O
?
-
-
-
-
?
p-nitrophenyl-N-acetyl octulosonic acid + H2O
?
-
-
-
-
?
phenyl alpha-sialoside + H2O
?
-
-
-
?
phenyl beta-sialoside + H2O
phenol + alpha-sialic acid
mutant enzymes Y370G, Y370A, Y370N and Y370T catalyze the hydrolysis of phenyl beta-sialoside with an inversion of the anomeric configuration. Mutant enzyme Y370A shows 4% of the activity of Y370G, mutant enzymes Y370N and Y370T show 9% of the activity of Y370G
-
-
?
phenyl beta-sialoside + lactose
phenol + sialyllactose
poly-alpha-2,8-lactose + H2O
?
-
-
-
-
?
polysialic acid + H2O
?
-
-
-
-
?
polysialic acid + H2O
sialic acid
pyridylamino-3'-sialyllactose + H2O
?
-
-
-
-
?
pyridylamino-6'-sialyllactose + H2O
?
-
-
-
-
?
red blood ghost cells + H2O
?
-
desialylation, preference for different species: in descending order mouse, rat, camel, goat, and dog
-
-
?
sialic acid + lactose
6'-sialyllactose
Q5L868
the enzyme is able to transfer sialyl from sialic acid dimer or oligomer to lactose with high efficiency and strict alpha2-6 regioselectivity
-
-
r
sialic acid tetramer with alpha-linked trifluoromethylumbelliferyl + H2O
?
-
hydrolysis with formation of two alpha-linked trifluoromethylumbelliferyl glycoside-containing species, trifluoromethylumbelliferone and the TFMU sialoside monomer
-
-
?
sialic acid trimer with alpha-linked trifluoromethylumbelliferyl + H2O
?
-
degraded with exclusive cleavage at the coumarin-sialoside bond
-
-
?
siallyllactose + H2O
?
-
about 7% activity compared to ganglioside GD3
-
-
?
sialyl-alpha-(2-8)-sialic acid + H2O
sialic acid
-
-
-
-
?
sialyl-alpha-2,3-lactose + H2O
?
sialyl-alpha-2,6-lactose + H2O
?
sialyloligosaccharides + H2O
?
-
-
-
-
?
submaximally mucin + H2O
?
transferrin + H2O
sialic acid + ?
vesicular GM3 + H2O
?
-
-
-
-
?
additional information
?
-
(N-glycolylneuraminic acid)(alpha2,3)Galbeta-p-nitrophenol + H2O
(N-glycolylneuraminic acid)(alpha2,3)Gal + p-nitrophenol
-
-
-
-
?
(N-glycolylneuraminic acid)(alpha2,3)Galbeta-p-nitrophenol + H2O
(N-glycolylneuraminic acid)(alpha2,3)Gal + p-nitrophenol
-
weak activity
-
-
?
(N-glycolylneuraminic acid)(alpha2,3)Galbeta-p-nitrophenol + H2O
(N-glycolylneuraminic acid)(alpha2,3)Gal + p-nitrophenol
-
-
-
-
?
(N-glycolylneuraminic acid)(alpha2,3)Galbeta-p-nitrophenol + H2O
(N-glycolylneuraminic acid)(alpha2,3)Gal + p-nitrophenol
-
-
-
-
?
(N-glycolylneuraminic acid)(alpha2,3)Galbeta-p-nitrophenol + H2O
(N-glycolylneuraminic acid)(alpha2,3)Gal + p-nitrophenol
-
-
-
-
?
(N-glycolylneuraminic acid)(alpha2,6)Galbeta-p-nitrophenol + H2O
(N-glycolylneuraminic acid)(alpha2,6)Gal + p-nitrophenol
-
low activity
-
-
?
(N-glycolylneuraminic acid)(alpha2,6)Galbeta-p-nitrophenol + H2O
(N-glycolylneuraminic acid)(alpha2,6)Gal + p-nitrophenol
-
weak activity
-
-
?
(N-glycolylneuraminic acid)(alpha2,6)Galbeta-p-nitrophenol + H2O
(N-glycolylneuraminic acid)(alpha2,6)Gal + p-nitrophenol
-
low activity
-
-
?
(N-glycolylneuraminic acid)(alpha2,6)GalNAcbeta-p-nitrophenol + H2O
(N-glycolylneuraminic acid)(alpha2,6)GalNAc + p-nitrophenol
-
low activity
-
-
?
(N-glycolylneuraminic acid)(alpha2,6)GalNAcbeta-p-nitrophenol + H2O
(N-glycolylneuraminic acid)(alpha2,6)GalNAc + p-nitrophenol
-
weak activity
-
-
?
(N-glycolylneuraminic acid)(alpha2,6)GalNAcbeta-p-nitrophenol + H2O
(N-glycolylneuraminic acid)(alpha2,6)GalNAc + p-nitrophenol
-
low activity
-
-
?
2'-(4-methylumbelliferyl) alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2'-(4-methylumbelliferyl) alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
Avian orthoavulavirus 1 Anhinga/US(FL)/44083/93
-
-
-
-
?
2'-(4-methylumbelliferyl) alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
?
2'-(4-methylumbelliferyl) alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
?
2'-(4-methylumbelliferyl) alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
-
?
2'-(4-methylumbelliferyl) alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
-
?
2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
?
2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
?
2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
-
?
2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
-
?
2'-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
-
?
2-(3-methoxyphenyl)-N-acetylneuraminic acid + H2O
3-methoxyphenol + N-acetylneuraminic acid
-
-
-
-
?
2-(3-methoxyphenyl)-N-acetylneuraminic acid + H2O
3-methoxyphenol + N-acetylneuraminic acid
-
-
-
-
?
2-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
?
2-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
synthetic, fluorogenic substrate
-
-
?
2-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetyl-alpha-D-neuraminic acid
-
-
-
-
?
2-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetyl-alpha-D-neuraminic acid
-
-
-
-
?
2-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetyl-alpha-D-neuraminic acid
-
-
-
-
?
2-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
-
?
2-(4-methylumbelliferyl)-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
-
?
2-(4-nitrophenyl)-alpha-D-N-acetylneuraminic acid + H2O
4-nitrophenol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(4-nitrophenyl)-alpha-D-N-acetylneuraminic acid + H2O
4-nitrophenol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(4-nitrophenyl)-alpha-D-N-acetylneuraminic acid + H2O
4-nitrophenol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(4-nitrophenyl)-alpha-D-N-acetylneuraminic acid + H2O
4-nitrophenol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(4-nitrophenyl)-alpha-D-N-acetylneuraminic acid + H2O
4-nitrophenol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(4-nitrophenyl)-alpha-D-N-acetylneuraminic acid + H2O
4-nitrophenol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(4-nitrophenyl)-alpha-D-N-acetylneuraminic acid + H2O
4-nitrophenol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(4-nitrophenyl)-alpha-D-N-acetylneuraminic acid + H2O
4-nitrophenol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(4-nitrophenyl)-alpha-D-N-acetylneuraminic acid + H2O
4-nitrophenol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(4-nitrophenyl)-alpha-D-N-acetylneuraminic acid + H2O
4-nitrophenol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(4-nitrophenyl)-alpha-D-N-acetylneuraminic acid + H2O
4-nitrophenol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(4-nitrophenyl)-alpha-D-N-acetylneuraminic acid + H2O
4-nitrophenol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(4-nitrophenyl)-alpha-D-N-acetylneuraminic acid + H2O
4-nitrophenol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(4-nitrophenyl)-alpha-D-N-acetylneuraminic acid + H2O
4-nitrophenol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-(4-nitrophenyl)-alpha-D-N-acetylneuraminic acid + H2O
4-nitrophenol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
2-chloro-5-(4-methoxyspiro(1,2-dioxetane-3,29-(5-chloro)tricyclo[3.3.1.13,7]decan)-4-yl-phenyl-5-acetamido-3,5-dideoxy-alpha-D-glycero-D-galacto-2-nonulopyranoside)onate + H2O
?
-
-
-
-
?
2-chloro-5-(4-methoxyspiro(1,2-dioxetane-3,29-(5-chloro)tricyclo[3.3.1.13,7]decan)-4-yl-phenyl-5-acetamido-3,5-dideoxy-alpha-D-glycero-D-galacto-2-nonulopyranoside)onate + H2O
?
-
-
-
-
?
2-chloro-5-(4-methoxyspiro(1,2-dioxetane-3,29-(5-chloro)tricyclo[3.3.1.13,7]decan)-4-yl-phenyl-5-acetamido-3,5-dideoxy-alpha-D-glycero-D-galacto-2-nonulopyranoside)onate + H2O
?
-
-
-
-
?
2-chloro-5-(4-methoxyspiro(1,2-dioxetane-3,29-(5-chloro)tricyclo[3.3.1.13,7]decan)-4-yl-phenyl-5-acetamido-3,5-dideoxy-alpha-D-glycero-D-galacto-2-nonulopyranoside)onate + H2O
?
-
-
-
-
?
2-chloro-5-(4-methoxyspiro(1,2-dioxetane-3,29-(5-chloro)tricyclo[3.3.1.13,7]decan)-4-yl-phenyl-5-acetamido-3,5-dideoxy-alpha-D-glycero-D-galacto-2-nonulopyranoside)onate + H2O
?
-
-
-
-
?
3'-siallyllactose + H2O
sialic acid + lactose
Q5L868
-
-
-
r
3'-siallyllactose + H2O
sialic acid + lactose
Q5L868
-
-
-
r
3'-sialyllactose + H2O
sialic acid + lactose
-
-
-
-
?
3'-sialyllactose + H2O
sialic acid + lactose
-
-
-
?
3'-sialyllactose + H2O
sialic acid + lactose
-
-
-
-
?
4-methylumbelliferyl alpha-2-oxo-3-deoxynononic acid + H2O
?
preferred substrate
-
-
?
4-methylumbelliferyl alpha-2-oxo-3-deoxynononic acid + H2O
?
preferred substrate
-
-
?
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
?
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + alpha-D-N-acetylneuraminic acid
-
about 1% activity compared to ganglioside GD3
-
-
?
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + alpha-D-N-acetylneuraminic acid
-
-
-
?
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + alpha-D-N-acetylneuraminic acid
-
-
-
?
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + alpha-D-N-acetylneuraminic acid
-
-
-
?
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + alpha-D-N-acetylneuraminic acid
-
-
-
?
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + alpha-D-N-acetylneuraminic acid
-
-
-
?
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
?
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid + H2O
?
-
-
-
?
4-methylumbelliferyl alpha-D-N-acetylneuraminic acid + H2O
?
-
-
-
?
4-methylumbelliferyl alpha-sialoside + H2O
?
48.9% activity compared to alpha(2-6)-sialyllactose
-
-
?
4-methylumbelliferyl alpha-sialoside + H2O
?
48.9% activity compared to alpha(2-6)-sialyllactose
-
-
?
4-methylumbelliferyl D-N-acetylneuraminyl-alpha-(2->3)-D-galactopyranoside + H2O
4-methylumbelliferol + N-acetylneuraminate + 4-methylumbelliferyl alpha-D-galactopyranoside
-
preference for the alpha2-3 isomer of 4-methylumbelliferyl alpha-D-N-acetylneuraminylgalactopyranoside
-
-
?
4-methylumbelliferyl D-N-acetylneuraminyl-alpha-(2->3)-D-galactopyranoside + H2O
4-methylumbelliferol + N-acetylneuraminate + 4-methylumbelliferyl alpha-D-galactopyranoside
-
preference for the alpha2-3 isomer of 4-methylumbelliferyl alpha-D-N-acetylneuraminylgalactopyranoside
-
-
?
4-methylumbelliferyl N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
Avian orthoavulavirus 1 Kansas
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
isozyme Neu-1 and Neu-3
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferol + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + alpha-D-N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
L0N7M7
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
?
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid + H2O
4-methylumbelliferone + N-acetylneuraminic acid
-
-
-
-
?
4-nitrophenyl acetate + H2O
4-nitrophenol + acetate
-
-
-
-
?
4-nitrophenyl acetate + H2O
4-nitrophenol + acetate
-
-
-
-
?
4-nitrophenyl alpha-sialoside + H2O
?
65.5% activity compared to alpha(2-6)-sialyllactose
-
-
?
4-nitrophenyl alpha-sialoside + H2O
?
65.5% activity compared to alpha(2-6)-sialyllactose
-
-
?
4-nitrophenyl O-(3,5-dideoxy-5-fluoro-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-3)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-(3,5-dideoxy-5-fluoro-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-3)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-(3,5-dideoxy-5-fluoro-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-3)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-(3,5-dideoxy-5-fluoro-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-3)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-(3,5-dideoxy-5-fluoro-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-6)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-(3,5-dideoxy-5-fluoro-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-6)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-(3,5-dideoxy-5-fluoro-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-6)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-(3,5-dideoxy-5-fluoro-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-6)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-(3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-3)-O-beta-D-galactopyranoside + H2O
?
-
about 30% cleavage
-
-
?
4-nitrophenyl O-(3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-3)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-(3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-3)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-(3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-3)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-(3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-3)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-(3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-6)-O-beta-D-galactopyranoside + H2O
?
-
about 5% cleavage
-
-
?
4-nitrophenyl O-(3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-6)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-(3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-6)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-(3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-6)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-(3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-6)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-(3-deoxy-5-O-methyl-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-3)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-(3-deoxy-5-O-methyl-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-3)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-(3-deoxy-5-O-methyl-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-3)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-(3-deoxy-5-O-methyl-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-3)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-(3-deoxy-5-O-methyl-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-6)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-(3-deoxy-5-O-methyl-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-6)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-(3-deoxy-5-O-methyl-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-6)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-(3-deoxy-5-O-methyl-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-6)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-(5-azido-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-3)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-(5-azido-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-3)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-(5-azido-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-3)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-(5-azido-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-3)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-(5-azido-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-6)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-(5-azido-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-6)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-(5-azido-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-6)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-(5-azido-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid)-(2-6)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-[5-(2-azidoacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-3)-O-beta-D-galactopyranoside + H2O
?
-
less than 10% cleavage
-
-
?
4-nitrophenyl O-[5-(2-azidoacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-3)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-[5-(2-azidoacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-3)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-[5-(2-azidoacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-3)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-[5-(2-azidoacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-3)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-[5-(2-azidoacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-6)-O-beta-D-galactopyranoside + H2O
?
-
less than 5% cleavage
-
-
?
4-nitrophenyl O-[5-(2-azidoacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-6)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-[5-(2-azidoacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-6)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-[5-(2-azidoacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-6)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-[5-(2-azidoacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-6)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-[5-(2-fluoroacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-3)-O-beta-D-galactopyranoside + H2O
?
-
about 50% cleavage
-
-
?
4-nitrophenyl O-[5-(2-fluoroacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-3)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-[5-(2-fluoroacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-3)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-[5-(2-fluoroacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-3)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-[5-(2-fluoroacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-3)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-[5-(2-fluoroacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-6)-O-beta-D-galactopyranoside + H2O
?
-
about 35% cleavage
-
-
?
4-nitrophenyl O-[5-(2-fluoroacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-6)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-[5-(2-fluoroacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-6)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-[5-(2-fluoroacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-6)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-[5-(2-fluoroacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-6)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-[5-(2-methoxyacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-3)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-[5-(2-methoxyacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-3)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-[5-(2-methoxyacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-3)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-[5-(2-methoxyacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-3)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-[5-(2-methoxyacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-6)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-[5-(2-methoxyacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-6)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-[5-(2-methoxyacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-6)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
4-nitrophenyl O-[5-(2-methoxyacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-6)-O-beta-D-galactopyranoside + H2O
?
-
-
-
-
?
5-bromo-4-chloro-3-indolyl-alpha-D-N-acetylneuraminic acid + H2O
5-bromo-4-chloro-3-hydroxyindole + N-acetylneuraminic acid
-
-
-
-
?
5-bromo-4-chloro-3-indolyl-alpha-D-N-acetylneuraminic acid + H2O
5-bromo-4-chloro-3-hydroxyindole + N-acetylneuraminic acid
-
-
-
-
?
5-bromo-4-chloro-3-indolyl-alpha-D-N-acetylneuraminic acid + H2O
?
-
-
-
-
?
5-bromo-4-chloro-3-indolyl-alpha-D-N-acetylneuraminic acid + H2O
?
-
-
-
-
?
5-bromo-4-chloro-indolyl beta-D-galactopyranosyl-alpha-2,6-N-acetyl-neuraminic acid + H2O
?
-
-
-
-
?
5-bromo-4-chloro-indolyl beta-D-galactopyranosyl-alpha-2,6-N-acetyl-neuraminic acid + H2O
?
-
-
-
-
?
5-N-acetyl-2-O-(3-methoxyphenyl)-alpha-D-neuraminic acid + H2O
?
-
-
-
-
?
5-N-acetyl-2-O-(3-methoxyphenyl)-alpha-D-neuraminic acid + H2O
?
-
-
-
-
?
6'-sialyllactose + H2O
sialic acid + lactose
Q5L868
-
-
-
r
6'-sialyllactose + H2O
sialic acid + lactose
Q5L868
-
-
-
r
6'-sialyllactose + H2O
sialic acid + lactose
-
-
-
-
?
6'-sialyllactose + H2O
sialic acid + lactose
-
-
-
?
6'-sialyllactose + H2O
sialic acid + lactose
isoform Neu3a shows low activity
-
-
?
6'-sialyllactose + H2O
sialic acid + lactose
L0N7M7
-
-
-
?
8-fluoromethylumbelliferyl alpha-2-oxo-3-deoxy-D-glycero-D-galacto-nononylgalactopyranoside + H2O
8-fluoromethylumbelliferyl alpha-D-galactopyranoside + 3-deoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosonate
-
-
-
?
8-fluoromethylumbelliferyl alpha-2-oxo-3-deoxy-D-glycero-D-galacto-nononylgalactopyranoside + H2O
8-fluoromethylumbelliferyl alpha-D-galactopyranoside + 3-deoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosonate
-
-
-
?
alpha(2-3')-sialyllactose + H2O
sialic acid + lactose
nanH encoded enzyme is highly specific for the (2-3')-sialyllactose
-
-
?
alpha(2-3')-sialyllactose + H2O
sialic acid + lactose
the nanB encoded enzyme hydrolyzes both 2-3'- and 2-6'-sialyllactose
-
-
?
alpha(2-3)-sialyllactose + H2O
sialic acid + lactose
89.8% activity compared to alpha(2-6)-sialyllactose
-
-
?
alpha(2-3)-sialyllactose + H2O
sialic acid + lactose
89.8% activity compared to alpha(2-6)-sialyllactose
-
-
?
alpha(2-3)-sialyllactose + H2O
sialic acid + lactose
-
-
-
-
?
alpha(2-3)-sialyllactose + H2O
sialic acid + lactose
-
preference for alpha(2-3)-linkages
-
-
?
alpha(2-3)-sialyllactose + H2O
sialic acid + lactose
-
high activity
-
-
?
alpha(2-3)-sialyllactose + H2O
sialic acid + lactose
-
-
-
-
?
alpha(2-3)-sialyllactose + H2O
sialic acid + lactose
-
-
-
-
?
alpha(2-3)-sialyllactose + H2O
sialic acid + lactose
-
formation of a covalent sialyl-enzyme intermediate
-
-
?
alpha(2-3)-sialyllactose + H2O
sialic acid + lactose
-
-
-
-
?
alpha(2-6)-sialyllactose + H2O
sialic acid + lactose
-
-
-
-
?
alpha(2-6)-sialyllactose + H2O
sialic acid + lactose
100% activity
-
-
?
alpha(2-6)-sialyllactose + H2O
sialic acid + lactose
100% activity
-
-
?
alpha(2-6)-sialyllactose + H2O
sialic acid + lactose
-
low activity
-
-
?
alpha(2-6)-sialyllactose + H2O
sialic acid + lactose
-
-
-
-
?
alpha(2-6)-sialyllactose + H2O
sialic acid + lactose
-
-
-
-
?
alpha(2-6)-sialyllactose + H2O
sialic acid + lactose
-
-
-
-
?
alpha(2-6)-sialyllactose + H2O
sialic acid + lactose
-
-
-
-
?
alpha(2-6)-sialyllactose + H2O
sialic acid + lactose
-
DELTA15Pd2,6ST-catalyzed trans-sialidase reactions follow a ping-pong bi-bi reaction mechanism, DELTA15Pd2,6ST preferentially cleaves alpha2,6-linked sialic acid
-
-
?
alpha(2-6)-sialyllactose + H2O
sialic acid + lactose
-
-
-
-
?
alpha(2-6)-sialyllactose + H2O
sialic acid + lactose
-
-
-
-
?
alpha(2-6)-sialyllactose + H2O
sialic acid + lactose
-
-
-
-
?
alpha(2-6)-sialyllactose + H2O
sialic acid + lactose
-
-
-
-
?
alpha-sialyllactose + H2O
sialic acid + lactose
-
-
-
-
?
alpha-sialyllactose + H2O
sialic acid + lactose
-
-
-
-
?
alpha-sialyllactose + H2O
sialic acid + lactose
-
-
-
-
?
alpha-sialyllactose + H2O
sialic acid + lactose
-
-
-
-
?
alpha-sialyllactose + H2O
sialic acid + lactose
-
-
-
-
?
alpha-sialyllactose + H2O
sialic acid + lactose
-
-
-
-
?
alpha-sialyllactose + H2O
sialic acid + lactose
-
-
-
-
?
alpha-sialyllactose + H2O
sialic acid + lactose
-
-
-
-
?
alpha-sialyllactose + H2O
sialic acid + lactose
-
-
-
-
?
alpha-sialyllactose + H2O
sialic acid + lactose
-
-
-
-
?
alpha-sialyllactose + H2O
sialic acid + lactose
-
-
-
-
?
alpha1-acid glycoprotein + H2O
?
-
-
-
-
?
alpha1-acid glycoprotein + H2O
?
-
-
-
?
alpha1-acid glycoprotein + H2O
?
-
-
-
?
alpha1-acid glycoprotein + H2O
?
-
-
-
-
?
bovine submaxillary gland mucin + H2O
sialic acid + ?
-
-
-
-
?
bovine submaxillary gland mucin + H2O
sialic acid + ?
-
-
-
?
colominic acid + H2O
?
-
-
-
-
?
colominic acid + H2O
?
-
-
-
-
?
colominic acid + H2O
?
Q5L868
-
-
-
?
colominic acid + H2O
?
Q5L868
-
-
-
?
colominic acid + H2O
?
-
-
-
-
?
colominic acid + H2O
?
-
-
-
?
colominic acid + H2O
?
-
-
-
?
colominic acid + H2O
?
-
-
-
-
?
colominic acid + H2O
?
-
-
-
?
colominic acid + H2O
?
-
-
-
-
?
colominic acid + H2O
?
-
-
-
-
?
colominic acid + H2O
?
-
-
-
-
?
colominic acid + H2O
sialic acid + lactose
i.e. (2-8')-sialyllactose
-
-
?
colominic acid + H2O
sialic acid + lactose
-
-
-
-
?
fetuin + H2O
?
-
-
-
-
?
fetuin + H2O
?
-
about 5% activity compared to ganglioside GD3
-
-
?
fetuin + H2O
?
Macrobdella sp.
-
-
-
-
?
fetuin + H2O
?
isoform Neu3a shows low activity
-
-
?
fetuin + H2O
Neu5Ac + ?
-
-
-
-
?
fetuin + H2O
Neu5Ac + ?
-
-
-
-
?
fetuin + H2O
Neu5Ac + ?
-
-
-
-
?
fetuin + H2O
sialic acid + ?
-
-
-
-
?
fetuin + H2O
sialic acid + ?
-
-
-
-
?
fetuin + H2O
sialic acid + ?
-
-
-
?
fetuin + H2O
sialic acid + ?
-
-
-
?
fetuin + H2O
sialic acid + ?
-
-
-
-
?
fetuin + H2O
sialic acid + ?
-
-
-
-
?
ganglioside GD1a + H2O
?
-
-
-
-
?
ganglioside GD1a + H2O
?
-
-
-
-
?
ganglioside GD1a + H2O
?
-
-
-
-
?
ganglioside GD1a + H2O
?
-
-
-
?
ganglioside GD1a + H2O
?
-
-
-
?
ganglioside GD1a + H2O
?
-
-
-
-
?
ganglioside GD1a + H2O
?
-
-
-
-
?
ganglioside GD1a + H2O
ganglioside GM1 + sialic acid
-
-
-
-
?
ganglioside GD1a + H2O
ganglioside GM1 + sialic acid
-
i.e. NeuAcalpha(2-3)-Galbeta(1-3)-GalNAcbeta(1-4)-NeuAcalpha(2-3)-Galbeta(1-4)-Glcbeta(1-1)-Cer, isozyme Neu-3, no activity with Neu-1
-
-
?
ganglioside GD1a + H2O
ganglioside GM1 + sialic acid
-
i.e. NeuAcalpha(2-3)-Galbeta(1-3)-GalNAcbeta(1-4)-NeuAcalpha(2-3)-Galbeta(1-4)-Glcbeta(1-1)-Cer, isozyme Neu-3, no activity with Neu-1
-
-
?
ganglioside GD1a + H2O
ganglioside GM1 + sialic acid
-
in transfected cells, mainly via cell-cell-interaction
-
-
?
ganglioside GD1a + H2O
sialic acid + ?
-
-
-
-
?
ganglioside GD1a + H2O
sialic acid + ?
-
-
-
?
ganglioside GD1a + H2O
sialic acid + ?
-
-
-
-
?
ganglioside GD1b + H2O
?
-
-
-
-
?
ganglioside GD1b + H2O
?
-
-
-
-
?
ganglioside GD1b + H2O
?
-
-
-
?
ganglioside GD1b + H2O
?
-
-
-
-
?
ganglioside GD1b + H2O
?
-
-
-
-
?
ganglioside GD3 + H2O
?
-
-
-
-
?
ganglioside GD3 + H2O
?
-
-
-
?
ganglioside GD3 + H2O
?
isoform Neu3a shows highest activity with ganglioside GD3
-
-
?
ganglioside GM1 + H2O
?
-
-
-
-
?
ganglioside GM1 + H2O
?
-
-
-
?
ganglioside GM1 + H2O
?
-
-
-
-
?
ganglioside GM1 + H2O
?
-
-
-
-
?
ganglioside GM3 + H2O
?
-
-
-
-
?
ganglioside GM3 + H2O
?
-
-
-
?
ganglioside GM3 + H2O
?
-
-
-
?
ganglioside GM3 + H2O
?
-
-
-
-
?
ganglioside GM3 + H2O
?
-
-
-
-
?
ganglioside GM3 + H2O
N-acetylneuraminate + beta-D-galactosyl-(1->4)-beta-D-glucosylceramide
-
-
-
-
?
ganglioside GM3 + H2O
N-acetylneuraminate + beta-D-galactosyl-(1->4)-beta-D-glucosylceramide
-
about 60% activity compared to ganglioside GD3
-
-
?
ganglioside GM3 + H2O
sialic acid + ?
-
-
-
-
?
ganglioside GM3 + H2O
sialic acid + ?
-
in transfected cells, mainly via cell-cell-interaction
-
-
?
ganglioside GM3 + H2O
sialic acid + ?
-
best substrate
-
-
?
ganglioside GT1b + H2O
?
-
-
-
-
?
ganglioside GT1b + H2O
?
-
-
-
-
?
ganglioside GT1b + H2O
?
-
-
-
?
glucomacropeptide + H2O
?
-
-
-
-
?
glucomacropeptide + H2O
?
-
-
-
-
?
glucomacropeptide + H2O
?
-
sialidase isoenzyme NA1
-
-
?
glucomacropeptide + H2O
?
-
sialidase isoenzyme NA2
-
-
?
mucin + H2O
sialic acid + ?
-
-
-
-
?
mucin + H2O
sialic acid + ?
-
-
-
-
?
mucin of bovine submaxillary gland + H2O
sialic acid + ?
-
-
-
-
?
mucin of bovine submaxillary gland + H2O
sialic acid + ?
-
-
-
-
?
N-acetylneuraminic acid-alpha-2,3-lactose + H2O
N-acetylneuraminic acid + lactose
-
-
-
-
?
N-acetylneuraminic acid-alpha-2,3-lactose + H2O
N-acetylneuraminic acid + lactose
-
-
-
-
?
N-acetylneuraminic acid-alpha-2,3-lactose + H2O
N-acetylneuraminic acid + lactose
-
-
-
-
?
N-acetylneuraminic acid-alpha-2,3-lactose + H2O
N-acetylneuraminic acid + lactose
-
-
-
-
?
N-acetylneuraminic acid-alpha-2,3-lactose + H2O
N-acetylneuraminic acid + lactose
-
-
-
-
?
N-acetylneuraminic acid-alpha-2,3-lactose + H2O
N-acetylneuraminic acid + lactose
-
-
-
-
?
N-acetylneuraminic acid-alpha-2,3-lactose + H2O
N-acetylneuraminic acid + lactose
-
-
-
-
?
N-acetylneuraminic acid-alpha-2,3-lactose + H2O
N-acetylneuraminic acid + lactose
-
-
-
-
?
N-acetylneuraminic acid-alpha-2,6-lactose + H2O
N-acetylneuraminic acid + lactose
-
-
-
-
?
N-acetylneuraminic acid-alpha-2,6-lactose + H2O
N-acetylneuraminic acid + lactose
-
-
-
-
?
N-acetylneuraminic acid-alpha-2,6-lactose + H2O
N-acetylneuraminic acid + lactose
-
-
-
-
?
N-acetylneuraminic acid-alpha-2,6-lactose + H2O
N-acetylneuraminic acid + lactose
-
-
-
-
?
N-acetylneuraminic acid-alpha-2,6-lactose + H2O
N-acetylneuraminic acid + lactose
-
-
-
-
?
N-acetylneuraminic acid-alpha-2,6-lactose + H2O
N-acetylneuraminic acid + lactose
-
-
-
-
?
N-acetylneuraminic acid-alpha-2,6-lactose + H2O
N-acetylneuraminic acid + lactose
-
-
-
-
?
N-acetylneuraminic acid-alpha-2,6-lactose + H2O
N-acetylneuraminic acid + lactose
-
-
-
-
?
N-acetylneuraminyllactose + H2O
N-acetylneuraminic acid + lactose
-
-
-
-
?
N-acetylneuraminyllactose + H2O
N-acetylneuraminic acid + lactose
-
-
-
-
?
N-acetylneuraminyllactose + H2O
N-acetylneuraminic acid + lactose
-
-
-
-
?
N-acetylneuraminyllactose + H2O
N-acetylneuraminic acid + lactose
-
-
-
-
?
Neu5,9Ac2(alpha2,3)Galbeta-p-nitrophenol + H2O
Neu5,9Ac2(alpha2,3)Gal + p-nitrophenol
-
low activity
-
-
?
Neu5,9Ac2(alpha2,3)Galbeta-p-nitrophenol + H2O
Neu5,9Ac2(alpha2,3)Gal + p-nitrophenol
-
weak activity
-
-
?
Neu5,9Ac2(alpha2,3)Galbeta-p-nitrophenol + H2O
Neu5,9Ac2(alpha2,3)Gal + p-nitrophenol
-
-
-
-
?
Neu5,9Ac2(alpha2,3)Galbeta-p-nitrophenol + H2O
Neu5,9Ac2(alpha2,3)Gal + p-nitrophenol
-
-
-
-
?
Neu5,9Ac2(alpha2,3)Galbeta-p-nitrophenol + H2O
Neu5,9Ac2(alpha2,3)Gal + p-nitrophenol
-
-
-
-
?
Neu5,9Ac2(alpha2,6)Galbeta-p-nitrophenol + H2O
Neu5,9Ac2(alpha2,6)Gal + p-nitrophenol
-
low activity
-
-
?
Neu5,9Ac2(alpha2,6)Galbeta-p-nitrophenol + H2O
Neu5,9Ac2(alpha2,6)Gal + p-nitrophenol
-
-
-
-
?
Neu5,9Ac2(alpha2,6)Galbeta-p-nitrophenol + H2O
Neu5,9Ac2(alpha2,6)Gal + p-nitrophenol
-
weak activity
-
-
?
Neu5,9Ac2(alpha2,6)Galbeta-p-nitrophenol + H2O
Neu5,9Ac2(alpha2,6)Gal + p-nitrophenol
-
-
-
-
?
Neu5,9Ac2(alpha2,6)GalNAcbeta-p-nitrophenol + H2O
Neu5,9Ac2(alpha2,6)GalNAc + p-nitrophenol
-
low activity
-
-
?
Neu5,9Ac2(alpha2,6)GalNAcbeta-p-nitrophenol + H2O
Neu5,9Ac2(alpha2,6)GalNAc + p-nitrophenol
-
-
-
-
?
Neu5,9Ac2(alpha2,6)GalNAcbeta-p-nitrophenol + H2O
Neu5,9Ac2(alpha2,6)GalNAc + p-nitrophenol
-
weak activity
-
-
?
Neu5,9Ac2(alpha2,6)GalNAcbeta-p-nitrophenol + H2O
Neu5,9Ac2(alpha2,6)GalNAc + p-nitrophenol
-
-
-
-
?
Neu5Ac(2-3)-alpha-lactose + H2O
Neu5Ac + lactose
-
-
-
-
?
Neu5Ac(2-3)-alpha-lactose + H2O
Neu5Ac + lactose
-
-
-
-
?
Neu5Ac(2-3)-alpha-lactose + H2O
Neu5Ac + lactose
-
-
-
-
?
Neu5Ac(2-6)-alpha-lactose + H2O
Neu5Ac + lactose
-
-
-
-
?
Neu5Ac(2-6)-alpha-lactose + H2O
Neu5Ac + lactose
-
-
-
-
?
Neu5Ac(2-6)-alpha-lactose + H2O
Neu5Ac + lactose
-
-
-
-
?
Neu5Ac(alpha2,3)Galbeta-p-nitrophenol + H2O
Neu5Ac(alpha2,3)Gal + 4-nitrophenol
-
-
-
-
?
Neu5Ac(alpha2,3)Galbeta-p-nitrophenol + H2O
Neu5Ac(alpha2,3)Gal + 4-nitrophenol
-
-
-
-
?
Neu5Ac(alpha2,3)Galbeta-p-nitrophenol + H2O
Neu5Ac(alpha2,3)Gal + p-nitrophenol
-
-
-
-
?
Neu5Ac(alpha2,3)Galbeta-p-nitrophenol + H2O
Neu5Ac(alpha2,3)Gal + p-nitrophenol
-
-
-
-
?
Neu5Ac(alpha2,6)Galbeta-p-nitrophenol + H2O
Neu5Ac(alpha2,6)Gal + p-nitrophenol
-
-
-
-
?
Neu5Ac(alpha2,6)Galbeta-p-nitrophenol + H2O
Neu5Ac(alpha2,6)Gal + p-nitrophenol
-
-
-
-
?
Neu5Ac(alpha2,6)GalNAcbeta-p-nitrophenol + H2O
Neu5Ac(alpha2,6)GalNAc + p-nitrophenol
-
-
-
-
?
Neu5Ac(alpha2,6)GalNAcbeta-p-nitrophenol + H2O
Neu5Ac(alpha2,6)GalNAc + p-nitrophenol
-
-
-
-
?
Neu5Ac(alpha2,6)GalNAcbeta-p-nitrophenol + H2O
Neu5Ac(alpha2,6)GalNAc + p-nitrophenol
-
-
-
-
?
Neu5Acalpha(2->3)Galbeta(1->)4GlcNAc + H2O
sialic acid + Galbeta(1->)4GlcNAc
-
-
-
-
?
Neu5Acalpha(2->3)Galbeta(1->)4GlcNAc + H2O
sialic acid + Galbeta(1->)4GlcNAc
-
-
-
-
?
Neu5Acalpha(2->3)Galbeta(1->4)GlcNAc + H2O
?
-
-
-
-
?
Neu5Acalpha(2->3)Galbeta(1->4)GlcNAc + H2O
?
-
-
-
-
?
Neu5Acalpha(2->3)Galbeta-4-nitrophenyl + H2O
?
-
-
-
?
Neu5Acalpha(2->3)Galbeta-4-nitrophenyl + H2O
?
-
-
-
?
Neu5Acalpha(2->3)Galbeta-4-nitrophenyl + H2O
?
-
-
-
?
Neu5Acalpha(2->3)Galbeta-4-nitrophenyl + H2O
?
-
-
-
-
?
Neu5Acalpha(2->3)Galbeta-4-nitrophenyl + H2O
?
-
-
-
?
Neu5Acalpha(2->6)Galbeta4-nitrophenyl + H2O
?
-
-
-
?
Neu5Acalpha(2->6)Galbeta4-nitrophenyl + H2O
?
-
-
-
?
Neu5Acalpha(2->6)Galbeta4-nitrophenyl + H2O
?
-
-
-
?
Neu5Acalpha(2->6)Galbeta4-nitrophenyl + H2O
?
-
-
-
-
?
Neu5Acalpha(2->6)Galbeta4-nitrophenyl + H2O
?
-
-
-
?
Neu5Gcalpha-(2-5)-O-glycolylNeu5Gc + H2O
2 Neu5Gcalpha
-
-
-
-
?
Neu5Gcalpha-(2-5)-O-glycolylNeu5Gc + H2O
2 Neu5Gcalpha
-
-
-
-
?
Neu5Gcalpha-(2-5)-O-glycolylNeu5Gc + H2O
2 Neu5Gcalpha
-
-
-
-
?
Neu5Gcalpha-(2-5)-O-glycolylNeu5Gc + H2O
2 Neu5Gcalpha
-
-
-
-
?
Neu5Gcalpha-(2-8)-Neu5Ac + H2O
Neu5Gc + Neu5Ac
-
preferred substrate
-
-
?
Neu5Gcalpha-(2-8)-Neu5Ac + H2O
Neu5Gc + Neu5Ac
-
preferred substrate
-
-
?
Neu5Gcalpha-(2-8)-Neu5Ac + H2O
Neu5Gc + Neu5Ac
-
preferred substrate
-
-
?
Neu5Gcalpha-(2-8)-Neu5Gc + H2O
Neu5Gc + Neu5Gc
-
low activity
-
-
?
Neu5Gcalpha-(2-8)-Neu5Gc + H2O
Neu5Gc + Neu5Gc
-
low activity
-
-
?
Neu5Gcalpha-(2-8)-Neu5Gc + H2O
Neu5Gc + Neu5Gc
-
-
-
-
?
orosomucoid + H2O
?
-
-
-
-
?
orosomucoid + H2O
?
-
-
-
-
?
orosomucoid + H2O
?
-
-
-
-
?
phenyl beta-sialoside + lactose
phenol + sialyllactose
-
-
-
-
?
phenyl beta-sialoside + lactose
phenol + sialyllactose
the Y370G mutant can transfer the sialic acid moiety from phenyl beta-sialoside to lactose in yields of up to 13%13%. Greater than 90% of the sialyllactose product formed in the coupling reactions is the alpha-2,6-isomer.
-
-
?
polysialic acid + H2O
sialic acid
-
preference for cleavage of polymers with (-5-O-glycolylNeu5Gc2-)-units, also cleaves polymers with (-8Neu5Acalpha2-)- and (-8Neu5Gcalpha2-)-units
-
-
?
polysialic acid + H2O
sialic acid
-
-
-
-
?
sialyl-alpha-2,3-lactose + H2O
?
-
-
-
-
?
sialyl-alpha-2,3-lactose + H2O
?
-
-
-
-
?
sialyl-alpha-2,3-lactose + H2O
?
-
-
-
?
sialyl-alpha-2,3-lactose + H2O
?
-
-
-
?
sialyl-alpha-2,3-lactose + H2O
?
-
-
-
-
?
sialyl-alpha-2,3-lactose + H2O
?
-
-
-
-
?
sialyl-alpha-2,3-lactose + H2O
?
-
-
-
-
?
sialyl-alpha-2,3-lactose + H2O
?
-
-
-
-
?
sialyl-alpha-2,3-lactose + H2O
?
-
-
-
-
?
sialyl-alpha-2,6-lactose + H2O
?
-
-
-
-
?
sialyl-alpha-2,6-lactose + H2O
?
-
-
-
-
?
sialyl-alpha-2,6-lactose + H2O
?
-
-
-
?
sialyl-alpha-2,6-lactose + H2O
?
-
-
-
?
sialyl-alpha-2,6-lactose + H2O
?
-
-
-
-
?
sialyl-alpha-2,6-lactose + H2O
?
-
-
-
-
?
sialyl-alpha-2,6-lactose + H2O
?
-
-
-
-
?
sialyl-alpha-2,6-lactose + H2O
?
-
-
-
-
?
sialyl-alpha-2,6-lactose + H2O
?
-
-
-
-
?
sialyllactose + H2O
?
-
-
-
-
?
sialyllactose + H2O
?
-
-
-
-
?
sialyllactose + H2O
?
-
-
-
-
?
sialyllactose + H2O
?
-
-
-
-
?
submaximally mucin + H2O
?
-
-
-
?
submaximally mucin + H2O
?
isoform Neu3a shows low activity
-
-
?
transferrin + H2O
?
-
-
-
?
transferrin + H2O
?
-
-
-
-
?
transferrin + H2O
?
-
-
-
?
transferrin + H2O
?
-
-
-
?
transferrin + H2O
?
-
-
-
-
?
transferrin + H2O
sialic acid + ?
-
-
-
-
?
transferrin + H2O
sialic acid + ?
-
-
-
-
?
additional information
?
-
-
essential enzyme, bacterial enzymes may serve as a colonization and virulence factor or as an important tool for nutrification
-
-
?
additional information
?
-
-
the sialidase prefers alpha2-3-linked sialic acids over the alpha2-6 isomers. The enzyme shows no trans-sialidase activity. The purified sialidase releases sialic acid from diverse substrates such as mucin, fetuin, epithelial cell glycans and colominic acid, no activity with asialofetuin
-
-
?
additional information
?
-
-
the sialidase prefers alpha2-3-linked sialic acids over the alpha2-6 isomers. The enzyme shows no trans-sialidase activity. The purified sialidase releases sialic acid from diverse substrates such as mucin, fetuin, epithelial cell glycans and colominic acid, no activity with asialofetuin
-
-
?
additional information
?
-
multifunctional enzyme with sialidase, receptor-binding, and fusion promotion activities
-
-
?
additional information
?
-
-
multifunctional enzyme with sialidase, receptor-binding, and fusion promotion activities
-
-
?
additional information
?
-
Avian orthoavulavirus 1 Kansas
multifunctional enzyme with sialidase, receptor-binding, and fusion promotion activities
-
-
?
additional information
?
-
Q5L868
the enzyme has no activities toward other substrates with beta-linkages or lacking sialic acid in the glycan moieties, including 4-methylumbelliferyl alpha- or 4-methylumbelliferyl beta-D-galactopyranoside, 4-nitrophenyl alpha- or 4-nitrophenyl beta-D-galactopyranoside, 2-nitrophenyl alpha-or 2-nitrophenyl beta-D-galactopyranoside, 3-nitrophenyl D-galactopyranoside, 4-nitrophenyl alpha- or 4-nitrophenyl beta-D-glucopyranoside, 4-nitrophenyl alpha- or 4-nitrophenyl beta-D-mannopyranoside, 4-nitrophenyl alpha-L-mannopyranoside, 4-nitrophenyl beta D-mannopyranoside, 4-nitrophenyl 2-acetylamino-2-deoxy-alpha- or 4-nitrophenyl 2-acetylamino-2-deoxy-beta-D-galactopyranoside, and 4-nitrophenyl 2-acetylamino-2-deoxy-beta-D-glucopyranoside
-
-
?
additional information
?
-
-
the enzyme has no activities toward other substrates with beta-linkages or lacking sialic acid in the glycan moieties, including 4-methylumbelliferyl alpha- or 4-methylumbelliferyl beta-D-galactopyranoside, 4-nitrophenyl alpha- or 4-nitrophenyl beta-D-galactopyranoside, 2-nitrophenyl alpha-or 2-nitrophenyl beta-D-galactopyranoside, 3-nitrophenyl D-galactopyranoside, 4-nitrophenyl alpha- or 4-nitrophenyl beta-D-glucopyranoside, 4-nitrophenyl alpha- or 4-nitrophenyl beta-D-mannopyranoside, 4-nitrophenyl alpha-L-mannopyranoside, 4-nitrophenyl beta D-mannopyranoside, 4-nitrophenyl 2-acetylamino-2-deoxy-alpha- or 4-nitrophenyl 2-acetylamino-2-deoxy-beta-D-galactopyranoside, and 4-nitrophenyl 2-acetylamino-2-deoxy-beta-D-glucopyranoside
-
-
?
additional information
?
-
Q5L868
the enzyme hydrolyzes alpha2-3- and alpha2-6-linked sialyllactose, as well as alpha2-8-linked disaccharides and polysaccharides, but with a preference for alpha2-8-linked saccharides over alpha2-3- and alpha2-6-linked substrates
-
-
?
additional information
?
-
-
the enzyme hydrolyzes alpha2-3- and alpha2-6-linked sialyllactose, as well as alpha2-8-linked disaccharides and polysaccharides, but with a preference for alpha2-8-linked saccharides over alpha2-3- and alpha2-6-linked substrates
-
-
?
additional information
?
-
Q5L868
the enzyme has no activities toward other substrates with beta-linkages or lacking sialic acid in the glycan moieties, including 4-methylumbelliferyl alpha- or 4-methylumbelliferyl beta-D-galactopyranoside, 4-nitrophenyl alpha- or 4-nitrophenyl beta-D-galactopyranoside, 2-nitrophenyl alpha-or 2-nitrophenyl beta-D-galactopyranoside, 3-nitrophenyl D-galactopyranoside, 4-nitrophenyl alpha- or 4-nitrophenyl beta-D-glucopyranoside, 4-nitrophenyl alpha- or 4-nitrophenyl beta-D-mannopyranoside, 4-nitrophenyl alpha-L-mannopyranoside, 4-nitrophenyl beta D-mannopyranoside, 4-nitrophenyl 2-acetylamino-2-deoxy-alpha- or 4-nitrophenyl 2-acetylamino-2-deoxy-beta-D-galactopyranoside, and 4-nitrophenyl 2-acetylamino-2-deoxy-beta-D-glucopyranoside
-
-
?
additional information
?
-
-
the enzyme has no activities toward other substrates with beta-linkages or lacking sialic acid in the glycan moieties, including 4-methylumbelliferyl alpha- or 4-methylumbelliferyl beta-D-galactopyranoside, 4-nitrophenyl alpha- or 4-nitrophenyl beta-D-galactopyranoside, 2-nitrophenyl alpha-or 2-nitrophenyl beta-D-galactopyranoside, 3-nitrophenyl D-galactopyranoside, 4-nitrophenyl alpha- or 4-nitrophenyl beta-D-glucopyranoside, 4-nitrophenyl alpha- or 4-nitrophenyl beta-D-mannopyranoside, 4-nitrophenyl alpha-L-mannopyranoside, 4-nitrophenyl beta D-mannopyranoside, 4-nitrophenyl 2-acetylamino-2-deoxy-alpha- or 4-nitrophenyl 2-acetylamino-2-deoxy-beta-D-galactopyranoside, and 4-nitrophenyl 2-acetylamino-2-deoxy-beta-D-glucopyranoside
-
-
?
additional information
?
-
Q5L868
the enzyme hydrolyzes alpha2-3- and alpha2-6-linked sialyllactose, as well as alpha2-8-linked disaccharides and polysaccharides, but with a preference for alpha2-8-linked saccharides over alpha2-3- and alpha2-6-linked substrates
-
-
?
additional information
?
-
-
the enzyme hydrolyzes alpha2-3- and alpha2-6-linked sialyllactose, as well as alpha2-8-linked disaccharides and polysaccharides, but with a preference for alpha2-8-linked saccharides over alpha2-3- and alpha2-6-linked substrates
-
-
?
additional information
?
-
-
isoform SiaBb1 preferentially hydrolyzes alpah2,3-linked sialic acid over alpha2,6-linked sialic acid from sialoglycan. Isoform SiaBb1 also has an SGNH hydrolase domain with sialate-O-acetylesterase activity
-
-
?
additional information
?
-
-
no activity with 4-nitrophenyl butyrate, 4-nitrophenyl valerate, 4-nitrophenyl decanoate, 4-nitrophenyl palmitate, and 4-nitrophenyl phosphate
-
-
?
additional information
?
-
-
isoform SiaBb1 preferentially hydrolyzes alpah2,3-linked sialic acid over alpha2,6-linked sialic acid from sialoglycan. Isoform SiaBb1 also has an SGNH hydrolase domain with sialate-O-acetylesterase activity
-
-
?
additional information
?
-
-
no activity with 4-nitrophenyl butyrate, 4-nitrophenyl valerate, 4-nitrophenyl decanoate, 4-nitrophenyl palmitate, and 4-nitrophenyl phosphate
-
-
?
additional information
?
-
-
essential enzyme, bacterial enzymes may serve as a colonization and virulence factor or as an important tool for nutrification
-
-
?
additional information
?
-
-
the enzyme cleaves sialic acids from RBC ghosts of sheep, horse, goat, cattle, pig and mice as well as mouse brain cells
-
-
?
additional information
?
-
-
the enzyme cleaves sialic acids from RBC ghosts of sheep, horse, goat, cattle, pig and mice as well as mouse brain cells
-
-
?
additional information
?
-
-
essential enzyme, enzyme containing culture filtrate possesses the ability to aggluinate and virus and shows receptor properties for erythrocytes, bacterial enzymes may serve as a colonization and virulence factor or as an important tool for nutrification
-
-
?
additional information
?
-
-
no activity with sialyl-alpha-(2-8)-sialic acid
-
-
?
additional information
?
-
-
presence of Clostridium perfringens neuraminidase up-regulates expression of interleukin-8 mRNA and protein in lung epithelial A459 and NCI-H292 cells. Enzyme significantly up-regulates IL-8 promoter activity as well as nuclear factor-kappaB reporter activity. Inhibition of nuclear factor-kappaB signaling suppresses interleukin-8 mRNA expression induced by the neuraminidase
-
-
?
additional information
?
-
-
no cleavage of 4-nitrophenyl O-[5-(2-methoxyacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-3)-O-beta-D-galactopyranoside and 4-nitrophenyl O-[5-(2-methoxyacetamido)-3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosylonic acid]-(2-6)-O-beta-D-galactopyranoside
-
-
?
additional information
?
-
-
siladiases possess activity against an alpha-2,3-specific linkage, an alpha-2,6-specific linkage, and an alpha-2,8-specific linkage. The observed activity is in the following order: alpha-2,3 > alpha-2,6 > alpha-2,8 sialic acid linkages
-
-
?
additional information
?
-
-
siladiases possess activity against an alpha-2,3-specific linkage, an alpha-2,6-specific linkage, and an alpha-2,8-specific linkage. The observed activity is in the following order: alpha-2,3 > alpha-2,6 > alpha-2,8 sialic acid linkages
-
-
?
additional information
?
-
-
essential enzyme, bacterial enzymes may serve as a colonization and virulence factor or as an important tool for nutrification
-
-
?
additional information
?
-
-
essential enzyme, bacterial enzymes may serve as a colonization and virulence factor or as an important tool for nutrification
-
-
?
additional information
?
-
-
the dimers Neu5Gcalpha-(2-8)-Neu5Ac and Neu5Gcalpha-(2-8)-Neu5Gc are poor substrates
-
-
?
additional information
?
-
-
enzyme is involved in the metabolism of gangliosides
-
-
?
additional information
?
-
-
preference for terminally (2-3)-sialylated substrates, gangliosides GD1a, GD1b, and GT1b are poor substrates
-
-
?
additional information
?
-
-
colominic acid, and gangliosides GM1 and GD1 are poor substrates
-
-
?
additional information
?
-
-
essential enzyme, bacterial enzymes may serve as a colonization and virulence factor or as an important tool for nutrification
-
-
?
additional information
?
-
-
usage of a glucomacropeptide from milk
-
-
?
additional information
?
-
-
endoNF is therefore an inverting glycosidase
-
-
?
additional information
?
-
-
does not hydrolyze the monomeric and dimeric sialic acid with alpha-linked trifluoromethylumbelliferyl significantly over a 2 h period
-
-
?
additional information
?
-
-
essential enzyme, bacterial enzymes may serve as a colonization and virulence factor or as an important tool for nutrification
-
-
?
additional information
?
-
-
usage of a glucomacropeptide from milk
-
-
?
additional information
?
-
-
enzyme is required for cellular signaling and for the production of cytokine interleukin-4 by activated T-lymphocytes, inherited enzyme defiency results in sialidosis or galactosialidosis, both severe metaboic disorders associated with lysosomal storage of oligosaccharides and glycopeptides
-
-
?
additional information
?
-
-
ganglioside substrate specificity of the isozymes, overview
-
-
?
additional information
?
-
-
hardly any activities on alpha(2-6)-sialyllactose and ganglioside GM1 and GM2
-
-
?
additional information
?
-
sialidase-3 is a key enzyme for ganglioside hydrolysis. Neu3 is an important regulator of insulin sensitivity and glucose tolerance
-
-
?
additional information
?
-
the Neu3 gene represents a physiological modulator of vascular smooth muscle cells responses that may contribute to plaque instability in atherosclerosis
-
-
?
additional information
?
-
-
increased CD15 and decreased CD15s expression during myeloid differentiation is sialidase dependent. Both CD15s synthesis and sialidase activity are induced by CD44 ligation, but the increase in sialidase activity dominates, such that the overall expression pattern upon CD44 ligation is a decrease in CD15s expression with an accompanying increase in CD15. The observed increase in CD15 results predominantly from conversion of CD15s to CD15 on glycoproteins
-
-
?
additional information
?
-
-
neuraminidase causes the desialylation of both PDGF and IGF-1 receptors and diminishes the intracellular signals induced by the mitogenic ligands PDGF-BB and IGF-2
-
-
?
additional information
?
-
-
the induction of hST3Gal V, which synthesizes ganglioside GM3 and reduction of Neu3 by phorbol 12-myristate 13-acetate, are linked for the expression of differentiation marker protein, CD41b surface antigen. Neu3 overexpression inhibits the PMA-induced ERK1/2 and p38 MAPK phosphorylation in the K-562 cells. Down-regulation of expression of CD41b surface antigen is dependent on expression of Neu3 gene. Neu3 inhibitor 2-deoxy-2,3-didehydro-D-N-acetylneuraminic acid induces morphological changes, showing megakaryocytic differentiation of K-562 cells, with expression of CD41b surface antigen, while specific glucosylceramide synthase inhibitor 1-phenyl-2-decanoylamino-3-morpholino-1-propanol inhibits megakaryocytic differentiation of K-562 cells
-
-
?
additional information
?
-
-
both alpha2-3- and alpha2-6-linked sialosides are suitable substrates for NEU2 although it cleaves alpha2-3-linked sialosides more efficiently. Twenty 4-nitrophenyl-tagged alpha(2,3)- or alpha(2,6)-linked sialyl galactosides containing different terminal sialic acid forms including common N-acetylneuraminic acid, non-human N-glycolylneuraminic acid, 2-keto-3-deoxy-D-glycero-D-galacto-nonulosonic acid, or their C5-derivatives are used as substrates, overview
-
-
?
additional information
?
-
-
substrate recognition of the membrane-associated sialidase NEU3 requires a hydrophobic aglycone, two-site model for enzyme recognition, requiring interaction at both the Neu5Ac residue and the hydrophobic aglycone. Evaluation of series of 11 synthetic trisaccharides. NEU3 substrate activity is directly dependent upon the hydrophobicity of the aglycone but has no apparent requirement for features of the ceramide headgroup. Trisaccharides with incorporated azide groups in the Neu5Ac residue at either C9 or the N5-Ac position are substrates, and in the case of the N5-azidoacetyl derivative, the activity is superior to that of GM3. Incorporation of larger aryl groups is tolerated only at C9, but not at N5-Ac
-
-
?
additional information
?
-
the key catalytic residues of the enzyme consist of the general acid-base D50 and the nucleophilic Y370-E225 pair, molecular modeling to predict residues involved in the recognition and hydrolysis of glycolipid substrates, homology modeling and molecular docking of NEU3, overview
-
-
?
additional information
?
-
-
the key catalytic residues of the enzyme consist of the general acid-base D50 and the nucleophilic Y370-E225 pair, molecular modeling to predict residues involved in the recognition and hydrolysis of glycolipid substrates, homology modeling and molecular docking of NEU3, overview
-
-
?
additional information
?
-
sialidase NEU3 shows high enzymatic specificity toward gangliosides
-
-
?
additional information
?
-
-
enzyme agglutinates erythrocytes from human blood
-
-
?
additional information
?
-
-
spontaneous hydrolysis of pyridinium salts of alpha-D-N-acetylneuraminic acid occurs via 2 different ways, effects on the enzymic reaction mechanism are investigated
-
-
?
additional information
?
-
-
egg or Madin Darby canine kidney cell isolated virus strains tend to exhibit highest activity against 3'-sialyl-bound sialic acid whereas Vero isolated strain favour 6'-sialyl-(N-acetyllactosamine)-bound sialic acid
-
-
?
additional information
?
-
-
neuraminidase substrate specificity study of human and avian influenza A viruses, using a library of twenty alpha23- or alpha26-linked para-nitrophenol-tagged sialylgalactosides and thirty-seven strains of human and avian influenza A viruses, overview. Neuraminidases of all viruses tested cleave both alpha2-3- and alpha2-6-linked sialosides but prefer alpha23-linked ones and the activity is dependent on the terminal sialic acid structure
-
-
?
additional information
?
-
-
substrate specificity of the viral enzyme with sialic acid, methyl 3'-sialyllactoside, methyl 6'-sialyllactoside, ligand conformations, enzyme-ligand interactions, and loop flexibility, analyzed by molecular docking and molecular dynamics simulations, and molecular modeling, overview. Methyl 3'-sialyllactoside has only weak interactions with the 150-loop, whereas the enzyme N1-methyl 6'-sialyllactoside complex shows strong interactions. The avian neuraminidase N1 preferentially cleaves sialic acid from alpha-(2-3)-Gal glycoconjugates over alpha-(2-6)-Gal, also due to the altered flexibility of loops in and around the active site
-
-
?
additional information
?
-
-
the enzyme shows higher activity on alpha2,3-linked sialic acid than alpha2,6-linked
-
-
?
additional information
?
-
the enzyme prefers cleaving alpha2,3- over alpha2,6-linked sialic acids
-
-
?
additional information
?
-
the enzyme prefers cleaving alpha2,3- over alpha2,6-linked sialic acids
-
-
?
additional information
?
-
plaque formation on MDCK and Vero cells at different temperatures, investigation of influence of different hemagglutinin and neuraminidase combinations on enzyme activity
-
-
?
additional information
?
-
plaque formation on MDCK and Vero cells at different temperatures, investigation of influence of different hemagglutinin and neuraminidase combinations on enzyme activity
-
-
?
additional information
?
-
-
plaque formation on MDCK and Vero cells at different temperatures, investigation of influence of different hemagglutinin and neuraminidase combinations on enzyme activity
-
-
?
additional information
?
-
plaque formation on MDCK and Vero cells, investigation of influence of different hemagglutinin and neuraminidase combinations on enzyme activity
-
-
?
additional information
?
-
plaque formation on MDCK and Vero cells, investigation of influence of different hemagglutinin and neuraminidase combinations on enzyme activity
-
-
?
additional information
?
-
-
plaque formation on MDCK and Vero cells, investigation of influence of different hemagglutinin and neuraminidase combinations on enzyme activity
-
-
?
additional information
?
-
-
egg or Madin Darby canine kidney cell isolated virus strains tend to exhibit highest activity against 3'-sialyl-bound sialic acid whereas Vero isolated strain favour 6'-sialyl-(N-acetyllactosamine)-bound sialic acid
-
-
?
additional information
?
-
-
essential enzyme, bacterial enzymes may serve as a colonization and virulence factor or as an important tool for nutrification
-
-
?
additional information
?
-
-
the enzyme modifies the ganglioside pattern of adjacent cells, involved in cell-cell-interaction
-
-
?
additional information
?
-
-
ganglioside substrate specificity of the isozymes, overview
-
-
?
additional information
?
-
isoform Neu3a shows no activity with ganglioside GM1
-
-
?
additional information
?
-
A0A024FSF5
isoform Neu3a shows no activity with ganglioside GM1
-
-
?
additional information
?
-
isoform Neu3a shows no activity with ganglioside GM1
-
-
?
additional information
?
-
-
isoform Neu3a shows no activity with ganglioside GM1
-
-
?
additional information
?
-
sialidase activities are not observed towards various sialoglycoconjugates
-
-
?
additional information
?
-
A0A024FSF5
sialidase activities are not observed towards various sialoglycoconjugates
-
-
?
additional information
?
-
sialidase activities are not observed towards various sialoglycoconjugates
-
-
?
additional information
?
-
-
sialidase activities are not observed towards various sialoglycoconjugates
-
-
?
additional information
?
-
L0N7M7
no activity with mucin, colominic acid, gangliosides and fetuin
-
-
?
additional information
?
-
-
no activity with mucin, colominic acid, gangliosides and fetuin
-
-
?
additional information
?
-
-
essential enzyme, bacterial enzymes may serve as a colonization and virulence factor or as an important tool for nutrification
-
-
?
additional information
?
-
-
no activity with sialyl-alpha-(2-8)-sialic acid
-
-
?
additional information
?
-
-
essential enzyme, bacterial enzymes may serve as a colonization and virulence factor or as an important tool for nutrification, enzyme is responsible for decomposition of organic material in various biotopes
-
-
?
additional information
?
-
-
essential enzyme, bacterial enzymes may serve as a colonization and virulence factor or as an important tool for nutrification, enzyme is responsible for decomposition of organic material in various biotopes
-
-
?
additional information
?
-
substrate specificity
-
-
?
additional information
?
-
substrate specificity
-
-
?
additional information
?
-
-
substrate specificity
-
-
?
additional information
?
-
-
essential enzyme, bacterial enzymes may serve as a colonization and virulence factor or as an important tool for nutrification
-
-
?
additional information
?
-
most strains of Pasteurella multocida produce sialidase activity which may contribute to colonization of the respiratory tract by the mucosal pathogen, or for production of lesions in an actiev infection
-
-
?
additional information
?
-
most strains of Pasteurella multocida produce sialidase activity which may contribute to colonization of the respiratory tract by the mucosal pathogen, or for production of lesions in an actiev infection
-
-
?
additional information
?
-
-
most strains of Pasteurella multocida produce sialidase activity which may contribute to colonization of the respiratory tract by the mucosal pathogen, or for production of lesions in an actiev infection
-
-
?
additional information
?
-
most strains of Pasteurella multocida produce sialidase activity which may contribute to colonization of the respiratory tract by the mucosal pathogen, or for production of lesions in an active infection
-
-
?
additional information
?
-
most strains of Pasteurella multocida produce sialidase activity which may contribute to colonization of the respiratory tract by the mucosal pathogen, or for production of lesions in an active infection
-
-
?
additional information
?
-
-
most strains of Pasteurella multocida produce sialidase activity which may contribute to colonization of the respiratory tract by the mucosal pathogen, or for production of lesions in an active infection
-
-
?
additional information
?
-
substrate specificity, no or poor activity with ganglioside GM1, colominic acid, and alpha(2-6')-sialyllactose
-
-
?
additional information
?
-
substrate specificity, no or poor activity with ganglioside GM1, colominic acid, and alpha(2-6')-sialyllactose
-
-
?
additional information
?
-
-
substrate specificity, no or poor activity with ganglioside GM1, colominic acid, and alpha(2-6')-sialyllactose
-
-
?
additional information
?
-
-
ganglioside GM1 and bovine serum albumin are poor substrates, no activity with 4-methylumbelliferyl-alpha-3-deoxy-D-glycero-D-galacto-2-nonulosonic acid
-
-
?
additional information
?
-
-
NanB may contribute to Strreptococcus pneumoniae colonization and pathogenesis
-
-
?
additional information
?
-
NanB may contribute to Strreptococcus pneumoniae colonization and pathogenesis
-
-
?
additional information
?
-
-
Streptococcus pneumoniae is able to utilize complex N-linked human glycoconjugates as a sole source of carbon to sustain growth and efficient growth is dependent upon the sequential deglycosylation of the glycoconjugate substrate by pneumococcal exoglycosidases NanA, BgaA, and StrH. The second pneumococcal neuraminidase, NanB, is involved in the deglycosylation of host glycoconjugates and NanB activity can partially compensate for the loss or dysfunction of NanA
-
-
?
additional information
?
-
Streptococcus pneumoniae is able to utilize complex N-linked human glycoconjugates as a sole source of carbon to sustain growth and efficient growth is dependent upon the sequential deglycosylation of the glycoconjugate substrate by pneumococcal exoglycosidases NanA, BgaA, and StrH. The second pneumococcal neuraminidase, NanB, is involved in the deglycosylation of host glycoconjugates and NanB activity can partially compensate for the loss or dysfunction of NanA
-
-
?
additional information
?
-
-
essential enzyme, bacterial enzymes may serve as a colonization and virulence factor or as an important tool for nutrification
-
-
?
additional information
?
-
-
essential enzyme, bacterial enzymes may serve as a colonization and virulence factor or as an important tool for nutrification
-
-
?
additional information
?
-
trans-sialidase 1 produces alpha2,3-sialyllactose from lactose by desialylating fetuin exhibiting transsialidase activity, substrate specificities for lactose, fetuin and synthetic substrates, overview. The enzyme is able to sialylate asialofetuin. Sialylation pattern of the N-glycans on fetuin catalyzed by the trans-sialidases, overview
-
-
?
additional information
?
-
-
the enzyme also performs transglycosylation reactions
-
-
?
additional information
?
-
-
in addition to hydrolysis, enzyme catalyzes transglycosylation of sialyl residues to lactose. Km value and kcat value for sialyl transfer from 4-nitrophenyl alpha-sialoside are 5.8 mM and 6.77 per s, for sialyl transfer from (trifluoromethyl)umbelliferyl alpha-sialoside 0.26 mM and 15.7 per s, respectively
-
-
?
additional information
?
-
-
trans-sialidase preferentially transfers sialic acid from sialyl-glycoconjugates to the terminal beta-galactosyl residues in acceptor molecules
-
-
?
additional information
?
-
-
the enzyme catalyses the alpha-(2,3)-sialylation of non-reducing terminal beta-galactose residues, it is largely intolerant of substitution of the galactose 2 and 4 positions whereas substitution of the galactose 6 position is well tolerated, even the addition of a bulky sugar residue, glucose or galactose, does not impact negatively on TcTS binding and turnover, which highlights the potential of internal 6-substituted galactose residues to serve as enzyme acceptor substrates, substrate binding mode and site, overview
-
-
?
additional information
?
-
-
the strict hydrolase of Trypanosoma rangeli shows no trans-sialidase activity
-
-
?
additional information
?
-
-
the enzyme is inactive towards Neu5,9Ac2(alpha2,6)-lactose, colomic acid and the gangliosides GM1, and GDI
-
-
?
additional information
?
-
-
the enzyme is inactive towards Neu5,9Ac2(alpha2,6)-lactose, colomic acid and the gangliosides GM1, and GDI
-
-
?
additional information
?
-
-
the enzyme is inactive towards Neu5,9Ac2(alpha2,6)-lactose, colomic acid and the gangliosides GM1, and GDI
-
-
?
additional information
?
-
-
essential enzyme, enzyme containing culture filtrate possesses the ability to agglutinate and virus and shows receptor properties for erythrocytes, bacterial enzymes may serve as a colonization and virulence factor or as an important tool for nutrification
-
-
?
additional information
?
-
-
no activity with sialyl-alpha-(2-8)-sialic acid
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1R/S)-1-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-propan-1-ol
-
13% inhibition at 1 mM
(1R/S)-1-[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-propan-1-ol
-
29% inhibition at 1 mM
(1R/S,4R,5R)-4-acetamido-5-(1-ethylpropoxy)-3-(4-phenethyl-[1,2,3]triazol-1-yl)cyclohex-2-ene-1-carboxylic acid
-
-
(1R/S,4R,5R)-4-acetamido-5-(1-ethylpropoxy)-3-[4-(1-hydroxy-1-methylethyl)[1,2,3]triazol-1-yl]cyclohex-2-ene-1-carboxylic acid
-
-
(2R,3R,4S)-3-(acetylamino)-2-[(1S,2S)-3-(acetylamino)-1,2-dihydroxypropyl]-4-hydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid
-
(2R,3R,4S)-3-(acetylamino)-2-[(1S,2S)-3-(benzoylamino)-1,2-dihydroxypropyl]-4-hydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid
-
(2R,3R,4S)-3-(acetylamino)-2-[(1S,2S)-3-(butyrylamino)-1,2-dihydroxypropyl]-4-hydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid
-
(2R,3R,4S)-3-(acetylamino)-2-[(1S,2S)-3-[(cyclopropylcarbonyl)amino]-1,2-dihydroxypropyl]-4-hydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid
-
(2R,4S,5R)-5-[(1R,2R)-1-(acetylamino)-2-ethoxybut-3-en-1-yl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
(2R,4S,5R)-5-[(1R,2R)-1-(acetylamino)-2-methoxybut-3-en-1-yl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
(2R,4S,5R)-5-[(1R,2R)-1-(acetylamino)-2-methoxypent-4-en-1-yl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
(2R,4S,5R)-5-[(1R,2S)-1-(acetylamino)-2-hydroxy-2-methylpentyl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
(2R,4S,5R)-5-[(1R,2S)-1-(acetylamino)-2-methoxy-2-methylpentyl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
(2R,4S,5R)-5-[(1S,2S)-1-(acetylamino)-2-hydroxybut-3-en-1-yl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
(2R,4S,5R)-5-[(1S,2S)-1-(acetylamino)-2-hydroxybutyl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
(2R,4S,5R)-5-[(2S)-1-(acetylamino)-2-hydroxypent-4-en-1-yl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
(2R,4S,5R)-5-[(2S)-1-(acetylamino)-2-hydroxypentyl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
(2R/S)-1-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-propan-2-ol
-
14% inhibition at 1 mM
(2R/S)-1-[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-propan-2-ol
-
10% inhibition at 1 mM
(3E)-3-(1,3-benzothiazol-2-yl)-4-(2,5-dimethylphenyl)but-3-enoate
-
-
(3E)-3-(1,3-benzothiazol-2-yl)-4-(2-ethoxyphenyl)but-3-enoate
-
-
(3E)-3-(1,3-benzothiazol-2-yl)-4-(3,4-dimethoxyphenyl)but-3-enoate
-
-
(3E)-3-(1,3-benzothiazol-2-yl)-4-(3-fluorophenyl)but-3-enoate
-
-
(3E)-3-(1,3-benzothiazol-2-yl)-4-[2-(propan-2-yloxy)phenyl]but-3-enoate
-
-
(3E)-3-(1,3-benzothiazol-2-yl)-4-[2-methyl-5-(trifluoromethyl)phenyl]but-3-enoate
-
-
(3R,4R,5R)-4-acetamido-3-(1-(diaminomethylamino)-3-hydroxypropan-2-yloxy)-5-((1S)-1,2,3-trihydroxypropyl)cyclohex-1-enecarboxylic acid
-
obtained by structure-based design using crystal structure PDB ID 2hty and in order to exploit experimentally identified potential benefits offered by the 150-cavity adjacent to the H5N1 neuramindase active site. Inhibitor shows low binding free energy
(3R,4R,5R)-4-acetamido-5-((1S)-2-carboxy-1,2-dihydroxyethyl)-3-(1-(diaminomethylamino)-3-hydroxypropan-2-yloxy)cyclohex-1-enecarboxylic acid
-
obtained by structure-based design using crystal structure PDB ID 2hty and in order to exploit experimentally identified potential benefits offered by the 150-cavity adjacent to the H5N1 neuramindase active site. Inhibitor shows low binding free energy
(3S,4R,5R)-4-acetamido-3-amino-5-(1-ethylpropoxy)cyclohex-1-ene-1-carboxylic acid
-
-
(3S,4R,5R)-4-acetamido-3-[4-((17alpha)-estra-1,3,5(10)-triene-3,17-dihydroxy-17-yl)[1,2,3]triazol-1-yl]-5-(1-ethylpropoxy)cyclohex-1-ene-1-carboxylic acid
-
-
(3S,4R,5R)-4-acetamido-5-(1-ethyl-propoxy)-3-[4-(1-hydroxypropyl)[1,2,3]triazol-1-yl]cyclohex-1-ene-1-carboxylic acid
-
-
(3S,4R,5R)-4-acetamido-5-(1-ethylpropoxy)-3-(4-phenethyl-[1,2,3]triazol-1-yl)cyclohex-1-ene-1-carboxylic acid
-
-
(3S,4R,5R)-4-acetamido-5-(1-ethylpropoxy)-3-guanidinocyclohex-1-ene-1-carboxylic acid
-
-
(3S,4R,5R)-4-acetamido-5-(1-ethylpropoxy)-3-[4-(1-hydroxy-1-methylethyl)[1,2,3]triazol-1-yl]cyclohex-1-ene-1-carboxylic acid
-
-
(3S,4R,5R)-4-acetamido-5-(1-ethylpropoxy)-3-[4-(1-hydroxycyclohexyl)[1,2,3]triazol-1-yl]cyclohex-1-ene-1-carboxylic acid
-
-
(3S,4R,5R)-4-acetamido-5-(1-ethylpropoxy)-3-[4-(1-hydroxycyclopentyl)[1,2,3]triazol-1-yl]cyclohex-1-ene-1-carboxylic acid
-
-
(3S,4R,5R)-4-acetamido-5-(1-ethylpropoxy)-3-[4-(3-hydroxypropyl)[1,2,3]triazol-1-yl]cyclohex-1-ene-1-carboxylic acid
-
-
(4R)-2-(2-carboxyphenyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-(2-carboxyphenyl)-3-(chloroacetyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-(2-carboxyphenyl)-3-(phenylacetyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-(2-carboxyphenyl)-3-glycyl-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-(2-hydroxy-3-methoxyphenyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-(2-hydroxy-3-methoxyphenyl)-3-(phenylacetyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-(2-hydroxyphenyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-(2-hydroxyphenyl)-3-(phenylacetyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-(2-nitrophenyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-(2-nitrophenyl)-3-(phenylacetyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-(4-cyanophenyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-(4-cyanophenyl)-3-(phenylacetyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-(4-cyanophenyl)-3-glycyl-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-(furan-2-yl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-(furan-2-yl)-3-(phenylacetyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-(furan-2-yl)-3-glycyl-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-phenyl-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-phenyl-3-(phenylacetyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-3-(chloroacetyl)-2-(2-hydroxy-3-methoxyphenyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-3-(chloroacetyl)-2-(2-hydroxyphenyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-3-(chloroacetyl)-2-(2-nitrophenyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-3-(chloroacetyl)-2-(4-cyanophenyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-3-(chloroacetyl)-2-(furan-2-yl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-3-(chloroacetyl)-2-phenyl-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-3-glycyl-2-(2-hydroxy-3-methoxyphenyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-3-glycyl-2-(2-hydroxyphenyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-3-glycyl-2-(2-nitrophenyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-3-glycyl-2-phenyl-1,3-thiazolidine-4-carboxylic acid
-
-
(6aS,12aS)-6a,12a-dihydro-6H-[1,3]dioxolo[5,6][1]benzofuro[3,2-c]chromen-3-ol
-
noncompetitive
(6R)-5-amino-2,6-anhydro-3,5-dideoxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]-L-threo-hex-2-enonic acid
-
competitive
1,3,6,7-tetrahydroxy-2-(3-methylbut-2-enyl)-8-(2-methylbut-3-en-2-yl)-9H-xanthen-9-one
competitive
1,3,8-trihydroxy-6-methylanthracene-9,10-dione
1,3-bis[1-[(beta-D-galactopyranosyl)]-1H-1,2,3-triazol-6-yl]-propane
-
8% inhibition at 1 mM
1,3-bis{1-[(methyl 6-deoxy-beta-D-galactopyranos-6-yl)]-1H-1,2,3-triazol-6-yl}-propane
-
16% inhibition at 1 mM
1,8-dihydroxyanthracene-9,10-dione
1-(beta-D-galactopyranosyl)-1H-1,2,3-[triazol-4-yl]-methanol
-
11% inhibition at 1 mM
11,17-dihydroxy-3,20-dioxopregn-4-en-21-yl cyclopentanecarboxylate
-
identified by ensemble-based virtual screening
2'-methoxy-isoliquiritigenin
-
-
2'-methoxyisoliquiritigenin
-
noncompetitive inhibition
2,3 didehydroneuraminic acid
-
-
2,3-dehydro-2-deoxy-N-acetylneuraminic acid
2,3-dehydro-2-deoxy-N-glycolylneuraminic acid
-
-
2,3-dehydro-2-deoxysialic acid
-
70.2% inhibition at 0.1 mM
2,3-didehydro-2-deoxy-N-acetylneuraminic acid
-
i.e. DANA, specific, competitive neuraminidase inhibitor
2,3-didehydro-N-acetylneuraminic acid
-
-
2,3-didehydroneuraminic acid
2,4-diaminohexahydropyrimidine-5-carbonitrile
-
identified by ensemble-based virtual screening
2,6-anhydro-3,5-dideoxy-5-glycolylamido-D-glycero-D-galactonon-2-enonic acid
-
-
2,6-anhydro-3-deoxy-D-glycero-D-galacto-non-2-enonic acid
-
-
2,6-anhydro-5-(2-azidoacetamido)-3,5-dideoxy-D-glycero-D-galacto-non-2-enonic acid
-
-
2,6-anhydro-9-azido-3,5,9-trideoxy-5-(2-hydroxyacetamido)-D-glycero-D-galacto-non-2-enonic acid
2,6-anhydro-9-azido-5-(2-azidoacetamido)-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
2-((E)-4'-hydroxyphenylidene)-4,6-dihydroxy-2,3-dihydrobenzofuran-3-one
2-((E)-4'-hydroxyphenylidene)-6-hydroxy-2,3-dihydrobenzofuran-3-one
2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(4-hydroxy-3-nitrophenyl)propanoic acid
-
identified by ensemble-based virtual screening
2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one
2-(3,4-dihydroxyphenyl)-4H-chromene-3,5,7-triol
2-(cyclohexylamino)ethanesulfonic acid
-
-
2-(E-4'-hydroxyphenylidene)-4,6-dihydroxy-2,3-dihydrobenzo-furan-3-one
-
-
2-(E-4'-hydroxyphenylidene)-6-hydroxy-2,3-dihydrobenzofuran-3-one
-
-
2-(E-benzylidene)-6-hydroxy-2,3-dihydrobenzofuran-3-one
-
-
2-([4,5-dimethyl-3-(propoxycarbonyl)thiophen-2-yl]carbamoyl)cyclohexanecarboxylate
-
-
2-deoxy-2,3 didehydro-N-acetyl-neuraminic acid
-
-
2-deoxy-2,3-dehydro-N-acetyl neuraminic acid
2-deoxy-2,3-dehydro-N-acetyl-D-neuraminic acid
2-deoxy-2,3-dehydro-N-acetylneuraminic acid
2-deoxy-2,3-didehydro-D-glycero-D-galacto-2-nonulopyranosonic acid
-
-
2-deoxy-2,3-didehydro-D-N-acetylneuraminic acid
2-Deoxy-2,3-didehydro-N-acetylneuraminic acid
2-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-aniline
-
30% inhibition at 1 mM
2-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-bromobenzene
-
33% inhibition at 1 mM
2-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-N-phthalimidylmethane
-
25% inhibition at 1 mM
2-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-phenylethane
-
16% inhibition at 1 mM
2-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-pyridine
-
13% inhibition at 1 mM
2-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-trifluoromethylbenzene
-
14% inhibition at 1 mM
2-[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-aniline
-
24% inhibition at 1 mM
2-[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-bromobenzene
-
29% inhibition at 1 mM
2-[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-pyridine
-
14% inhibition at 1 mM
2-[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-trifluoromethylbenzene
-
11% inhibition at 1 mM
3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one
3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
3-(2-amino-1-hydroxyethyl)-4-[(methylsulfonyl)amino]benzoic acid
-
1 mM, 17% inhibition
3-(acetylamino)-4-morpholin-4-ylbenzoic acid
-
-
3-amino-4-(benzylthio)benzoic acid
-
-
3-amino-4-(pyridin-3-ylamino)benzoic acid
-
-
3-amino-4-[(phenylacetyl)amino]benzoic acid
-
-
3-hydroxy-4-[(E)-naphthalen-1-yldiazenyl]naphthalene-2,7-disulfonic acid
-
identified by ensemble-based virtual screening
3-[(aminoacetyl)amino]-4-(benzylthio)benzoic acid
-
-
3-[(diaminomethylene)amino]-4-[(methylamino)carbonyl]benzoic acid
-
-
3-[(diaminomethylene)amino]-4-[(methylsulfinyl)amino]benzoic acid
-
1 mM, 29% inhibition
3-[(diaminomethylene)amino]-4-[(phenylacetyl)amino]benzoic acid
-
1 mM, 54% inhibition
3-[(diaminomethylene)amino]-5-(hydroxymethyl)-4-[(methylsulfonyl)amino]benzoic acid
-
1 mM, 11% inhibition
3-[(diaminomethylene)amino]-5-[(E)-(hydroxyimino)methyl]-4-[(methylsulfonyl)amino]benzoic acid
-
1 mM, 46% inhibition
3-[(diaminomethylene)amino]-5-[(E)-(hydroxyimino)methyl]benzoic acid
-
1 mM, 35% inhibition
3-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-propan-1-ol
-
27% inhibition at 1 mM
3-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-pyridine
-
15% inhibition at 1 mM
3-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-trifluoromethylbenzene
-
31% inhibition at 1 mM
3-[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-propan-1-ol
-
24% inhibition at 1 mM
3-[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-pyridine
-
20% inhibition at 1 mM
3-[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-trifluoromethylbenzene
-
3% inhibition at 1 mM
4,5-diacetamido-2-fluorobenzoate
8% inhibition of isoform NEU4 at 1 mM
4,5-diacetamido-2-fluorobenzoic acid
23% inhibition of isoform NEU3 at 1 mM; 37% inhibition of isoform NEU2 at 1 mM
4,5-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid
4-(acetylamino)-3,5-bis(guanidino)-2-ethoxybenzoic acid
-
-
4-(acetylamino)-3-(2,3-dihydroxypropyl)benzoic acid
-
1 mM, 17% inhibition
4-(acetylamino)-3-(2-aminoethyl)benzoic acid
-
1 mM, 25% inhibition
4-(acetylamino)-3-(2-hydroxyethyl)benzoic acid
-
1 mM, 16% inhibition
4-(acetylamino)-3-(hydroxymethyl)benzoic acid
-
-
4-(acetylamino)-3-[(diaminomethylene)amino]benzoic acid
-
1 mM, 41% inhibition
4-(acetylamino)-3-[(Z)-(hydroxyimino)methyl]benzoic acid
-
1 mM, 24% inhibition
4-(acetylamino)-5-(guanidino)-2-(cyclopentyloxy)benzoic acid
-
-
4-(acetylamino)-5-(guanidino)-2-butoxybenzoic acid
-
-
4-(acetylamino)-5-(guanidino)-2-isopropoxybenzoic acid
-
-
4-(benzylamino)-3-[(diaminomethylene)amino]benzoic acid
-
1 mM, 9% inhibition
4-(benzylthio)-3-[(diaminomethylene)amino]benzoic acid
-
1 mM, 43% inhibition
4-acetamido-5-(2-ethylbutanamido)-2-fluorobenzoic acid
23% inhibition of isoform NEU2 at 1 mM; less than 5% inhibition of isoform NEU4 at 1 mM
4-acetamido-5-(2-methylbutanamido)-2-fluorobenzoic acid
7% inhibition of isoform NEU2 at 1 mM
4-acetamido-5-(2-naphthamido)-2-fluorobenzoic acid
10% inhibition of isoform NEU4 at 1 mM; 33% inhibition of isoform NEU2 at 1 mM; 8% inhibition of isoform NEU3 at 1 mM
4-acetamido-5-(biphenyl-4-ylcarboxamido)-2-fluorobenzoic acid
10% inhibition of isoform NEU4 at 1 mM; 60% inhibition of isoform NEU2 at 1 mM; 8% inhibition of isoform NEU3 at 1 mM
4-acetamido-5-benzamido-2-fluorobenzoic acid
17% inhibition of isoform NEU2 at 1 mM
4-acetamido-5-cyclohexanecarboxamido-2-fluorobenzoic acid
17% inhibition of isoform NEU2 at 1 mM; 6% inhibition of isoform NEU4 at 1 mM
4-acetamido-5-cyclopropanecarboxamido-2-fluorobenzoic acid
20% inhibition of isoform NEU2 at 1 mM; less than 5% inhibition of isoform NEU4 at 1 mM
4-acetamido-5-isobutyramido-2-fluorobenzoic acid
11% inhibition of isoform NEU4 at 1 mM; 15% inhibition of isoform NEU2 at 1 mM
4-acetamido-5-pentanamido-2-fluorobenzoic acid
13% inhibition of isoform NEU3 at 1 mM; 25% inhibition of isoform NEU2 at 1 mM; less than 5% inhibition of isoform NEU4 at 1 mM
4-acetamido-5-pivalamido-2-fluorobenzoic acid
less than 5% inhibition of isoform NEU4 at 1 mM
4-aminophenyl thioglucoside derivatives of sialic acid
-
-
-
4-azido-5-isobutyrylamino-2,3-didehydro-2,3,4,5-tetradeoxy-d-glycero-d-galacto-2-nonulopyranosic acid
-
i.e. BCX 2798. Effectively inhibits the activities of the hemagglutinin-neuraminidase of human parainfluenza viruses in vitro and protects mice from lethal infection with a recombinant Sendai virus whose hemagglutinin-neuraminidase was replaced with that of human parainfluenza virus-1
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid
substrate inhibition
4-nitrophenyl oxamic acid
-
-
4-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-aniline
-
19% inhibition at 1 mM
4-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-butan-1-ol
-
26% inhibition at 1 mM
4-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-butanoic acid
-
10% inhibition at 1 mM
4-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-trifluoromethylbenzene
-
9% inhibition at 1 mM
4-[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-aniline
-
34% inhibition at 1 mM
4-[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-bromobenzene
-
3% inhibition at 1 mM
4-[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-butan-1-ol
-
27% inhibition at 1 mM
4-[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-trifluoromethylbenzene
-
10% inhibition at 1 mM
5,6,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one
5,7,4'-trihydroxy-8-methoxyflavone
-
-
5,7-dihydroxy-2-(2-hydroxyphenyl)-4H-chromen-4-one
5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
5,7-dihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one
5,7-dihydroxy-2-phenyl-4H-chromen-4-one
5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one
5-(acetylamino)-2,6-anhydro-3,5,9-trideoxy-9-(pentanoylamino)-L-glycero-L-altro-non-2-enonic acid
-
5-(acetylamino)-2,6-anhydro-3,5,9-trideoxy-9-[(3-methylbutanoyl)amino]-L-glycero-L-altro-non-2-enonic acid
-
5-(acetylamino)-2,6-anhydro-9-[(cyclopentylcarbonyl)amino]-3,5,9-trideoxy-L-glycero-L-altro-non-2-enonic acid
-
5-(acetylamino)-4-aminopyridine-2-carboxylic acid
-
1 mM, 14% inhibition
5-(acetylamino)-6-aminopyridine-2-carboxylic acid
-
-
5-(acetylamino)pyridine-2-carboxylic acid
-
1 mM, 22% inhibition
5-(ethanethioylamino)pyridine-2-carboxylic acid
-
-
5-acetamido-2,6-anhydro-3,5-dideoxy-9-O-methyl-D-glycero-D-galacto-non-2-enonic acid
5-acetamido-2,6-anhydro-3,5-dideoxy-D-glycero-D-galactonon-2-enonic acid
-
-
5-acetamido-2,6-anhydro-9-azido-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
5-acetamido-2-(4-N-5-dimethylaminonaphthalene-1-sulfonyl-2-difluoromethylphenyl)3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosonic acid
-
irreversible and competitive
5-acetamido-9-aminopropyl-2,6-anhydro-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
5-hydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-4H-chromen-4-one
5-methyl-4-methylidene-2-phenyl-4H-chromene
5-[(methylsulfonyl)amino]pyridine-2-carboxylic acid
-
1 mM, 25% inhibition
6,6-dimethyl-1-(3-[(3-nitrobenzyl)oxy]phenyl)-1,3,5-triazinane-2,4-diimine
-
identified by ensemble-based virtual screening
6-chloro-9,10-dihydro-4,5,7-trihydroxy-9,10-dioxo-2-anthracenecarboxylic acid
7,4'-di-O-galloyltricetinflavan
-
-
7-hydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
7-O-galloyltricetinflavan
-
-
9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid
alpha-D-N-acetylneuraminic acid
Berberine
-
reversible non-competitive inhibition
chondroitin sulfate A
-
-
CID2601775
-
the IUPAC name is 2-[(4-amino-5-cyclopropyl-1,2,4-triazol-3-yl)sulfanyl]-N-(cyclopentylcarbamoyl)acetamide
CID9796290
-
the IUPAC name is 6-[2-[[2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]ethylamino]pyridine-3-carbonitrile
Cl-
-
recombinant mutant: increase in concentration from 5 to 150 mM results in a decrease in activity of 50%, native enzyme: increase in concentration from 10 to 150 mM results in a decrease in activity of 20%
cudratricusxanthone
competitive
cudraxanthone L
competitive
cudraxanthone M
competitive
D-glucosamine 6-sulfate
-
slight inhibition at 10 mM
D-glucose 6-sulfate
-
slight inhibition at 10 mM
dihydroisoquinoline derivative
-
-
Galp(beta1,2)Galf(beta1,4)GlcNAc
-
-
Galp(beta1,2)Galf(beta1,4)GlcNAcOBn
-
-
Galp(beta1,2)Galf(beta1,4)GlcNAcol
-
-
Galp(beta1,2)[Galp(beta1,3)]Gal
-
-
Galp(beta1,2)[Galp(beta1,3)]GalOBn
-
-
Galp(beta1,2)[Galp(beta1,3)]Galol
-
-
Galp(beta1,2)[Galp(beta1,3)]Galp(beta1,6)[Galf(beta1,4)]GlcNAc
-
-
Galp(beta1,2)[Galp(beta1,3)]Galp(beta1,6)[Galf(beta1,4)]GlcNAcOBn
-
-
Galp(beta1,2)[Galp(beta1,3)]Galp(beta1,6)[Galf(beta1,4)]GlcNAcol
-
-
Galp(beta1,3)Galp(beta1,6)[Galf(beta1,4)]GlcNAc
-
-
Galp(beta1,3)Galp(beta1,6)[Galf(beta1,4)]GlcNAcOBn
-
-
Galp(beta1,3)Galp(beta1,6)[Galf(beta1,4)]GlcNAcol
-
-
Galp(beta1,6)GlcNAcOBn
-
-
Galp(beta1,6)GlcNAcol
-
-
Galp(beta1,6)[Galf(beta1,4)]GlcNAc
-
-
Galp(beta1,6)[Galf(beta1,4)]GlcNAcol
-
-
glyasperin C
-
20% inhibition at 0.2 mM
glyasperin D
-
20% inhibition at 0.2 mM
glycyrin
-
10% inhibition at 0.2 mM
glycyrol
-
strong inhibitory activity, noncompetitive inhibition
hinokiflavone-sialic acid
-
-
isoglycyrol
-
noncompetitive inhibition
isoliquiritigenin
-
strong inhibitory activity, noncompetitive inhibition
isoliquiritin
-
noncompetitive inhibition
isoliquiritin apioside
-
noncompetitive inhibition
kaempferol 3-O-beta-xylopyranosyl-(1->2)-beta-D-glucopyranoside
-
-
kumatakenin
-
noncompetitive inhibition
L-Cysteine hydrochloride
-
-
Li+
-
9% inhibition at 10 mM
licocoumarone
-
noncompetitive inhibition
licoflavonol
-
noncompetitive inhibition
licopyranocoumarin
-
10% inhibition at 0.2 mM
licorisoflavan A
-
30% inhibition at 0.2 mM
liquiritigenin
-
noncompetitive inhibition
liquiritin
-
noncompetitive inhibition
liquiritin apioside
-
noncompetitive inhibition
lung surfactant protein A
-
lung surfactant protein D has greater neuraminidase inhibitory activity than mannose-binding lectin, which in turn has greater activity than lung surfactant protein A
-
lung surfactant protein D
-
neuraminidase inhibition by lung surfactant protein D correlates with binding of its carbohydrate recognition domain to oligomannose oligosaccharides on the viral hemagglutinin. The effects of lung surfactant protein D are additive with oseltamivir. Neuraminidase inhibition is observed using fetuin or MDCK cells as a substrate, but not in assays using a soluble sialic acid analogue. Lung surfactant protein D has greater neuraminidase inhibitory activity than mannose-binding lectin, which in turn has greater activity than lung surfactant protein A
-
luteolin 7-O-beta-D-glucopyranoside
-
-
macluraxanthone
competitive
mannose-binding lectin
-
lung surfactant protein D has greater neuraminidase inhibitory activity than mannose-binding lectin, which in turn has greater activity than lung surfactant protein A
-
methyl 4-(acetylamino)-3,5-bis(guanidino)-2-ethoxybenzoate
-
-
methyl 4-(acetylamino)-3-amino-5-hydroxycyclopent-1-ene-1-carboxylate
-
-
methyl 4-(acetylamino)-5-amino-2-(3-methylbutoxy)benzoate
-
-
methyl thioglucoside derivatives of sialic acid
-
-
-
methyl [1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-carboxylate
-
28% inhibition at 1 mM
methyl [1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-carboxylate
-
30% inhibition at 1 mM
N-(4-nitrophenyl)-oxamic acid
N-acetyl-2,3-dehydro-2-deoxyneuraminic acid
-
-
N-acetylneuraminic acid
-
-
N-benzyl-N-methyl-1-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-methylamine
-
22% inhibition at 1 mM
N-benzyl-N-methyl-1-[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-methylamine
-
17% inhibition at 1 mM
Neu5Ac
-
i.e. alpha-D-N-acetylneuraminic acid, competitive, 17% inhibition at 2 mM, 20% inhibition at 5 mM with substrate 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid
ononin
-
30% inhibition at 0.2 mM
oseltamivir phosphate
i.e. Tamiflu
p-hydroxy oxamic acid
-
-
p-hydroxymercuribenzoate
-
0.001 mM, complete inhibition
p-hydroxyoxamic acid
-
competitive
p-nitrophenyloxamic acid
-
competitive
palmatine
-
reversible non-competitive inhibition
plant extract
-
extracts of Laminaria saccharina, Fucus vesiculosus, Achillea millefolium, Allium cepa and Hypericum perforatum decrease activity. Extracts of pollen and garlic powder (Allium sativum) produce maximum inhibitory effect, 2fold inhibition after preoral administration
-
pseudodehydrocorydaline
-
-
pterocarpin
-
noncompetitive
pyridoxal 5'-phosphate
-
65% inhibition at 1 mM
rhamnocitrin
-
i.e. 3,4',5-trihydroxy-7-methoxyflavone
S-(2,4-diaminobutyl)-dihydrogen phosphorothioate
-
identified by ensemble-based virtual screening
SDS
0.9% residual activity at 5 mM
sialyl-2en
-
inhibits competitively the hydrolysis of Neu5Gcalpha-(2-5)-O-glycolylNeu5Gc
[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-benzene
-
15% inhibition at 1 mM
[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-methanolO-(R/S)-epoxypropyl ether
-
27% inhibition at 1 mM
[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-phenylmethane
-
37% inhibition at 1 mM
[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-2-phenylethane
-
14% inhibition at 1 mM
[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-benzene
-
14% inhibition at 1 mM
[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-methanol
-
28% inhibition at 1 mM
[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-methanol O-(R/S)-epoxypropyl ether
-
25% inhibition at 1 mM
[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-N-phthalimidylmethane
-
11% inhibition at 1 mM
[1-(methyl 6-deoxy-beta-D-galactopyranos-yl)-1H-1,2,3-triazol-4-yl]-phenylmethane
-
29% inhibition at 1 mM
(2R,4S,5R)-5-[(1R,2R)-1-(acetylamino)-2-ethoxybut-3-en-1-yl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
-
-
(2R,4S,5R)-5-[(1R,2R)-1-(acetylamino)-2-ethoxybut-3-en-1-yl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
-
-
(2R,4S,5R)-5-[(1R,2R)-1-(acetylamino)-2-methoxybut-3-en-1-yl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
-
-
(2R,4S,5R)-5-[(1R,2R)-1-(acetylamino)-2-methoxybut-3-en-1-yl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
-
-
(2R,4S,5R)-5-[(1R,2R)-1-(acetylamino)-2-methoxypent-4-en-1-yl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
-
-
(2R,4S,5R)-5-[(1R,2R)-1-(acetylamino)-2-methoxypent-4-en-1-yl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
-
-
(2R,4S,5R)-5-[(1R,2S)-1-(acetylamino)-2-hydroxy-2-methylpentyl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
-
-
(2R,4S,5R)-5-[(1R,2S)-1-(acetylamino)-2-hydroxy-2-methylpentyl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
-
-
(2R,4S,5R)-5-[(1R,2S)-1-(acetylamino)-2-methoxy-2-methylpentyl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
-
i.e. A-315675
(2R,4S,5R)-5-[(1R,2S)-1-(acetylamino)-2-methoxy-2-methylpentyl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
-
i.e. A-315675
(2R,4S,5R)-5-[(1S,2S)-1-(acetylamino)-2-hydroxybut-3-en-1-yl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
-
-
(2R,4S,5R)-5-[(1S,2S)-1-(acetylamino)-2-hydroxybut-3-en-1-yl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
-
-
(2R,4S,5R)-5-[(1S,2S)-1-(acetylamino)-2-hydroxybutyl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
-
-
(2R,4S,5R)-5-[(1S,2S)-1-(acetylamino)-2-hydroxybutyl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
-
-
(2R,4S,5R)-5-[(2S)-1-(acetylamino)-2-hydroxypent-4-en-1-yl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
-
-
(2R,4S,5R)-5-[(2S)-1-(acetylamino)-2-hydroxypent-4-en-1-yl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
-
-
(2R,4S,5R)-5-[(2S)-1-(acetylamino)-2-hydroxypentyl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
-
-
(2R,4S,5R)-5-[(2S)-1-(acetylamino)-2-hydroxypentyl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
-
-
1,3,8-trihydroxy-6-methylanthracene-9,10-dione
-
-
1,3,8-trihydroxy-6-methylanthracene-9,10-dione
-
-
1,8-dihydroxyanthracene-9,10-dione
-
-
1,8-dihydroxyanthracene-9,10-dione
-
-
2,3-dehydro-2-deoxy-N-acetylneuraminic acid
-
treatment of cultured human aortic smooth muscle cells induces significant up-regulation in smooth muscle cell proliferation in response to fetal bovine serum
2,3-dehydro-2-deoxy-N-acetylneuraminic acid
-
-
2,3-dehydro-2-deoxy-N-acetylneuraminic acid
competitive inhibitor; competitive inhibitor
2,3-dehydro-2-deoxy-N-acetylneuraminic acid
-
-
2,3-dehydro-2-deoxy-N-acetylneuraminic acid
-
33% inhibition at 1 mM
2,3-dehydro-2-deoxy-N-acetylneuraminic acid
-
weak inhibitor
2,3-didehydroneuraminic acid
-
competitive
2,3-didehydroneuraminic acid
-
-
2,6-anhydro-9-azido-3,5,9-trideoxy-5-(2-hydroxyacetamido)-D-glycero-D-galacto-non-2-enonic acid
-
2,6-anhydro-9-azido-3,5,9-trideoxy-5-(2-hydroxyacetamido)-D-glycero-D-galacto-non-2-enonic acid
-
2,6-anhydro-9-azido-3,5,9-trideoxy-5-(2-hydroxyacetamido)-D-glycero-D-galacto-non-2-enonic acid
-
2,6-anhydro-9-azido-3,5,9-trideoxy-5-(2-hydroxyacetamido)-D-glycero-D-galacto-non-2-enonic acid
-
-
2,6-anhydro-9-azido-3,5,9-trideoxy-5-(2-hydroxyacetamido)-D-glycero-D-galacto-non-2-enonic acid
-
2,6-anhydro-9-azido-5-(2-azidoacetamido)-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
-
2,6-anhydro-9-azido-5-(2-azidoacetamido)-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
-
2,6-anhydro-9-azido-5-(2-azidoacetamido)-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
-
2,6-anhydro-9-azido-5-(2-azidoacetamido)-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
-
-
2,6-anhydro-9-azido-5-(2-azidoacetamido)-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
-
2-((E)-4'-hydroxyphenylidene)-4,6-dihydroxy-2,3-dihydrobenzofuran-3-one
-
-
2-((E)-4'-hydroxyphenylidene)-4,6-dihydroxy-2,3-dihydrobenzofuran-3-one
-
-
2-((E)-4'-hydroxyphenylidene)-6-hydroxy-2,3-dihydrobenzofuran-3-one
-
-
2-((E)-4'-hydroxyphenylidene)-6-hydroxy-2,3-dihydrobenzofuran-3-one
-
-
2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one
-
-
2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one
-
-
2-(3,4-dihydroxyphenyl)-4H-chromene-3,5,7-triol
-
-
2-(3,4-dihydroxyphenyl)-4H-chromene-3,5,7-triol
-
-
2-deoxy-2,3-dehydro-N-acetyl neuraminic acid
competitive inhibition
2-deoxy-2,3-dehydro-N-acetyl neuraminic acid
-
2-deoxy-2,3-dehydro-N-acetyl-D-neuraminic acid
-
-
2-deoxy-2,3-dehydro-N-acetyl-D-neuraminic acid
-
-
2-deoxy-2,3-dehydro-N-acetyl-D-neuraminic acid
-
-
2-deoxy-2,3-dehydro-N-acetyl-D-neuraminic acid
-
-
2-deoxy-2,3-dehydro-N-acetylneuraminic acid
-
2-deoxy-2,3-dehydro-N-acetylneuraminic acid
-
2-deoxy-2,3-dehydro-N-acetylneuraminic acid
-
2-deoxy-2,3-dehydro-N-acetylneuraminic acid
-
2-deoxy-2,3-dehydro-N-acetylneuraminic acid
-
2-deoxy-2,3-dehydro-N-acetylneuraminic acid
-
-
2-deoxy-2,3-dehydro-N-acetylneuraminic acid
-
inhibition occurs in the micromolar range
2-deoxy-2,3-dehydro-N-acetylneuraminic acid
-
-
2-deoxy-2,3-dehydro-N-acetylneuraminic acid
-
inhibition occurs in the micromolar range
2-deoxy-2,3-dehydro-N-acetylneuraminic acid
-
2-deoxy-2,3-dehydro-N-acetylneuraminic acid
-
-
2-deoxy-2,3-dehydro-N-acetylneuraminic acid
-
inhibition occurs in the micromolar range
2-deoxy-2,3-dehydro-N-acetylneuraminic acid
-
2-deoxy-2,3-dehydro-N-acetylneuraminic acid
-
inhibition occurs in the micromolar range
2-deoxy-2,3-didehydro-D-N-acetylneuraminic acid
-
induces morphological changes, showing megakaryocytic differentiation of K-562 cells, with expression of CD41b surface antigen
2-deoxy-2,3-didehydro-D-N-acetylneuraminic acid
-
-
2-Deoxy-2,3-didehydro-N-acetylneuraminic acid
-
-
2-Deoxy-2,3-didehydro-N-acetylneuraminic acid
-
-
2-Deoxy-2,3-didehydro-N-acetylneuraminic acid
-
-
2-Deoxy-2,3-didehydro-N-acetylneuraminic acid
-
-
2-Deoxy-2,3-didehydro-N-acetylneuraminic acid
-
-
2-Deoxy-2,3-didehydro-N-acetylneuraminic acid
-
-
2-Deoxy-2,3-didehydro-N-acetylneuraminic acid
-
-
2-Deoxy-2,3-didehydro-N-acetylneuraminic acid
-
-
2-Deoxy-2,3-didehydro-N-acetylneuraminic acid
-
-
2-Deoxy-2,3-didehydro-N-acetylneuraminic acid
-
-
2-Deoxy-2,3-didehydro-N-acetylneuraminic acid
-
-
2-Deoxy-2,3-didehydro-N-acetylneuraminic acid
-
i.e. NeuAc2,3en, competitive
2-Deoxy-2,3-didehydro-N-acetylneuraminic acid
-
-
2-Deoxy-2,3-didehydro-N-acetylneuraminic acid
-
-
3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one
-
-
3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one
-
-
3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
-
-
3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
-
-
4,5-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid
-
-
4,5-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid
-
-
4-hydroxymercuribenzoate
-
-
4-hydroxymercuribenzoate
-
cytosolic and intralysosomal sialidase, not membrane-associated sialidases I and II
5,6,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
-
-
5,6,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
-
-
5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one
-
-
5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one
-
-
5,7-dihydroxy-2-(2-hydroxyphenyl)-4H-chromen-4-one
-
-
5,7-dihydroxy-2-(2-hydroxyphenyl)-4H-chromen-4-one
-
-
5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
-
-
5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
-
-
5,7-dihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one
-
-
5,7-dihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one
-
-
5,7-dihydroxy-2-phenyl-4H-chromen-4-one
-
-
5,7-dihydroxy-2-phenyl-4H-chromen-4-one
-
-
5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one
-
-
5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one
-
-
5-acetamido-2,6-anhydro-3,5-dideoxy-9-O-methyl-D-glycero-D-galacto-non-2-enonic acid
-
5-acetamido-2,6-anhydro-3,5-dideoxy-9-O-methyl-D-glycero-D-galacto-non-2-enonic acid
-
5-acetamido-2,6-anhydro-3,5-dideoxy-9-O-methyl-D-glycero-D-galacto-non-2-enonic acid
-
5-acetamido-2,6-anhydro-3,5-dideoxy-9-O-methyl-D-glycero-D-galacto-non-2-enonic acid
-
-
5-acetamido-2,6-anhydro-3,5-dideoxy-9-O-methyl-D-glycero-D-galacto-non-2-enonic acid
-
5-acetamido-2,6-anhydro-9-azido-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
-
5-acetamido-2,6-anhydro-9-azido-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
-
5-acetamido-2,6-anhydro-9-azido-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
-
5-acetamido-2,6-anhydro-9-azido-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
-
-
5-acetamido-2,6-anhydro-9-azido-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
-
5-acetamido-9-aminopropyl-2,6-anhydro-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
-
5-acetamido-9-aminopropyl-2,6-anhydro-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
-
5-acetamido-9-aminopropyl-2,6-anhydro-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
-
5-acetamido-9-aminopropyl-2,6-anhydro-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
-
-
5-acetamido-9-aminopropyl-2,6-anhydro-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
-
5-hydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
-
-
5-hydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
-
-
5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-4H-chromen-4-one
-
-
5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-4H-chromen-4-one
-
-
5-methyl-4-methylidene-2-phenyl-4H-chromene
-
-
5-methyl-4-methylidene-2-phenyl-4H-chromene
-
-
6-chloro-9,10-dihydro-4,5,7-trihydroxy-9,10-dioxo-2-anthracenecarboxylic acid
-
-
6-chloro-9,10-dihydro-4,5,7-trihydroxy-9,10-dioxo-2-anthracenecarboxylic acid
-
strong inhibitor
7-hydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
-
-
7-hydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
-
-
9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid
-
-
9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid
-
-
A-315675
-
-
alpha-D-N-acetylneuraminic acid
-
-
alpha-D-N-acetylneuraminic acid
-
-
alpha-D-N-acetylneuraminic acid
-
-
apigenin
-
-
asteropine A
-
a conotoxin-like peptide from the marine sponge Asteropus simplex, competitive inhibition
-
asteropine A
-
a conotoxin-like peptide from the marine sponge Asteropus simplex, competitive inhibition
-
asteropine A
-
a conotoxin-like peptide from the marine sponge Asteropus simplex, competitive inhibition
-
Ca2+
Q5L868
-
Ca2+
-
90% residual activity at 10 mM
calopocarpin
-
noncompetitive inhibition
calopocarpin
-
noncompetitive inhibition
Co2+
-
isoforms Am0705 and Am2085 show complete inhibition at 2 mM Co2+, whereas isoforms Am0707 and Am1757 can maintain more than 60% of their enzymatic activities
cristacarpin
-
noncompetitive inhibition
cristacarpin
-
noncompetitive inhibition
Cu2+
-
complete inhibition at 2 mM
Cu2+
2.9% residual activity at 5 mM
Cu2+
-
30% residual activity at 5 mM
Cu2+
-
95% inhibition at 10 mM
Cu2+
-
cytosolic and intralysosomal sialidase, not membrane-associated sialidases I and II
Cu2+
-
about 40% residual activity at 1 mM
demethylmedicarpin
-
noncompetitive inhibition
demethylmedicarpin
-
noncompetitive inhibition
dinatin
-
-
dithiothreitol
-
-
EDTA
-
complete inhibition of isoforms Am0705, Am1757 and Am2085 at 2 mM. Isoform Am0707 retains 57.9% of its enzymatic activity after the addition of 2 mM EDTA
EDTA
-
20% inhibition at 1 mM, 54% at 10 mM
erystagallin A
-
noncompetitive inhibition
erystagallin A
-
noncompetitive inhibition
erysubin D
-
competitive inhibitor
erysubin D
-
competitive inhibitor
erysubin E
-
noncompetitive inhibition
erysubin E
-
noncompetitive inhibition
erythribyssin D
-
i.e. 3-hydroxy-[2',2'-(3'-hydroxy)-dimethylpyrano]-(5',6':10,9)-(6aR,11aR)pterocarpan
erythribyssin D
-
i.e. 3-hydroxy-[2',2'-(3'-hydroxy)-dimethylpyrano]-(5',6':10,9)-(6aR,11aR)pterocarpan
erythribyssin L
-
i.e. 9-hydroxy-10-prenyl-[2',2'-(3'-hydroxy)-dimethylpyrano]-(5',6':2,3)-(6aR,11aR)pterocarpan
erythribyssin L
-
i.e. 9-hydroxy-10-prenyl-[2',2'-(3'-hydroxy)-dimethylpyrano]-(5',6':2,3)-(6aR,11aR)pterocarpan
erythribyssin M
-
3-hydroxy-[2',2'-(3'-hydroxy)-dimethylpyrano]-(5',6':10,9)-(6aS,11aS)pterocarpan
erythribyssin M
-
3-hydroxy-[2',2'-(3'-hydroxy)-dimethylpyrano]-(5',6':10,9)-(6aS,11aS)pterocarpan
erythribyssin O
-
noncompetitive inhibition
erythribyssin O
-
noncompetitive inhibition
eryvarin D
-
noncompetitive inhibition
eryvarin D
-
noncompetitive inhibition
Fe2+
-
2 mM Fe2+ fully inactivates isoform Am2085
Fe2+
33.7% residual activity at 5 mM
Fe2+
-
about 10% residual activity at 1 mM
Fe3+
-
2 mM Fe3+ decreases the activity of isoforms Am1757 and Am0707 to 54.5% and 68.2%, respectively
Fe3+
-
56% residual activity at 10 mM
Hg2+
-
-
Hg2+
-
high concentrations, 50% inhibition at 5.2 mM
isoneorautenol
-
noncompetitive inhibition
isoneorautenol
-
noncompetitive inhibition
K+
Q5L868
-
laninamivir
-
-
luteolin
-
-
Mg2+
-
1 m Mg2+ reduces activities of isoforms Am0707 and Am2085 to 58.2% and 58.6%, respectively
Mn2+
Q5L868
-
Mn2+
-
28% inhibition at 10 mM
myricetin
-
-
N-(4-nitrophenyl)-oxamic acid
-
-
N-(4-nitrophenyl)-oxamic acid
-
-
N-bromosuccinimide
-
-
N-bromosuccinimide
-
strain L
N-bromosuccinimide
-
competitive
N-ethylmaleimide
-
-
N-ethylmaleimide
-
competitive
Na+
Q5L868
-
neorautenol
-
noncompetitive inhibition
neorautenol
-
noncompetitive inhibition
Neu5Ac2en
-
inhibits competitively the hydrolysis of KDNalpha-(2-8)-KDN
Neu5Ac2en
-
i.e. 2-deoxy-2,3-dehydro-alpha-D-N-acetylneuraminic acid, competitive, 49% inhibition at 0.1 mM, 75% inhibition at 0.5 mM with substrate 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid
NH4+
Q5L868
-
Ni2+
-
2 mM Ni2+ significantly decreases the activity of isoforms Am0705, Am0707 and Am1757 (44.3%, 28.5% and 5.3%, respectively) and fully inhibits isoform Am2085
oseltamivir
-
-
oseltamivir
-
the robust neuraminidase activity of the 2009H1N1 virus is responsible for the high sensitivity of the virus to oseltamivir
oseltamivir
-
molecular dynamics simulation study. In comparison with oseltamivir and zanamivir, peramivir shows strong direct ligand-enzyme hydrogen bonding, less space available in the N1 pocket, and it interacts tightly, via its OH group, with the D51 residue located in the 150-loop region
oseltamivir carboxylate
-
-
oseltamivir carboxylate
-
oseltamivir carboxylate
-
-
oseltamivir carboxylate
-
-
p-chloromercuribenzoate
-
18% residual activity at 10 mM
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
-
50% inhibition at 0.065 mM
peramivir
-
-
peramivir
-
molecular dynamics simulation study
phaseollin
-
competitive inhibitor
phaseollin
-
competitive inhibitor
quercetin
-
-
sophorapterocarpan A
-
noncompetitive inhibition
sophorapterocarpan A
-
noncompetitive inhibition
sulfuretin
-
-
sulfuretin
-
i.e. 2-(Z-3',4'-dihydroxyphenylidene)-6-hydroxy-2,3-dihydrobenzofuran-3-one
zanamivir
-
-
zanamivir
-
inhibition occurs in the nanomolar range
zanamivir
-
inhibition occurs in the millimolar range
zanamivir
-
inhibition occurs in the millimolar range
zanamivir
-
molecular dynamics simulation study
zanamivir
-
inhibition occurs in the millimolar range
Zn2+
-
complete inhibition at 2 mM
Zn2+
31.9% residual activity at 5 mM
Zn2+
-
61% residual activity at 10 mM
additional information
-
isoform Am0707is not inhibited by EDTA
-
additional information
EDTA does not cause a significant decrease in activity
-
additional information
-
EDTA does not cause a significant decrease in activity
-
additional information
-
EDTA has no significant effect on the enzyme activity
-
additional information
-
not inhibited by EDTA
-
additional information
-
a 95% (v/v) ethanol extract of Corydalis turtschaninovii rhizome shows neuraminidase inhibitory activity (68% at 0.03 mg/ml); not inhibited by corydaline and tetrahydrocoptisine
-
additional information
-
the motility of the organism is decreased in vivo in presence of 2,3-didehydroneuraminic acid and sialic acid containing compounds
-
additional information
-
no inhibition by EDTA
-
additional information
no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of isoform NEU1 at 1 mM; no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of NEU2 isoform at 1 mM; no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of NEU3 isoform at 1 mM; no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of NEU4 isoform at 1 mM
-
additional information
no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of isoform NEU1 at 1 mM; no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of NEU2 isoform at 1 mM; no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of NEU3 isoform at 1 mM; no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of NEU4 isoform at 1 mM
-
additional information
no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of isoform NEU1 at 1 mM; no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of NEU2 isoform at 1 mM; no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of NEU3 isoform at 1 mM; no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of NEU4 isoform at 1 mM
-
additional information
no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of isoform NEU1 at 1 mM; no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of NEU2 isoform at 1 mM; no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of NEU3 isoform at 1 mM; no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of NEU4 isoform at 1 mM
-
additional information
-
no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of isoform NEU1 at 1 mM; no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of NEU2 isoform at 1 mM; no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of NEU3 isoform at 1 mM; no inhibition by 4-acetamido-5-cyclopentanecarboxamido-2-fluoro benzoic acid of NEU4 isoform at 1 mM
-
additional information
-
design of a sialidase inhibitor selective against human NEU2, inhibitor docking using also the crystal structure of the enzyme, overview
-
additional information
-
no inhibition by asteropine A
-
additional information
-
construction of homologous and heterologous dimers and trimers and trimers of inhibitors such as oseltamivir(R)-CH2-(R)oseltamivir, oseltamivir(R)-O-zanamivir, oseltamivir(R)-CH2-2-deoxy-2,3-dehydro-N-acetylneuraminic acid and calculation of molecular properties and ligand efficiency values
-
additional information
-
design Influenza NA inhibitors that exhibit increased activity based on thiazolidine ring, evaluation of thiazolidine-4-carboxylic acid derivatives as Influenza neuraminidase inhibitors
-
additional information
-
inhibitory activity of triazole-containing carbocycles related to oseltamivir against virus-like particles containing the influenza virus neuraminidase-1 activity, overview
-
additional information
-
no inhibition by 5-amino sialic acid and sialic acid methyl ester
-
additional information
-
no inhibition by EDTA
-
additional information
-
not inhibited by 4-[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-butanoic acid and 4-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-bromobenzene
-
additional information
-
construction of octyl galactosides and octyl N-acetyl-lactosamines as trans-sialidase inhibitors, inhibitor screening of the beta-thiogalactopyranoside library, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.058
(2R,3R,4S)-3-(acetylamino)-2-[(1S,2S)-3-(acetylamino)-1,2-dihydroxypropyl]-4-hydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid
Homo sapiens
-
0.013
(2R,3R,4S)-3-(acetylamino)-2-[(1S,2S)-3-(benzoylamino)-1,2-dihydroxypropyl]-4-hydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid
Homo sapiens
-
0.032
(2R,3R,4S)-3-(acetylamino)-2-[(1S,2S)-3-(butyrylamino)-1,2-dihydroxypropyl]-4-hydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid
Homo sapiens
-
0.68
(2R,3R,4S)-3-(acetylamino)-2-[(1S,2S)-3-[(cyclopropylcarbonyl)amino]-1,2-dihydroxypropyl]-4-hydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid
Homo sapiens
-
0.12
(3E)-3-(1,3-benzothiazol-2-yl)-4-(2,5-dimethylphenyl)but-3-enoate
Trypanosoma cruzi
-
-
0.16
(3E)-3-(1,3-benzothiazol-2-yl)-4-(2-ethoxyphenyl)but-3-enoate
Trypanosoma cruzi
-
-
0.18
(3E)-3-(1,3-benzothiazol-2-yl)-4-(3,4-dimethoxyphenyl)but-3-enoate
Trypanosoma cruzi
-
-
0.12
(3E)-3-(1,3-benzothiazol-2-yl)-4-(3-fluorophenyl)but-3-enoate
Trypanosoma cruzi
-
-
0.15
(3E)-3-(1,3-benzothiazol-2-yl)-4-[2-(propan-2-yloxy)phenyl]but-3-enoate
Trypanosoma cruzi
-
-
0.15
(3E)-3-(1,3-benzothiazol-2-yl)-4-[2-methyl-5-(trifluoromethyl)phenyl]but-3-enoate
Trypanosoma cruzi
-
-
0.0181
(4R)-2-(2-carboxyphenyl)-1,3-thiazolidine-4-carboxylic acid
influenza A virus
-
pH and temperature not specified in the publication
0.0107
(4R)-2-(2-carboxyphenyl)-3-(chloroacetyl)-1,3-thiazolidine-4-carboxylic acid
influenza A virus
-
pH and temperature not specified in the publication
0.00192
(4R)-2-(2-carboxyphenyl)-3-(phenylacetyl)-1,3-thiazolidine-4-carboxylic acid
influenza A virus
-
pH and temperature not specified in the publication
0.00028
(4R)-2-(2-carboxyphenyl)-3-glycyl-1,3-thiazolidine-4-carboxylic acid
influenza A virus
-
pH and temperature not specified in the publication
0.0123
(4R)-2-(2-hydroxy-3-methoxyphenyl)-1,3-thiazolidine-4-carboxylic acid
influenza A virus
-
pH and temperature not specified in the publication
0.00162
(4R)-2-(2-hydroxy-3-methoxyphenyl)-3-(phenylacetyl)-1,3-thiazolidine-4-carboxylic acid
influenza A virus
-
pH and temperature not specified in the publication
0.0202
(4R)-2-(2-hydroxyphenyl)-1,3-thiazolidine-4-carboxylic acid
influenza A virus
-
pH and temperature not specified in the publication
0.00065
(4R)-2-(2-hydroxyphenyl)-3-(phenylacetyl)-1,3-thiazolidine-4-carboxylic acid
influenza A virus
-
pH and temperature not specified in the publication
0.0225
(4R)-2-(2-nitrophenyl)-1,3-thiazolidine-4-carboxylic acid
influenza A virus
-
pH and temperature not specified in the publication
0.00187
(4R)-2-(2-nitrophenyl)-3-(phenylacetyl)-1,3-thiazolidine-4-carboxylic acid
influenza A virus
-
pH and temperature not specified in the publication
0.0234
(4R)-2-(4-cyanophenyl)-1,3-thiazolidine-4-carboxylic acid
influenza A virus
-
pH and temperature not specified in the publication
0.00247
(4R)-2-(4-cyanophenyl)-3-(phenylacetyl)-1,3-thiazolidine-4-carboxylic acid
influenza A virus
-
pH and temperature not specified in the publication
0.00081
(4R)-2-(4-cyanophenyl)-3-glycyl-1,3-thiazolidine-4-carboxylic acid
influenza A virus
-
pH and temperature not specified in the publication
0.0431
(4R)-2-(furan-2-yl)-1,3-thiazolidine-4-carboxylic acid
influenza A virus
-
pH and temperature not specified in the publication
0.00289
(4R)-2-(furan-2-yl)-3-(phenylacetyl)-1,3-thiazolidine-4-carboxylic acid
influenza A virus
-
pH and temperature not specified in the publication
0.00098
(4R)-2-(furan-2-yl)-3-glycyl-1,3-thiazolidine-4-carboxylic acid
influenza A virus
-
pH and temperature not specified in the publication
0.0213
(4R)-2-phenyl-1,3-thiazolidine-4-carboxylic acid
influenza A virus
-
pH and temperature not specified in the publication
0.00121
(4R)-2-phenyl-3-(phenylacetyl)-1,3-thiazolidine-4-carboxylic acid
influenza A virus
-
pH and temperature not specified in the publication
0.00792
(4R)-3-(chloroacetyl)-2-(2-hydroxy-3-methoxyphenyl)-1,3-thiazolidine-4-carboxylic acid
influenza A virus
-
pH and temperature not specified in the publication
0.00584
(4R)-3-(chloroacetyl)-2-(2-hydroxyphenyl)-1,3-thiazolidine-4-carboxylic acid
influenza A virus
-
pH and temperature not specified in the publication
0.00765
(4R)-3-(chloroacetyl)-2-(2-nitrophenyl)-1,3-thiazolidine-4-carboxylic acid
influenza A virus
-
pH and temperature not specified in the publication
0.00864
(4R)-3-(chloroacetyl)-2-(4-cyanophenyl)-1,3-thiazolidine-4-carboxylic acid
influenza A virus
-
pH and temperature not specified in the publication
0.0129
(4R)-3-(chloroacetyl)-2-(furan-2-yl)-1,3-thiazolidine-4-carboxylic acid
influenza A virus
-
pH and temperature not specified in the publication
0.00753
(4R)-3-(chloroacetyl)-2-phenyl-1,3-thiazolidine-4-carboxylic acid
influenza A virus
-
pH and temperature not specified in the publication
0.00014
(4R)-3-glycyl-2-(2-hydroxy-3-methoxyphenyl)-1,3-thiazolidine-4-carboxylic acid
influenza A virus
-
pH and temperature not specified in the publication
0.00021
(4R)-3-glycyl-2-(2-hydroxyphenyl)-1,3-thiazolidine-4-carboxylic acid
influenza A virus
-
pH and temperature not specified in the publication
0.00102
(4R)-3-glycyl-2-(2-nitrophenyl)-1,3-thiazolidine-4-carboxylic acid
influenza A virus
-
pH and temperature not specified in the publication
0.00053
(4R)-3-glycyl-2-phenyl-1,3-thiazolidine-4-carboxylic acid
influenza A virus
-
pH and temperature not specified in the publication
0.0032
(6aS,12aS)-6a,12a-dihydro-6H-[1,3]dioxolo[5,6][1]benzofuro[3,2-c]chromen-3-ol
Clostridium perfringens
-
-
0.00008
1,3,6,7-tetrahydroxy-2-(3-methylbut-2-enyl)-8-(2-methylbut-3-en-2-yl)-9H-xanthen-9-one
Clostridium perfringens
pH 5.0, 37°C
0.11 - 0.76
1,3,8-trihydroxy-6-methylanthracene-9,10-dione
0.71 - 1
1,8-dihydroxyanthracene-9,10-dione
0.0243
2'-methoxy-isoliquiritigenin
unidentified influenza virus
-
-
0.2
2,3-dehydro-2-deoxy-N-acetylneuraminic acid
Streptococcus pneumoniae
-
-
0.034
2,6-anhydro-3,5-dideoxy-5-glycolylamido-D-glycero-D-galactonon-2-enonic acid
Homo sapiens
-
pH 5.5, 37°C
2.1
2,6-anhydro-3-deoxy-D-glycero-D-galacto-non-2-enonic acid
Homo sapiens
-
pH 5.5, 37°C
0.0083
2,6-anhydro-5-(2-azidoacetamido)-3,5-dideoxy-D-glycero-D-galacto-non-2-enonic acid
Homo sapiens
-
pH 5.5, 37°C
0.013 - 10
2,6-anhydro-9-azido-3,5,9-trideoxy-5-(2-hydroxyacetamido)-D-glycero-D-galacto-non-2-enonic acid
0.013 - 16
2,6-anhydro-9-azido-5-(2-azidoacetamido)-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
0.0000223 - 0.0000256
2-((E)-4'-hydroxyphenylidene)-4,6-dihydroxy-2,3-dihydrobenzofuran-3-one
0.000022 - 0.0000229
2-((E)-4'-hydroxyphenylidene)-6-hydroxy-2,3-dihydrobenzofuran-3-one
0.022 - 0.16
2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one
1
2-(3,4-dihydroxyphenyl)-4H-chromene-3,5,7-triol
0.21
2-([4,5-dimethyl-3-(propoxycarbonyl)thiophen-2-yl]carbamoyl)cyclohexanecarboxylate
Trypanosoma cruzi
-
-
0.0086 - 3.7
2-deoxy-2,3-dehydro-N-acetylneuraminic acid
0.039 - 0.13
3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one
0.11 - 0.23
3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
0.58
3-(acetylamino)-4-morpholin-4-ylbenzoic acid
Trypanosoma cruzi
-
-
0.7
3-amino-4-(benzylthio)benzoic acid
Trypanosoma cruzi
-
-
0.74
3-amino-4-(pyridin-3-ylamino)benzoic acid
Trypanosoma cruzi
-
-
1.2
3-amino-4-[(phenylacetyl)amino]benzoic acid
Trypanosoma cruzi
-
-
1
3-[(aminoacetyl)amino]-4-(benzylthio)benzoic acid
Trypanosoma cruzi
-
-
0.76
3-[(diaminomethylene)amino]-4-[(methylamino)carbonyl]benzoic acid
Trypanosoma cruzi
-
-
0.014 - 0.13
4,5-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid
0.000032
4-(acetylamino)-3,5-bis(guanidino)-2-ethoxybenzoic acid
influenza A virus
-
pH 3.5, 37°C
0.54
4-(acetylamino)-3-(hydroxymethyl)benzoic acid
Trypanosoma cruzi
-
-
0.000041
4-(acetylamino)-5-(guanidino)-2-(cyclopentyloxy)benzoic acid
influenza A virus
-
pH 3.5, 37°C
0.00004
4-(acetylamino)-5-(guanidino)-2-butoxybenzoic acid
influenza A virus
-
pH 3.5, 37°C
0.000049
4-(acetylamino)-5-(guanidino)-2-isopropoxybenzoic acid
influenza A virus
-
pH 3.5, 37°C
0.552 - 5
4-acetamido-5-(biphenyl-4-ylcarboxamido)-2-fluorobenzoic acid
0.05 - 0.055
5,6,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
0.1 - 0.13
5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one
0.07 - 0.36
5,7-dihydroxy-2-(2-hydroxyphenyl)-4H-chromen-4-one
0.078 - 0.57
5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
1
5,7-dihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one
0.34 - 0.89
5,7-dihydroxy-2-phenyl-4H-chromen-4-one
0.23 - 0.38
5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one
0.01
5-(acetylamino)-2,6-anhydro-3,5,9-trideoxy-9-(pentanoylamino)-L-glycero-L-altro-non-2-enonic acid
Homo sapiens
-
0.565
5-(acetylamino)-2,6-anhydro-3,5,9-trideoxy-9-[(3-methylbutanoyl)amino]-L-glycero-L-altro-non-2-enonic acid
Homo sapiens
-
0.135
5-(acetylamino)-2,6-anhydro-9-[(cyclopentylcarbonyl)amino]-3,5,9-trideoxy-L-glycero-L-altro-non-2-enonic acid
Homo sapiens
-
0.44
5-(acetylamino)-6-aminopyridine-2-carboxylic acid
Trypanosoma cruzi
-
-
0.54
5-(ethanethioylamino)pyridine-2-carboxylic acid
Trypanosoma cruzi
-
-
0.013 - 3
5-acetamido-2,6-anhydro-3,5-dideoxy-9-O-methyl-D-glycero-D-galacto-non-2-enonic acid
0.018
5-acetamido-2,6-anhydro-3,5-dideoxy-D-glycero-D-galactonon-2-enonic acid
Homo sapiens
-
pH 5.5, 37°C
0.0087 - 3.3
5-acetamido-2,6-anhydro-9-azido-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
1 - 10
5-acetamido-9-aminopropyl-2,6-anhydro-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
1
5-hydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
0.14 - 1
5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-4H-chromen-4-one
1
5-methyl-4-methylidene-2-phenyl-4H-chromene
0.00058
6-chloro-9,10-dihydro-4,5,7-trihydroxy-9,10-dioxo-2-anthracenecarboxylate
Trypanosoma cruzi
-
in 50 mM Tris-HCl pH7.5, at 25°C
0.1
6-chloro-9,10-dihydro-4,5,7-trihydroxy-9,10-dioxo-2-anthracenecarboxylic acid
Homo sapiens
-
IC50 above 0.1 mM, in 50 mM Tris-HCl pH 7.5, at 25°C
0.47 - 1
7-hydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
0.43 - 0.8
9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid
0.0000012
A-315675
Influenza A virus (A/Brisbane/59/2007(H1N1))
-
-
0.0000289 - 0.0000457
apigenin
0.0135
Berberine
Clostridium perfringens
-
in 50 mM sodium acetate buffer (pH 5.0), at 22°C
0.00157 - 0.00755
calopocarpin
0.0251
coptisine
Clostridium perfringens
-
in 50 mM sodium acetate buffer (pH 5.0), at 22°C
0.00228 - 0.02203
cristacarpin
0.000245
cudratricusxanthone
Clostridium perfringens
pH 5.0, 37°C
0.000228
cudraxanthone L
Clostridium perfringens
pH 5.0, 37°C
0.000186
cudraxanthone M
Clostridium perfringens
pH 5.0, 37°C
0.006
curcumin
Clostridium perfringens
-
in 50 mM sodium acetate buffer (pH 5.0), at 22°C
0.0413
dehydrocorybulbine
Clostridium perfringens
-
in 50 mM sodium acetate buffer (pH 5.0), at 22°C
0.00639 - 0.02954
demethylmedicarpin
0.000026 - 0.0000463
dinatin
0.00204 - 0.02774
erystagallin A
0.0013 - 0.01948
erysubin E
0.0462 - 0.0771
erythribyssin D
0.00279 - 0.02714
erythribyssin L
0.07773 - 0.2054
erythribyssin M
0.00035 - 0.00132
erythribyssin O
0.00209 - 0.0033
eryvarin D
4.43
Galp(beta1,2)Galf(beta1,4)GlcNAc
Trypanosoma cruzi
-
-
0.85
Galp(beta1,2)Galf(beta1,4)GlcNAcOBn
Trypanosoma cruzi
-
-
1.67
Galp(beta1,2)Galf(beta1,4)GlcNAcol
Trypanosoma cruzi
-
-
0.86
Galp(beta1,2)[Galp(beta1,3)]Gal
Trypanosoma cruzi
-
-
1.13
Galp(beta1,2)[Galp(beta1,3)]GalOBn
Trypanosoma cruzi
-
-
0.93
Galp(beta1,2)[Galp(beta1,3)]Galol
Trypanosoma cruzi
-
-
0.85
Galp(beta1,2)[Galp(beta1,3)]Galp(beta1,6)[Galf(beta1,4)]GlcNAc
Trypanosoma cruzi
-
-
0.7
Galp(beta1,2)[Galp(beta1,3)]Galp(beta1,6)[Galf(beta1,4)]GlcNAcOBn
Trypanosoma cruzi
-
-
0.61
Galp(beta1,2)[Galp(beta1,3)]Galp(beta1,6)[Galf(beta1,4)]GlcNAcol
Trypanosoma cruzi
-
-
0.76
Galp(beta1,3)Galp(beta1,6)[Galf(beta1,4)]GlcNAc
Trypanosoma cruzi
-
-
1.14
Galp(beta1,3)Galp(beta1,6)[Galf(beta1,4)]GlcNAcOBn
Trypanosoma cruzi
-
-
1.26
Galp(beta1,3)Galp(beta1,6)[Galf(beta1,4)]GlcNAcol
Trypanosoma cruzi
-
-
2.22
Galp(beta1,6)GlcNAc
Trypanosoma cruzi
-
-
1.11
Galp(beta1,6)GlcNAcOBn
Trypanosoma cruzi
-
-
0.98
Galp(beta1,6)GlcNAcol
Trypanosoma cruzi
-
-
0.86 - 1.33
Galp(beta1,6)[Galf(beta1,4)]GlcNAc
0.94
Galp(beta1,6)[Galf(beta1,4)]GlcNAcol
Trypanosoma cruzi
-
-
0.0969
glaucine
Clostridium perfringens
-
in 50 mM sodium acetate buffer (pH 5.0), at 22°C
0.0031
glycyrol
unidentified influenza virus
-
-
0.0924
isoglycyrol
unidentified influenza virus
-
-
0.009
isoliquiritigenin
unidentified influenza virus
-
-
0.124
isoliquiritin
unidentified influenza virus
-
-
0.0129
isoliquiritin apioside
unidentified influenza virus
-
-
0.01412 - 0.06475
isoneorautenol
0.037
Jatrorrhizine
Clostridium perfringens
-
in 50 mM sodium acetate buffer (pH 5.0), at 22°C
0.0364
kumatakenin
unidentified influenza virus
-
-
0.00000311 - 0.00804
laninamivir
0.0278
licocoumarone
unidentified influenza virus
-
-
0.0206
licoflavonol
unidentified influenza virus
-
-
0.0468
liquiritigenin
unidentified influenza virus
-
-
0.0823
liquiritin
unidentified influenza virus
-
-
0.0182
liquiritin apioside
unidentified influenza virus
-
-
0.0000326 - 0.0000533
luteolin
0.000186
macluraxanthone
Clostridium perfringens
pH 5.0, 37°C
0.000036
methyl 4-(acetylamino)-3,5-bis(guanidino)-2-ethoxybenzoate
influenza A virus
-
pH 3.5, 37°C
0.000038
methyl 4-(acetylamino)-5-amino-2-(3-methylbutoxy)benzoate
influenza A virus
-
pH 3.5, 37°C
0.0189
N-acetyl-2,3-dehydro-2-deoxyneuraminic acid
Clostridium perfringens
-
at pH 7.2 and 37°C
0.6
N-acetylneuraminic acid
Streptococcus pneumoniae
-
-
0.01982 - 0.05311
neorautenol
0.0000000032 - 0.14252
oseltamivir
0.0000003 - 0.003367
oseltamivir carboxylate
0.0128
palmatine
Clostridium perfringens
-
in 50 mM sodium acetate buffer (pH 5.0), at 22°C
0.0000003 - 0.0344
peramivir
0.0314 - 0.03355
phaseollin
0.0652
pseudocoptisine
Clostridium perfringens
-
in 50 mM sodium acetate buffer (pH 5.0), at 22°C
0.0326
pseudodehydrocorydaline
Clostridium perfringens
-
in 50 mM sodium acetate buffer (pH 5.0), at 22°C
0.0014
pterocarpin
Clostridium perfringens
-
-
0.02534
quercetin
Clostridium perfringens
-
-
0.0422
siastatin B
Clostridium perfringens
-
at pH 7.2 and 37°C
0.00201 - 0.01159
sophorapterocarpan A
0.0000277 - 0.0000512
sulfuretin
0.0000005 - 0.03936
zanamivir
0.11
1,3,8-trihydroxy-6-methylanthracene-9,10-dione
Trypanosoma cruzi
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.76
1,3,8-trihydroxy-6-methylanthracene-9,10-dione
Homo sapiens
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.71
1,8-dihydroxyanthracene-9,10-dione
Trypanosoma cruzi
-
in 50 mM Tris-HCl pH 7.5, at 25°C
1
1,8-dihydroxyanthracene-9,10-dione
Homo sapiens
-
IC50 above 1.0 mM, in 50 mM Tris-HCl pH 7.5, at 25°C
0.013
2,6-anhydro-9-azido-3,5,9-trideoxy-5-(2-hydroxyacetamido)-D-glycero-D-galacto-non-2-enonic acid
Vibrio cholerae
with Neu5Acalpha(2->6)Galbeta4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.018
2,6-anhydro-9-azido-3,5,9-trideoxy-5-(2-hydroxyacetamido)-D-glycero-D-galacto-non-2-enonic acid
Vibrio cholerae
with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.15
2,6-anhydro-9-azido-3,5,9-trideoxy-5-(2-hydroxyacetamido)-D-glycero-D-galacto-non-2-enonic acid
Homo sapiens
with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.19
2,6-anhydro-9-azido-3,5,9-trideoxy-5-(2-hydroxyacetamido)-D-glycero-D-galacto-non-2-enonic acid
Homo sapiens
with Neu5Acalpha(2->6)Galbeta4-nitrophenyl as substrate, at pH 5.0 and 37°C
1.4
2,6-anhydro-9-azido-3,5,9-trideoxy-5-(2-hydroxyacetamido)-D-glycero-D-galacto-non-2-enonic acid
Clostridium perfringens
with Neu5Acalpha(2->6)Galbeta4-nitrophenyl as substrate, at pH 5.0 and 37°C
1.9
2,6-anhydro-9-azido-3,5,9-trideoxy-5-(2-hydroxyacetamido)-D-glycero-D-galacto-non-2-enonic acid
Clostridium perfringens
with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
10
2,6-anhydro-9-azido-3,5,9-trideoxy-5-(2-hydroxyacetamido)-D-glycero-D-galacto-non-2-enonic acid
Streptococcus pneumoniae
-
IC50 above 10 mM, with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
10
2,6-anhydro-9-azido-3,5,9-trideoxy-5-(2-hydroxyacetamido)-D-glycero-D-galacto-non-2-enonic acid
Salmonella enterica subsp. enterica serovar Typhimurium
IC50 above 10 mM, with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.013
2,6-anhydro-9-azido-5-(2-azidoacetamido)-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
Homo sapiens
with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.013
2,6-anhydro-9-azido-5-(2-azidoacetamido)-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
Homo sapiens
with Neu5Acalpha(2->6)Galbeta4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.014
2,6-anhydro-9-azido-5-(2-azidoacetamido)-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
Vibrio cholerae
with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.11
2,6-anhydro-9-azido-5-(2-azidoacetamido)-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
Vibrio cholerae
with Neu5Acalpha(2->6)Galbeta4-nitrophenyl as substrate, at pH 5.0 and 37°C
1
2,6-anhydro-9-azido-5-(2-azidoacetamido)-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
Streptococcus pneumoniae
-
IC50 above 1.0 mM, with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
1.2
2,6-anhydro-9-azido-5-(2-azidoacetamido)-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
Clostridium perfringens
with Neu5Acalpha(2->6)Galbeta4-nitrophenyl as substrate, at pH 5.0 and 37°C
1.6
2,6-anhydro-9-azido-5-(2-azidoacetamido)-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
Clostridium perfringens
with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
16
2,6-anhydro-9-azido-5-(2-azidoacetamido)-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
Salmonella enterica subsp. enterica serovar Typhimurium
with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.0000223
2-((E)-4'-hydroxyphenylidene)-4,6-dihydroxy-2,3-dihydrobenzofuran-3-one
influenza A virus
-
pH 6.5, 37°C
0.0000254
2-((E)-4'-hydroxyphenylidene)-4,6-dihydroxy-2,3-dihydrobenzofuran-3-one
influenza B virus
-
pH 6.5, 37°C
0.0000256
2-((E)-4'-hydroxyphenylidene)-4,6-dihydroxy-2,3-dihydrobenzofuran-3-one
influenza A virus
-
pH 6.5, 37°C
0.000022
2-((E)-4'-hydroxyphenylidene)-6-hydroxy-2,3-dihydrobenzofuran-3-one
influenza A virus
-
pH 6.5, 37°C
0.0000221
2-((E)-4'-hydroxyphenylidene)-6-hydroxy-2,3-dihydrobenzofuran-3-one
influenza A virus
-
pH 6.5, 37°C
0.0000229
2-((E)-4'-hydroxyphenylidene)-6-hydroxy-2,3-dihydrobenzofuran-3-one
influenza B virus
-
pH 6.5, 37°C
0.022
2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one
Trypanosoma cruzi
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.058
2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one
Trypanosoma cruzi
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.13
2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one
Homo sapiens
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.16
2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one
Homo sapiens
-
in 50 mM Tris-HCl pH 7.5, at 25°C
1
2-(3,4-dihydroxyphenyl)-4H-chromene-3,5,7-triol
Homo sapiens
-
IC50 above 1.0 mM, in 50 mM Tris-HCl pH 7.5, at 25°C
1
2-(3,4-dihydroxyphenyl)-4H-chromene-3,5,7-triol
Trypanosoma cruzi
-
IC50 above 1.0 mM, in 50 mM Tris-HCl pH 7.5, at 25°C
0.0086
2-deoxy-2,3-dehydro-N-acetylneuraminic acid
Vibrio cholerae
with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.01
2-deoxy-2,3-dehydro-N-acetylneuraminic acid
Vibrio cholerae
with Neu5Acalpha(2->6)Galbeta4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.013
2-deoxy-2,3-dehydro-N-acetylneuraminic acid
Clostridium perfringens
with Neu5Acalpha(2->6)Galbeta4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.018
2-deoxy-2,3-dehydro-N-acetylneuraminic acid
Homo sapiens
with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.02
2-deoxy-2,3-dehydro-N-acetylneuraminic acid
Clostridium perfringens
with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.02
2-deoxy-2,3-dehydro-N-acetylneuraminic acid
Salmonella enterica subsp. enterica serovar Typhimurium
with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.032
2-deoxy-2,3-dehydro-N-acetylneuraminic acid
Homo sapiens
with Neu5Acalpha(2->6)Galbeta4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.143
2-deoxy-2,3-dehydro-N-acetylneuraminic acid
Homo sapiens
-
3.7
2-deoxy-2,3-dehydro-N-acetylneuraminic acid
Streptococcus pneumoniae
-
with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.039
3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one
Trypanosoma cruzi
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.13
3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one
Homo sapiens
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.11
3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
Trypanosoma cruzi
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.23
3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
Homo sapiens
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.014
4,5-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid
Trypanosoma cruzi
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.13
4,5-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid
Homo sapiens
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.552
4-acetamido-5-(biphenyl-4-ylcarboxamido)-2-fluorobenzoic acid
Homo sapiens
isoform NEU2
5
4-acetamido-5-(biphenyl-4-ylcarboxamido)-2-fluorobenzoic acid
Homo sapiens
IC50 above 5 mM, isoform NEU3
5
4-acetamido-5-(biphenyl-4-ylcarboxamido)-2-fluorobenzoic acid
Homo sapiens
IC50 above 5 mM, isoform NEU4
0.05
5,6,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
Trypanosoma cruzi
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.055
5,6,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
Homo sapiens
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.1
5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one
Trypanosoma cruzi
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.13
5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one
Homo sapiens
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.07
5,7-dihydroxy-2-(2-hydroxyphenyl)-4H-chromen-4-one
Homo sapiens
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.36
5,7-dihydroxy-2-(2-hydroxyphenyl)-4H-chromen-4-one
Trypanosoma cruzi
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.078
5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
Trypanosoma cruzi
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.57
5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
Homo sapiens
-
in 50 mM Tris-HCl pH 7.5, at 25°C
1
5,7-dihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one
Homo sapiens
-
IC50 above 1.0 mM, in 50 mM Tris-HCl pH 7.5, at 25°C
1
5,7-dihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one
Trypanosoma cruzi
-
IC50 above 1.0 mM, in 50 mM Tris-HCl pH 7.5, at 25°C
0.34
5,7-dihydroxy-2-phenyl-4H-chromen-4-one
Trypanosoma cruzi
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.89
5,7-dihydroxy-2-phenyl-4H-chromen-4-one
Homo sapiens
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.23
5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one
Trypanosoma cruzi
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.38
5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one
Homo sapiens
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.013
5-acetamido-2,6-anhydro-3,5-dideoxy-9-O-methyl-D-glycero-D-galacto-non-2-enonic acid
Vibrio cholerae
with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.013
5-acetamido-2,6-anhydro-3,5-dideoxy-9-O-methyl-D-glycero-D-galacto-non-2-enonic acid
Salmonella enterica subsp. enterica serovar Typhimurium
with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.041
5-acetamido-2,6-anhydro-3,5-dideoxy-9-O-methyl-D-glycero-D-galacto-non-2-enonic acid
Homo sapiens
with Neu5Acalpha(2->6)Galbeta4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.12
5-acetamido-2,6-anhydro-3,5-dideoxy-9-O-methyl-D-glycero-D-galacto-non-2-enonic acid
Vibrio cholerae
with Neu5Acalpha(2->6)Galbeta4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.31
5-acetamido-2,6-anhydro-3,5-dideoxy-9-O-methyl-D-glycero-D-galacto-non-2-enonic acid
Clostridium perfringens
with Neu5Acalpha(2->6)Galbeta4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.46
5-acetamido-2,6-anhydro-3,5-dideoxy-9-O-methyl-D-glycero-D-galacto-non-2-enonic acid
Clostridium perfringens
with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
1.1
5-acetamido-2,6-anhydro-3,5-dideoxy-9-O-methyl-D-glycero-D-galacto-non-2-enonic acid
Homo sapiens
with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
3
5-acetamido-2,6-anhydro-3,5-dideoxy-9-O-methyl-D-glycero-D-galacto-non-2-enonic acid
Streptococcus pneumoniae
-
with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.0087
5-acetamido-2,6-anhydro-9-azido-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
Vibrio cholerae
with Neu5Acalpha(2->6)Galbeta4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.02
5-acetamido-2,6-anhydro-9-azido-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
Vibrio cholerae
with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.021
5-acetamido-2,6-anhydro-9-azido-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
Salmonella enterica subsp. enterica serovar Typhimurium
with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.031
5-acetamido-2,6-anhydro-9-azido-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
Homo sapiens
with Neu5Acalpha(2->6)Galbeta4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.04
5-acetamido-2,6-anhydro-9-azido-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
Clostridium perfringens
with Neu5Acalpha(2->6)Galbeta4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.043
5-acetamido-2,6-anhydro-9-azido-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
Homo sapiens
with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
0.059
5-acetamido-2,6-anhydro-9-azido-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
Clostridium perfringens
with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
3.3
5-acetamido-2,6-anhydro-9-azido-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
Streptococcus pneumoniae
-
with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
1
5-acetamido-9-aminopropyl-2,6-anhydro-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
Clostridium perfringens
IC50 above 1.0 mM, with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
1
5-acetamido-9-aminopropyl-2,6-anhydro-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
Vibrio cholerae
IC50 above 1.0 mM, with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
1
5-acetamido-9-aminopropyl-2,6-anhydro-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
Clostridium perfringens
IC50 above 1.0 mM, with Neu5Acalpha(2->6)Galbeta4-nitrophenyl as substrate, at pH 5.0 and 37°C
1
5-acetamido-9-aminopropyl-2,6-anhydro-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
Vibrio cholerae
IC50 above 1.0 mM, with Neu5Acalpha(2->6)Galbeta4-nitrophenyl as substrate, at pH 5.0 and 37°C
2.3
5-acetamido-9-aminopropyl-2,6-anhydro-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
Salmonella enterica subsp. enterica serovar Typhimurium
with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
2.4
5-acetamido-9-aminopropyl-2,6-anhydro-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
Homo sapiens
with Neu5Acalpha(2->6)Galbeta4-nitrophenyl as substrate, at pH 5.0 and 37°C
5.4
5-acetamido-9-aminopropyl-2,6-anhydro-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
Streptococcus pneumoniae
-
with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
10
5-acetamido-9-aminopropyl-2,6-anhydro-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
Homo sapiens
IC50 above 10 mM, with Neu5Acalpha(2->3)Galbeta-4-nitrophenyl as substrate, at pH 5.0 and 37°C
1
5-hydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
Homo sapiens
-
IC50 above 1.0 mM, in 50 mM Tris-HCl pH 7.5, at 25°C
1
5-hydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
Trypanosoma cruzi
-
IC50 above 1.0 mM, in 50 mM Tris-HCl pH 7.5, at 25°C
0.14
5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-4H-chromen-4-one
Trypanosoma cruzi
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.89
5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-4H-chromen-4-one
Homo sapiens
-
in 50 mM Tris-HCl pH 7.5, at 25°C
1
5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-4H-chromen-4-one
Homo sapiens
-
IC50 above 1.0 mM, in 50 mM Tris-HCl pH 7.5, at 25°C
1
5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-4H-chromen-4-one
Trypanosoma cruzi
-
IC50 above 1.0 mM, in 50 mM Tris-HCl pH 7.5, at 25°C
1
5-methyl-4-methylidene-2-phenyl-4H-chromene
Homo sapiens
-
IC50 above 1.0 mM, in 50 mM Tris-HCl pH 7.5, at 25°C
1
5-methyl-4-methylidene-2-phenyl-4H-chromene
Trypanosoma cruzi
-
IC50 above 1.0 mM, in 50 mM Tris-HCl pH 7.5, at 25°C
0.47
7-hydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
Homo sapiens
-
in 50 mM Tris-HCl pH 7.5, at 25°C
1
7-hydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
Trypanosoma cruzi
-
IC50 above 1.0 mM, in 50 mM Tris-HCl pH 7.5, at 25°C
0.43
9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid
Trypanosoma cruzi
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.8
9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid
Homo sapiens
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.0000289
apigenin
influenza A virus
-
pH 6.5, 37°C
0.0000316
apigenin
influenza A virus
-
pH 6.5, 37°C
0.0000457
apigenin
influenza B virus
-
pH 6.5, 37°C
0.00157
calopocarpin
Clostridium perfringens
-
-
0.00755
calopocarpin
Vibrio cholerae serotype O1
-
-
0.00228
cristacarpin
Clostridium perfringens
-
-
0.02203
cristacarpin
Vibrio cholerae serotype O1
-
-
0.00639
demethylmedicarpin
Clostridium perfringens
-
-
0.02954
demethylmedicarpin
Vibrio cholerae serotype O1
-
-
0.000026
dinatin
influenza A virus
-
pH 6.5, 37°C
0.0000332
dinatin
influenza B virus
-
pH 6.5, 37°C
0.0000463
dinatin
influenza A virus
-
pH 6.5, 37°C
0.00204
erystagallin A
Clostridium perfringens
-
-
0.02774
erystagallin A
Vibrio cholerae serotype O1
-
-
0.02639
erysubin D
Clostridium perfringens
-
-
0.02639
erysubin D
Vibrio cholerae serotype O1
-
-
0.0013
erysubin E
Clostridium perfringens
-
-
0.01948
erysubin E
Vibrio cholerae serotype O1
-
-
0.0462
erythribyssin D
Vibrio cholerae serotype O1
-
-
0.0771
erythribyssin D
Clostridium perfringens
-
-
0.00279
erythribyssin L
Clostridium perfringens
-
-
0.02714
erythribyssin L
Vibrio cholerae serotype O1
-
-
0.07773
erythribyssin M
Vibrio cholerae serotype O1
-
-
0.2054
erythribyssin M
Clostridium perfringens
-
-
0.00035
erythribyssin O
Vibrio cholerae serotype O1
-
-
0.00132
erythribyssin O
Clostridium perfringens
-
-
0.00209
eryvarin D
Clostridium perfringens
-
-
0.0033
eryvarin D
Vibrio cholerae serotype O1
-
-
0.86
Galp(beta1,6)[Galf(beta1,4)]GlcNAc
Trypanosoma cruzi
-
-
1.33
Galp(beta1,6)[Galf(beta1,4)]GlcNAc
Trypanosoma cruzi
-
-
0.01412
isoneorautenol
Clostridium perfringens
-
-
0.06475
isoneorautenol
Vibrio cholerae serotype O1
-
-
0.00000311
laninamivir
influenza B virus
-
wild type enzyme, strain B/Kochi/60/2011, pH and temperature not specified in the publication
0.00000419
laninamivir
influenza B virus
-
wild type enzyme, strain B/Kochi/41/2011, pH and temperature not specified in the publication
0.00000468
laninamivir
influenza B virus
-
wild type enzyme, strain B/Kochi/59/2011, pH and temperature not specified in the publication
0.00001161
laninamivir
influenza B virus
-
mutant enzyme P139S, strain B/Kochi/41/2011, pH and temperature not specified in the publication
0.00001343
laninamivir
influenza B virus
-
mutant enzyme Q138R, strain B/Kochi/60/2011, pH and temperature not specified in the publication
0.00001747
laninamivir
influenza B virus
-
mutant enzyme G140R, strain B/Kochi/59/2011, pH and temperature not specified in the publication
0.00036
laninamivir
unidentified influenza virus
-
wild type enzyme, at 37°C, pH not specified in the publication
0.0009
laninamivir
unidentified influenza virus
-
mutant enzyme V94I, at 37°C, pH not specified in the publication
0.00181
laninamivir
unidentified influenza virus
-
mutant enzyme R152K, at 37°C, pH not specified in the publication
0.00649
laninamivir
unidentified influenza virus
-
mutant enzyme R152K/V94I, at 37°C, pH not specified in the publication
0.00804
laninamivir
unidentified influenza virus
-
mutant enzyme R368K, at 37°C, pH not specified in the publication
0.0000326
luteolin
influenza A virus
-
pH 6.5, 37°C
0.0000337
luteolin
influenza A virus
-
pH 6.5, 37°C
0.0000533
luteolin
influenza B virus
-
pH 6.5, 37°C
0.017
myricetin
Trypanosoma cruzi
-
in 50 mM Tris-HCl pH7.5, at 25°C
0.15
myricetin
Homo sapiens
-
in 50 mM Tris-HCl pH 7.5, at 25°C
0.01982
neorautenol
Clostridium perfringens
-
-
0.05311
neorautenol
Vibrio cholerae serotype O1
-
-
0.0000000032
oseltamivir
influenza A virus
-
pH 6.5, 37°C
0.000000015
oseltamivir
influenza A virus
-
pH 6.5, 37°C
0.000000217
oseltamivir
influenza B virus
-
pH 6.5, 37°C
0.000021
oseltamivir
influenza A virus
-
-
0.0004
oseltamivir
Influenza A virus (A/Brisbane/59/2007(H1N1))
-
IC50 above 0.0004 mM
0.00142
oseltamivir
unidentified influenza virus
-
mutant enzyme V94I, at 37°C, pH not specified in the publication
0.00148
oseltamivir
unidentified influenza virus
-
wild type enzyme, at 37°C, pH not specified in the publication
0.07812
oseltamivir
unidentified influenza virus
-
mutant enzyme R152K/V94I, at 37°C, pH not specified in the publication
0.10048
oseltamivir
unidentified influenza virus
-
mutant enzyme R368K, at 37°C, pH not specified in the publication
0.14252
oseltamivir
unidentified influenza virus
-
mutant enzyme R152K, at 37°C, pH not specified in the publication
0.0000003
oseltamivir carboxylate
influenza A virus
mutant enzyme R292K, pH and temperature not specified in the publication
0.0000007
oseltamivir carboxylate
influenza A virus
wild type enzyme, pH and temperature not specified in the publication
0.0000007
oseltamivir carboxylate
influenza A virus
mutant enzyme E119G, pH and temperature not specified in the publication
0.0000022
oseltamivir carboxylate
influenza A virus
wild type enzyme, pH and temperature not specified in the publication
0.00000228
oseltamivir carboxylate
influenza B virus
-
mutant enzyme Q138R, strain B/Kochi/60/2011, pH and temperature not specified in the publication
0.0000026
oseltamivir carboxylate
influenza B virus
-
wild type enzyme, strain B/Kochi/60/2011, pH and temperature not specified in the publication
0.0000029
oseltamivir carboxylate
influenza A virus
mutant enzyme D198N, pH and temperature not specified in the publication
0.0000039
oseltamivir carboxylate
influenza B virus
-
wild type enzyme, strain B/Kochi/59/2011, pH and temperature not specified in the publication
0.00000498
oseltamivir carboxylate
influenza B virus
-
wild type enzyme, strain B/Kochi/41/2011, pH and temperature not specified in the publication
0.0000054
oseltamivir carboxylate
influenza A virus
mutant enzyme E119A, pH and temperature not specified in the publication
0.0000121
oseltamivir carboxylate
unidentified influenza virus
-
wild-type, pH 6.5, 37°C
0.0000125
oseltamivir carboxylate
influenza A virus
mutant enzyme ER152K, pH and temperature not specified in the publication
0.0000136
oseltamivir carboxylate
influenza A virus
mutant enzyme E119G, pH and temperature not specified in the publication
0.000016
oseltamivir carboxylate
influenza A virus
mutant enzyme E119D, pH and temperature not specified in the publication
0.0000182
oseltamivir carboxylate
unidentified influenza virus
-
recombinant head domain, pH 6.5, 37°C
0.00002
oseltamivir carboxylate
influenza A virus
-
pH and temperature not specified in the publication
0.0000218
oseltamivir carboxylate
influenza A virus
mutant enzyme E119A, pH and temperature not specified in the publication
0.00002305
oseltamivir carboxylate
influenza B virus
-
mutant enzyme G140R, strain B/Kochi/59/2011, pH and temperature not specified in the publication
0.0000231
oseltamivir carboxylate
influenza A virus
mutant enzyme R292K, pH and temperature not specified in the publication
0.0000244
oseltamivir carboxylate
influenza A virus
mutant enzyme N294S, pH and temperature not specified in the publication
0.00002525
oseltamivir carboxylate
influenza B virus
-
mutant enzyme P139S, strain B/Kochi/41/2011, pH and temperature not specified in the publication
0.0000445
oseltamivir carboxylate
influenza A virus
mutant enzyme N294S, pH and temperature not specified in the publication
0.0000975
oseltamivir carboxylate
influenza A virus
mutant enzyme H274Y, pH and temperature not specified in the publication
0.0001572
oseltamivir carboxylate
influenza A virus
mutant enzyme E119G/H274Y, pH and temperature not specified in the publication
0.0001916
oseltamivir carboxylate
influenza A virus
mutant enzyme E119D, pH and temperature not specified in the publication
0.0003514
oseltamivir carboxylate
influenza A virus
mutant enzyme E119D/H274Y, pH and temperature not specified in the publication
0.00059
oseltamivir carboxylate
influenza A virus
mutant enzyme D198N/H274Y, pH and temperature not specified in the publication
0.000792
oseltamivir carboxylate
influenza A virus
mutant enzyme H274Y, pH and temperature not specified in the publication
0.00082
oseltamivir carboxylate
influenza A virus
mutant enzyme E119A/H274Y, pH and temperature not specified in the publication
0.001762
oseltamivir carboxylate
influenza A virus
mutant enzyme E119G/H274Y, pH and temperature not specified in the publication
0.002682
oseltamivir carboxylate
influenza A virus
mutant enzyme E119D/H274Y, pH and temperature not specified in the publication
0.003367
oseltamivir carboxylate
influenza A virus
mutant enzyme E119A/H274Y, pH and temperature not specified in the publication
0.0000003
peramivir
influenza A virus
wild type enzyme, pH and temperature not specified in the publication
0.0000006
peramivir
influenza A virus
mutant enzyme R292K, pH and temperature not specified in the publication
0.0000007
peramivir
influenza A virus
mutant enzyme N294S, pH and temperature not specified in the publication
0.00000076
peramivir
influenza B virus
-
wild type enzyme, strain B/Kochi/41/2011, pH and temperature not specified in the publication
0.00000079
peramivir
influenza B virus
-
wild type enzyme, strain B/Kochi/60/2011, pH and temperature not specified in the publication
0.0000009
peramivir
influenza A virus
mutant enzyme D198N, pH and temperature not specified in the publication
0.00000097
peramivir
influenza B virus
-
wild type enzyme, strain B/Kochi/59/2011, pH and temperature not specified in the publication
0.0000011
peramivir
influenza A virus
mutant enzyme R152K, pH and temperature not specified in the publication
0.0000013
peramivir
influenza A virus
wild type enzyme, pH and temperature not specified in the publication
0.0000014
peramivir
influenza A virus
mutant enzyme N294S, pH and temperature not specified in the publication
0.0000021
peramivir
influenza A virus
mutant enzyme E119A, pH and temperature not specified in the publication
0.0000022
peramivir
influenza A virus
mutant enzyme R292K, pH and temperature not specified in the publication
0.0000095
peramivir
influenza A virus
mutant enzyme E119A, pH and temperature not specified in the publication
0.0000152
peramivir
influenza A virus
mutant enzyme H274Y, pH and temperature not specified in the publication
0.00001614
peramivir
influenza B virus
-
mutant enzyme Q138R, strain B/Kochi/60/2011, pH and temperature not specified in the publication
0.0000245
peramivir
influenza A virus
mutant enzyme E119G, pH and temperature not specified in the publication
0.0000304
peramivir
influenza A virus
mutant enzyme H274Y, pH and temperature not specified in the publication
0.000031
peramivir
influenza A virus
mutant enzyme E119D, pH and temperature not specified in the publication
0.0000508
peramivir
influenza A virus
mutant enzyme D198N/H274Y, pH and temperature not specified in the publication
0.0001135
peramivir
Influenza A virus (A/Brisbane/59/2007(H1N1))
-
-
0.000127
peramivir
influenza B virus
-
mutant enzyme P139S, strain B/Kochi/41/2011, pH and temperature not specified in the publication
0.0001273
peramivir
influenza B virus
-
mutant enzyme G140R, strain B/Kochi/59/2011, pH and temperature not specified in the publication
0.0001421
peramivir
influenza A virus
mutant enzyme E119G, pH and temperature not specified in the publication
0.00016
peramivir
unidentified influenza virus
-
mutant enzyme V94I, at 37°C, pH not specified in the publication
0.0002
peramivir
unidentified influenza virus
-
wild type enzyme, at 37°C, pH not specified in the publication
0.001867
peramivir
influenza A virus
mutant enzyme E119D, pH and temperature not specified in the publication
0.002117
peramivir
influenza A virus
mutant enzyme E119D/H274Y, pH and temperature not specified in the publication
0.003492
peramivir
influenza A virus
mutant enzyme E119A/H274Y, pH and temperature not specified in the publication
0.004374
peramivir
influenza A virus
mutant enzyme E119A/H274Y, pH and temperature not specified in the publication
0.0114
peramivir
unidentified influenza virus
-
mutant enzyme R152K/V94I, at 37°C, pH not specified in the publication
0.0148
peramivir
unidentified influenza virus
-
mutant enzyme R368K, at 37°C, pH not specified in the publication
0.0344
peramivir
unidentified influenza virus
-
mutant enzyme R152K, at 37°C, pH not specified in the publication
0.0314
phaseollin
Vibrio cholerae serotype O1
-
-
0.03355
phaseollin
Clostridium perfringens
-
-
0.00201
sophorapterocarpan A
Clostridium perfringens
-
-
0.01159
sophorapterocarpan A
Vibrio cholerae serotype O1
-
-
0.0000277
sulfuretin
influenza A virus
-
pH 6.5, 37°C
0.0000296
sulfuretin
influenza A virus
-
pH 6.5, 37°C
0.0000512
sulfuretin
influenza B virus
-
pH 6.5, 37°C
0.0000005
zanamivir
Influenza A virus (A/Brisbane/59/2007(H1N1))
-
-
0.0000009
zanamivir
influenza A virus
wild type enzyme, pH and temperature not specified in the publication
0.0000011
zanamivir
influenza A virus
mutant enzyme R292K, pH and temperature not specified in the publication
0.0000013
zanamivir
influenza B virus
-
wild type enzyme, strain B/Kochi/60/2011, pH and temperature not specified in the publication
0.0000014
zanamivir
influenza A virus
mutant enzyme H274Y, pH and temperature not specified in the publication
0.0000014
zanamivir
influenza A virus
mutant enzyme N294S, pH and temperature not specified in the publication
0.00000156
zanamivir
influenza B virus
-
wild type enzyme, strain B/Kochi/41/2011, pH and temperature not specified in the publication
0.0000016
zanamivir
influenza A virus
mutant enzyme N294S, pH and temperature not specified in the publication
0.00000175
zanamivir
influenza B virus
-
wild type enzyme, strain B/Kochi/59/2011, pH and temperature not specified in the publication
0.0000019
zanamivir
influenza A virus
wild type enzyme, pH and temperature not specified in the publication
0.0000029
zanamivir
influenza A virus
mutant enzyme D198N/H274Y, pH and temperature not specified in the publication
0.0000031
zanamivir
influenza A virus
mutant enzyme R292K, pH and temperature not specified in the publication
0.0000037
zanamivir
influenza A virus
mutant enzyme D198N, pH and temperature not specified in the publication
0.000004
zanamivir
influenza A virus
mutant enzyme R152K, pH and temperature not specified in the publication
0.0000068
zanamivir
influenza A virus
mutant enzyme H274Y, pH and temperature not specified in the publication
0.00001019
zanamivir
influenza A virus
mutant enzyme E119G, pH and temperature not specified in the publication
0.0000122
zanamivir
influenza B virus
-
mutant enzyme Q138R, strain B/Kochi/60/2011, pH and temperature not specified in the publication
0.00001998
zanamivir
influenza B virus
-
mutant enzyme P139S, strain B/Kochi/41/2011, pH and temperature not specified in the publication
0.00002371
zanamivir
influenza B virus
-
mutant enzyme G140R, strain B/Kochi/59/2011, pH and temperature not specified in the publication
0.0000499
zanamivir
influenza A virus
mutant enzyme E119A/H274Y, pH and temperature not specified in the publication
0.0000521
zanamivir
influenza A virus
mutant enzyme E119A, pH and temperature not specified in the publication
0.0000957
zanamivir
influenza A virus
mutant enzyme E119A/H274Y, pH and temperature not specified in the publication
0.0000959
zanamivir
influenza A virus
mutant enzyme E119A, pH and temperature not specified in the publication
0.0001221
zanamivir
influenza A virus
mutant enzyme E119D/H274Y, pH and temperature not specified in the publication
0.0001233
zanamivir
influenza A virus
mutant enzyme E119D/H274Y, pH and temperature not specified in the publication
0.0001447
zanamivir
influenza A virus
mutant enzyme E119G/H274Y, pH and temperature not specified in the publication
0.0002019
zanamivir
influenza A virus
mutant enzyme E119G/H274Y, pH and temperature not specified in the publication
0.0002511
zanamivir
influenza A virus
mutant enzyme E119D, pH and temperature not specified in the publication
0.000525
zanamivir
influenza A virus
mutant enzyme E119D, pH and temperature not specified in the publication
0.00066
zanamivir
unidentified influenza virus
-
mutant enzyme V94I, at 37°C, pH not specified in the publication
0.00068
zanamivir
unidentified influenza virus
-
wild type enzyme, at 37°C, pH not specified in the publication
0.0008329
zanamivir
influenza A virus
mutant enzyme E119G, pH and temperature not specified in the publication
0.00099
zanamivir
influenza A virus
-
wild-type enzyme
0.00103
zanamivir
influenza A virus
-
mutant enzyme R156K
0.00242
zanamivir
influenza A virus
-
mutant enzyme N294D
0.00287
zanamivir
influenza A virus
-
mutant enzyme E425G
0.00312
zanamivir
influenza A virus
-
mutant enzyme H274Y
0.00498
zanamivir
influenza A virus
-
mutant enzyme D198N
0.00502
zanamivir
influenza A virus
-
mutant enzyme I222L
0.0053
zanamivir
Homo sapiens
-
pH 5.5, 37°C
0.01768
zanamivir
unidentified influenza virus
-
mutant enzyme R368K, at 37°C, pH not specified in the publication
0.01776
zanamivir
unidentified influenza virus
-
mutant enzyme R152K/V94I, at 37°C, pH not specified in the publication
0.03936
zanamivir
unidentified influenza virus
-
mutant enzyme R152K, at 37°C, pH not specified in the publication
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
D84A
the mutation significantly lowers the activity of the enzyme, but this mutant remains a retaining glycosidase
R171L
the mutant has higher activity on a N-acetylneuraminic acid-based substrate than wild type enzyme
Y358H
the mutation significantly lowers the activity of the enzyme, but this mutant remains a retaining glycosidase
D84A
-
the mutation significantly lowers the activity of the enzyme, but this mutant remains a retaining glycosidase
-
R171L
-
the mutant has higher activity on a N-acetylneuraminic acid-based substrate than wild type enzyme
-
Y358H
-
the mutation significantly lowers the activity of the enzyme, but this mutant remains a retaining glycosidase
-
E258D
site-directed mutagenesis, mutation of a catalytic residue, highly reduced sialidase activity, slightly reduced HA activity, mutant shows reduced fusion promotion activity
E347K
A2THD4, A7L4X3, A7UC53, A7UC55, A7UC57, A7UC61, A7UC62, A7UC63, A7UC64, A7UC67, A7UC69, A7UC70, Q83758, Q914X2, Q9W8Z8 the mutation affects the reactivity of polyclonal serum to the variant strain
I192M
-
naturally occuring mutant with a single nucleotide mutation T-A at position 576, isolation of a NDV variant with highly increased fusogenic activity in vitro and decreased haemagglutinating activity, as compared with the wild-type parental strain, phenotype of the virus in cell cultures, embryonated chicken eggs and day-old chickens, overview
R498K
site-directed mutagenesis, mutation of a catalytic residue, reduced sialidase activity, slightly reduced HA activity, mutant shows reduced fusion promotion activity
R498Q
site-directed mutagenesis, mutation of a catalytic residue, highly reduced sialidase activity, slightly reduced HA activity, mutant shows reduced fusion promotion activity
S418A
site-directed mutagenesis, mutation of a catalytic residue, unaltered sialidase activity, altered HA activity, mutant shows reduced fusion promotion activity
Y262F
site-directed mutagenesis, mutation of a catalytic residue, retaining of nearly all sialidase activity, altered HA activity, mutant shows reduced fusion promotion activity
Y262S
site-directed mutagenesis, mutation of a catalytic residue, loss of nearly all sialidase activity, highly reduced HA activity, mutant shows reduced fusion promotion activity
Y317A
site-directed mutagenesis, mutation of a catalytic residue, loss of nearly all sialidase activity, highly reduced HA activity, mutant shows reduced fusion promotion activity
Y317F
site-directed mutagenesis, mutation of a catalytic residue, reduced sialidase activity, altered HA activity, mutant shows reduced fusion promotion activity
Y317S
site-directed mutagenesis, mutation of a catalytic residue, highly reduced sialidase activity, highly reduced HA activity, mutant shows reduced fusion promotion activity
I192M
Avian orthoavulavirus 1 Anhinga/US(FL)/44083/93
-
naturally occuring mutant with a single nucleotide mutation T-A at position 576, isolation of a NDV variant with highly increased fusogenic activity in vitro and decreased haemagglutinating activity, as compared with the wild-type parental strain, phenotype of the virus in cell cultures, embryonated chicken eggs and day-old chickens, overview
-
E347K
Avian orthoavulavirus 1 Herts/33
-
the mutation affects the reactivity of polyclonal serum to the variant strain
-
R498K
Avian orthoavulavirus 1 Kansas
-
site-directed mutagenesis, mutation of a catalytic residue, reduced sialidase activity, slightly reduced HA activity, mutant shows reduced fusion promotion activity
-
R498Q
Avian orthoavulavirus 1 Kansas
-
site-directed mutagenesis, mutation of a catalytic residue, highly reduced sialidase activity, slightly reduced HA activity, mutant shows reduced fusion promotion activity
-
S418A
Avian orthoavulavirus 1 Kansas
-
site-directed mutagenesis, mutation of a catalytic residue, unaltered sialidase activity, altered HA activity, mutant shows reduced fusion promotion activity
-
Y317A
Avian orthoavulavirus 1 Kansas
-
site-directed mutagenesis, mutation of a catalytic residue, loss of nearly all sialidase activity, highly reduced HA activity, mutant shows reduced fusion promotion activity
-
Y317F
Avian orthoavulavirus 1 Kansas
-
site-directed mutagenesis, mutation of a catalytic residue, reduced sialidase activity, altered HA activity, mutant shows reduced fusion promotion activity
-
E347K
Avian orthoavulavirus 1 ZJ-01/00
-
the mutation affects the reactivity of polyclonal serum to the variant strain
-
E581A
-
the mutation results in complete loss of sialidase activity
A160G
site-directed mutagenesis, the mutant shows slightly reduced activity compared to the wild-type enzyme
A160G/M87G/I105G
site-directed mutagenesis, inactive mutant
D234N
the mutation results in significantly lower levels of sialidase activity (25%) compared to the wild type and is associated with sialosis
D50S
site-directed mutagenesis, the mutant shows reduced activity compared to the wild-type enzyme
E113A
site-directed mutagenesis, inactive mutant
E225S
site-directed mutagenesis, almost inactive mutant
E51D
site-directed mutagenesis, the mutant shows reduced activity compared to the wild-type enzyme
E51S
site-directed mutagenesis, the mutant shows increased activity compared to the wild-type enzyme
G162A
site-directed mutagenesis, the mutant shows highly reduced activity compared to the wild-type enzyme
G413A
-
site-directed mutagenesis, activity and localization in the cell similar to the wild-type enzyme
G419STOP
site-directed mutagenesis, the C-terminal 10-residue truncation leads to an increase in activity compared to the wild-type enzyme
H277F
site-directed mutagenesis, the mutant shows increased activity compared to the wild-type enzyme
I105G
site-directed mutagenesis, the mutant shows highly reduced activity compared to the wild-type enzyme
I407STOP
site-directed mutagenesis, almost inactive mutant
K45A
the mutant shows about 3fold increased activity towards 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid compared to the wild type
L408STOP
site-directed mutagenesis, the large deletion leads to inactivation of the mutant
L415A
-
site-directed mutagenesis, 30-50% reduced activity compared to the wild-type enzyme, no internalization due to impaired endocytosis, location in the plasma membrane and the cytosol
M87G
site-directed mutagenesis, the mutant shows highly reduced activity compared to the wild-type enzyme
M87G/I105G
site-directed mutagenesis, inactive mutant
N88D
site-directed mutagenesis, the mutant shows highly reduced activity compared to the wild-type enzyme
Q112A
the mutant shows nearly 4fold increased activity towards 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid compared to the wild type
Q270A
the mutant shows about 4fold increased activity towards 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid compared to the wild type
Q270E
the mutant shows about wild type activity
R114A
site-directed mutagenesis, the mutant shows reduced activity compared to the wild-type enzyme
R114Q
site-directed mutagenesis, the mutant shows reduced activity compared to the wild-type enzyme
R245A
site-directed mutagenesis, inactive mutant
R25H
site-directed mutagenesis, the mutant shows reduced activity compared to the wild-type enzyme
R340A
site-directed mutagenesis, almost inactive mutant
R45V
site-directed mutagenesis, inactive mutant
T403STOP
site-directed mutagenesis, inactive mutant
V107M
site-directed mutagenesis, the mutant shows highly reduced activity compared to the wild-type enzyme
V217A
the mutation results in significantly lower levels of sialidase activity (44%) compared to the wild type and is associated with sialosis
V217M/G243R
-
the mutation is associated with sialidosis type I phenotype
Y179F
site-directed mutagenesis, inactive mutant
Y181F
site-directed mutagenesis, inactive mutant
Y370C
site-directed mutagenesis, the mutant shows reduced activity compared to the wild-type enzyme
Y412A
-
site-directed mutagenesis, 55-70% reduced activity compared to the wild-type enzyme, no internalization due to impaired endocytosis, location in the plasma membrane and the cytosol
N173S
-
mutant sensitive to 4-azido-5-isobutyrylamino-2,3-didehydro-2,3,4,5-tetradeoxy-d-glycero-d-galacto-2-nonulopyranosic acid in neuraminidase inhibition assays but more than 10000fold less sensitive to the compound in hemagglutination inhibition tests than a recombinant Sendai virus whose hemagglutinin-neuraminidase is replaced with that of human parainfluenza virus-1. Its susceptibility to 4-azido-5-isobutyrylamino-2,3-didehydro-2,3,4,5-tetradeoxy-d-glycero-d-galacto-2-nonulopyranosic acid in plaque reduction assays is reduced fivefold and does not differ from that of recombinant Sendai virus whose hemagglutinin-neuraminidase was replaced with that of human parainfluenza virus-1 in mice. The N173S mutant fails to be efficiently eluted from erythrocytes and released from cells. It demonstrates reduced growth in cell culture and superior growth in mice. Rresults are consistent with the loss of the N-linked glycan at residue 173 in the mutant. Study suggests that the N-linked glycan at residue 173 masks a second receptor-binding site
D198N/H274Y
the mutation confers reduced inhibition to zanamivir, oseltamivir, and peramivir
E119A
the mutation confers reduced inhibition to zanamivir
E119A/H274Y
the mutation confers reduced inhibition to zanamivir, oseltamivir, and peramivir
E119D/H274Y
the mutation confers reduced inhibition to zanamivir, oseltamivir, and peramivir
E119G
the mutation confers reduced inhibition to zanamivir
E119G/H274Y
the mutation confers reduced inhibition to zanamivir, oseltamivir, and peramivir
E227G
-
mutation results in an impairment of growth of the concerned virus
E245G
-
neuraminidase activity is 73% of wild-type value. IC50 for zanamivir is 2.9fold higher than wild-type value. IC50 for oseltamivir is 2.3fold higher than wild-type value
E277G
-
mutation results in an impairment of growth of the concerned virus
I222L
-
neuraminidase activity is 82% of wild-type value. IC50 for zanamivir is 5.1fold higher than wild-type value. IC50 for oseltamivir is 18fold higher than wild-type value
N146K/A272V/Del245-248
-
revertant constructed from mutant N146K/S219T/A272V/Del245-248 for analysis of resistance to oseltamivir
N146K/S219T/A272V
-
revertant constructed from mutant N146K/S219T/A272V/Del245-248 for analysis of resistance to oseltamivir
N146K/S219T/A272V/Del245-248
-
mutant isolated from an oseltamivir-resistant virus from an immunocompromised child. The deletion is the sole change responsible for resistance
N146K/S219T/Del245-248
-
revertant constructed from mutant N146K/S219T/A272V/Del245-248 for analysis of resistance to oseltamivir
N294D
-
neuraminidase activity is 74% of wild-type value. IC50 for zanamivir is 2.4fold higher than wild-type value. IC50 for oseltamivir is 2.3fold higher than wild-type value
N294S
the mutation confers reduced inhibition to oseltamivir (63.6fold increase in IC50 compared to the wild type)
Q136K
the neuraminidase mutation has no effect on oseltamivir susceptibility but causes approximately a 300fold and a 70fold reduction in zanamivir and peramivir susceptibility, respectively. The mutant strain displays greater viral fitness than the wild-type virus in MDCK cells but equivalent infectivity and transmissibility in a ferret model
R152K
the mutant exhibits reduced inhibition to oseltamivir (17.9fold in IC50 values) but shows wild type inhibition to zanamivir and peramivir
R156K
-
neuraminidase activity is 71% of wild-type value
R292K
the mutant exhibits reduced inhibition to oseltamivir (33fold in IC50 values) but shows wild type inhibition to zanamivir and peramivir
S179A
-
mutation results in an impairment of growth of the concerned virus
S219T/A272V/Del245-248
-
revertant constructed from mutant N146K/S219T/A272V/Del245-248 for analysis of resistance to oseltamivir
W178L
-
mutation results in an impairment of growth of the concerned virus
H274Y
-
the mutation confers resistance to oseltamivir, the viral fitness of the A/Brisbane/59/2007-like H274Y variant is not impaired
D199E
-
the mutant shows increased enzyme activity compared to the wild type enzyme
E119D
-
the mutation confers reduced inhibition by oseltamivir (a 95-fold increase in the 50% inhibitory concentration) and highly reduced inhibition by zanamivir, peramivir. and laninamivir (2660fold, 460fold, and 651fold increases in the 50% inhibitory concentration, respectively)
E119G
-
the mutation confers mainly reduced to highly reduced inhibition by zanamivir, peramivir, and laninamivir, but remains susceptible to oseltamivir
H275Y
the major oseltamivir resistance mutation H275Y causes a significant decrease in the enzyme's ability to bind oseltamivir
H275Y/I223V
the mutations result in extreme impairment of oseltamivir's inhibition potency
H275Y/S247N
the mutations result in extreme impairment of oseltamivir's inhibition potency
I223V
the substitution alone confers only a moderate reduction in oseltamivir affinity
I321V
-
the mutant shows normal inhibition by zanamivir, peramivir, laninamivir and oseltamivir compared to the wild type enzyme
K432E
-
the mutant shows normal inhibition by zanamivir, peramivir, laninamivir and oseltamivir compared to the wild type enzyme
N200S
-
the mutant shows normal inhibition by zanamivir, peramivir, laninamivir and oseltamivir compared to the wild type enzyme
N248D
-
the mutant shows normal inhibition by zanamivir, peramivir, laninamivir and oseltamivir compared to the wild type enzyme
N270K
-
the mutant shows normal inhibition by zanamivir, peramivir, laninamivir and oseltamivir compared to the wild type enzyme
N369K
-
the mutant shows normal inhibition by zanamivir, peramivir, laninamivir and oseltamivir compared to the wild type enzyme
N386K
-
the mutant shows normal inhibition by zanamivir, peramivir, laninamivir and oseltamivir compared to the wild type enzyme
P458T
-
the mutant with decreased activity exhibits highly reduced inhibition by zanamivir, peramivir, laninamivir and oseltamivir compared to the wild type enzyme
Q136K
-
the mutation confers mainly reduced to highly reduced inhibition by zanamivir, peramivir, and laninamivir, but remains susceptible to oseltamivir
R152K
-
the mutant remains susceptible to peramivir, but confers reduced inhibition by zanamivir, oseltamivir, and laninamivir
S247N
the substitution alone confers only a moderate reduction in oseltamivir affinity
V264I
-
the mutant shows normal inhibition by zanamivir, peramivir, laninamivir and oseltamivir compared to the wild type enzyme
E119D
-
the mutation confers reduced inhibition by oseltamivir (a 95-fold increase in the 50% inhibitory concentration) and highly reduced inhibition by zanamivir, peramivir. and laninamivir (2660fold, 460fold, and 651fold increases in the 50% inhibitory concentration, respectively)
-
N200S
-
the mutant shows normal inhibition by zanamivir, peramivir, laninamivir and oseltamivir compared to the wild type enzyme
-
N248D
-
the mutant shows normal inhibition by zanamivir, peramivir, laninamivir and oseltamivir compared to the wild type enzyme
-
N386K
-
the mutant shows normal inhibition by zanamivir, peramivir, laninamivir and oseltamivir compared to the wild type enzyme
-
R152K
-
the mutant remains susceptible to peramivir, but confers reduced inhibition by zanamivir, oseltamivir, and laninamivir
-
A284T
the mutation decreases enzymatic activity
H155Y
the mutation decreases enzymatic activity
I400M
the mutation decreases enzymatic activity
K432E
the mutation decreases enzymatic activity
M257I
the mutation decreases enzymatic activity
N369H
the mutation increases enzymatic activity
S372H
the mutation decreases enzymatic activity
S372N
the mutation decreases enzymatic activity
S389R
the mutation decreases enzymatic activity for transferrin and increases enzymatic activity for fetuin
S434D
the mutation decreases enzymatic activity
V99I
the mutation increases enzymatic activity
W403R
the mutation decreases enzymatic activity
Y347N
the mutation increases enzymatic activity
G140R
-
the mutation is associated with reduced susceptibility to neuraminidase inhibitors
P139S
-
the mutation is associated with reduced susceptibility to neuraminidase inhibitors
Q138R
-
the mutation is associated with reduced susceptibility to neuraminidase inhibitors
R152K
the mutation leads to resistance against nfluenza virus neuraminidase inhibitors
G140R
-
the mutation is associated with reduced susceptibility to neuraminidase inhibitors
-
P139S
-
the mutation is associated with reduced susceptibility to neuraminidase inhibitors
-
Q138R
-
the mutation is associated with reduced susceptibility to neuraminidase inhibitors
-
G140R
-
the mutation is associated with reduced susceptibility to neuraminidase inhibitors
-
P139S
-
the mutation is associated with reduced susceptibility to neuraminidase inhibitors
-
Q138R
-
the mutation is associated with reduced susceptibility to neuraminidase inhibitors
-
G140R
-
the mutation is associated with reduced susceptibility to neuraminidase inhibitors
-
P139S
-
the mutation is associated with reduced susceptibility to neuraminidase inhibitors
-
Q138R
-
the mutation is associated with reduced susceptibility to neuraminidase inhibitors
-
Y370A
catalyzes the hydrolysis of phenyl beta-sialoside with an inversion of the anomeric configuration, 4% of the activity with Y370G
Y370N
catalyzes the hydrolysis of phenyl beta-sialoside with an inversion of the anomeric configuration, 9% of the activity with Y370N
Y370T
catalyzes the hydrolysis of phenyl beta-sialoside with an inversion of the anomeric configuration, 9% of the activity with Y370T
D79V/S366N
-
mutation isolated in influenza virus subtype H3N1
E83G
-
mutation isolated in influenza virus subtype H3N2
H274Y
-
mutant isolated from patient infected with H5N1. Ratio Ki mutant/Ki wild-type for inhibition by oseltamivir is 265, for inhibition by zanamivir is 1.9, respectively
L206I
-
mutation isolated in influenza virus subtype H4N1
N294S
-
mutant isolated from patient infected with H5N1. Ratio Ki mutant/Ki wild-type for inhibition by oseltamivir is 81, for inhibition by zanamivir is 7.2, respectively
R152K
-
the mutation mediates reduced inhibition by oseltamivir, zanamivir, peramivir and laninamivir (10-100fold increase of IC50 value compared to the wild type enzyme)
R152K/V94I
-
the mutations mediate reduced inhibition by oseltamivir, zanamivir, peramivir and laninamivir (10-100fold increase of IC50 value compared to the wild type enzyme)
R368K
-
the mutation mediates reduced inhibition by oseltamivir, zanamivir and laninamivir (96-57fold increase of IC50 value compared to the wild type enzyme) as well as peramivir (172fold increase of IC50 value compared to the wild type enzyme)
V94IK
-
the mutant shows normal inhibition by oseltamivir, zanamivir, peramivir and laninamivir
Y252H
-
mutant isolated from patient infected with H5N1. Ratio Ki mutant/Ki wild-type for inhibition by oseltamivir is 0.1, for inhibition by zanamivir is 1.2, respectively
R152K
-
the mutation mediates reduced inhibition by oseltamivir, zanamivir, peramivir and laninamivir (10-100fold increase of IC50 value compared to the wild type enzyme)
-
R152K/V94I
-
the mutations mediate reduced inhibition by oseltamivir, zanamivir, peramivir and laninamivir (10-100fold increase of IC50 value compared to the wild type enzyme)
-
R368K
-
the mutation mediates reduced inhibition by oseltamivir, zanamivir and laninamivir (96-57fold increase of IC50 value compared to the wild type enzyme) as well as peramivir (172fold increase of IC50 value compared to the wild type enzyme)
-
V94IK
-
the mutant shows normal inhibition by oseltamivir, zanamivir, peramivir and laninamivir
-
H274Y
-
mutant isolated from patient infected with H5N1. Ratio Ki mutant/Ki wild-type for inhibition by oseltamivir is 265, for inhibition by zanamivir is 1.9, respectively
-
N294S
-
mutant isolated from patient infected with H5N1. Ratio Ki mutant/Ki wild-type for inhibition by oseltamivir is 81, for inhibition by zanamivir is 7.2, respectively
-
Y252H
-
mutant isolated from patient infected with H5N1. Ratio Ki mutant/Ki wild-type for inhibition by oseltamivir is 0.1, for inhibition by zanamivir is 1.2, respectively
-
R294K
the substitution confers neuraminidase inhibitor oseltamivir resistance, The mutation results in reduced enzyme catalytic efficiency along with lower viral fitness
R294K
-
the substitution confers neuraminidase inhibitor oseltamivir resistance, The mutation results in reduced enzyme catalytic efficiency along with lower viral fitness
-
R294K
-
the substitution confers neuraminidase inhibitor oseltamivir resistance, The mutation results in reduced enzyme catalytic efficiency along with lower viral fitness
-
Y370F
site-directed mutagenesis, inactive mutant
Y370F
catalytically inactive (0.1% activity compared to the wild type)
D198N
-
neuraminidase activity is 10% of wild-type value. IC50 for zanamivir is 5fold higher than wild-type value. IC50 for oseltamivir is 5.5fold higher than wild-type value
D198N
the mutation moderately affects the susceptibility to neuraminidase inhibitors
E119D
-
neuraminidase activity is 1.3% of wild-type value
E119D
the mutation confers reduced inhibition to zanamivir, oseltamivir, and peramivir
H274Y
-
neuraminidase activity is 104% of wild-type value. IC50 for zanamivir is 3.2fold higher than wild-type value. IC50 for oseltamivir is 9.4fold higher than wild-type value
H274Y
-
mutant resistant to oseltamivir, used for design of multi-binding-site inhibitors
H274Y
the mutation confers highly reduced inhibition to oseltamivir (1131.4fold increase in IC50 values compared to the wild type) and reduced inhibition to peramivir by 50.6fold
Y370G
catalyzes the hydrolysis of phenyl beta-sialoside with an inversion of the anomeric configuration
Y370G
the mutation produces an efficient catalyst for the transfer of N-acetylneuraminic acid from an artificial substrate (i.e., phenyl N-acetyl-beta-D-neuraminide) to a sugar acceptor (e.g., D-lactose, D-glucose, D-mannose, D-raffinose, D-allose, or D-fructose) to give N-acetyl-alpha-neuraminide coupled carbohydrate products. In addition, this mutant enzyme catalyzes the transfer of a sugar residue from the artificial substrate 2-fluorophenyl N-acetyl-beta-D-neuraminide to methyl glycopyranoside acceptors
E335K
-
the mutation is associated with neurovirulence of Urabe AM9 mumps virus vaccine
E335K
Mumps orthorubulavirus Urabe AM9
-
the mutation is associated with neurovirulence of Urabe AM9 mumps virus vaccine
-
D59A
-
catalytic acid/base residue mutation, crystal structure determination, altered catalytic mechanism and enzyme-substrate structure compared to the wild-type enzyme, respectively
D59A
-
replacement of putative acid/base catalyst, demonstration of the half-reaction with formation of sialyl-enzyme intermediate. Activity is restored by addition of azide and a sialyl azide product is formed
additional information
-
a mutant strain, with cysteine residue of the active site being exchanged for other amino acids, is insensitive to inhibition by mercury ions
additional information
purified truncated NanH protein devoid of its signal sequence as a mature enzyme fused with the 6-His tag at the N-terminal region can cleave alpha-2,3- and alpah-2,6-linked sialic acid from sialic acid-containing substrates and is able to catalyse the transfer of sialic acid using several sialoconjugates as donor
additional information
-
purified truncated NanH protein devoid of its signal sequence as a mature enzyme fused with the 6-His tag at the N-terminal region can cleave alpha-2,3- and alpah-2,6-linked sialic acid from sialic acid-containing substrates and is able to catalyse the transfer of sialic acid using several sialoconjugates as donor
additional information
-
purified truncated NanH protein devoid of its signal sequence as a mature enzyme fused with the 6-His tag at the N-terminal region can cleave alpha-2,3- and alpah-2,6-linked sialic acid from sialic acid-containing substrates and is able to catalyse the transfer of sialic acid using several sialoconjugates as donor
-
additional information
mutations of residues expected to interact directly with the sialic acid N5-acetyl (A160, M87, I105) and C7-C9 glycerol side-chain (E113, Y179, Y181) reduce enzymatic activity. Truncations at the N- or C-terminus of more than 10 residues abolish enzyme activity
additional information
-
mutations of residues expected to interact directly with the sialic acid N5-acetyl (A160, M87, I105) and C7-C9 glycerol side-chain (E113, Y179, Y181) reduce enzymatic activity. Truncations at the N- or C-terminus of more than 10 residues abolish enzyme activity
additional information
-
construction of a soluble truncation mutant, amino acid residues 137-575, lacking the N-terminal hydrophobic membrane anchoring region, mutant shows increased sensitivity to inhibition by DANA
additional information
-
study on the effects of single-point amino acid substitutions on the structure and function of neuraminidase proteins. The rate of tolerant random one amino acid substitutions is 47%. Rates of tolerant substitutions for the stalk and for the surface and inner portion are 79%, 54%, and 19%, respectively. The ratio of mutations with which the enzyme loses neuraminidase activity, but is transported to the cell surface, decreases in proportion to the distance from the structural center of enzyme active site
additional information
-
construction of insertion mutant enzyme by deleting the 20-aa segment, residues 49-68, from the stalk region of 2009H1N1 neuraminidase, and inserting this segment, designated 09s60, into the stalk region of H5N1 neuraminidase
additional information
-
construction of insertion mutant enzyme by deleting the 20-aa segment, residues 49-68, from the stalk region of 2009H1N1 neuraminidase, and inserting this segment, designated 09s60, into the stalk region of H5N1 neuraminidase
-
additional information
-
construction of insertion mutant enzyme by deleting the 20-aa segment, residues 49-68, from the stalk region of 2009H1N1 neuraminidase, and inserting this segment, designated 09s60, into the stalk region of H5N1 neuraminidase
-
additional information
-
study on the effects of single-point amino acid substitutions on the structure and function of neuraminidase proteins. The rate of tolerant random one amino acid substitutions is 47%. Rates of tolerant substitutions for the stalk and for the surface and inner portion are 79%, 54%, and 19%, respectively. The ratio of mutations with which the enzyme loses neuraminidase activity, but is transported to the cell surface, decreases in proportion to the distance from the structural center of enzyme active site
-
additional information
-
replacement of the F protein of parainfluenza virus 5 major domains, M1, M2, M3, and M4, and five minor domains, A to E, in the middle region of the PIV5 F protein with the simian virus 41, SV41, F counterparts individually or in combination. A chimera designated M(1+2), which harbored SV41 F-derived domains M1 and M2, mediates cell-cell fusion with the coexpressed SV41 hemagglutinin-neuraminidase protein, suggesting that these domains are involved in determining the hemagglutinin-neuraminidase protein specificity. Another chimera which harbors the SV41 F-derived domain B in addition to domains M1 and M2 shows increased specificity for the SV41 hemagglutinin-neuraminidase protein compared to that of M(1+2), although it is capable of mediating cell-cell fusion by itself
additional information
-
amino acids R180, D204, E264, Y268, Y303, E407, R422, R512, Y540, E551 constitute the neuraminidase active site and directly interact with sialic acid
additional information
Mumps orthorubulavirus Urabe AM9
-
amino acids R180, D204, E264, Y268, Y303, E407, R422, R512, Y540, E551 constitute the neuraminidase active site and directly interact with sialic acid
-
additional information
in macrophages from isoform Neu1 deficient mice, a model for sialidosis, oversialylated lysosomal membrane protein Lamp-1 enhances lysosomal exocytosis. Silencing of Lamp-1 reverts this phenotype by interfering with the docking of lysosomes at the plasma membrane. In Neu1-/- mice the excessive exocytosis of serine proteases in the bone niche leads to inactivation of extracellular serpins, premature degradation of VCAM-1, and loss of bone marrow retention
additional information
-
neuramindase-1 deficiency in mice results in a tight-skin phenotype. Normal septation of Neu-1 null mice does not occur in neonatal mice, resulting in enlarged alveoli that are maintained in adults. Elastin fibers develop abnormally and elastin, fibrillin-1, fibrillin-2, and fibrillin-5 show overlapping distributions. Myofibroblasts distribute randomly around the alveolar walls. Concentration of elastin is significantly reduced in the aorta of mutant mice
additional information
insertional inactivation of nanH results in a mutant, which is not deficient in sialidase production, but exhibits reduced activity
additional information
insertional inactivation of nanH results in a mutant, which is not deficient in sialidase production, but exhibits reduced activity
additional information
-
insertional inactivation of nanH results in a mutant, which is not deficient in sialidase production, but exhibits reduced activity
additional information
insertional inactivation of nanH, encoding the second sialidase of the organism, results in a mutant, which is not deficient in sialidase production, but exhibits reduced activity
additional information
insertional inactivation of nanH, encoding the second sialidase of the organism, results in a mutant, which is not deficient in sialidase production, but exhibits reduced activity
additional information
-
insertional inactivation of nanH, encoding the second sialidase of the organism, results in a mutant, which is not deficient in sialidase production, but exhibits reduced activity
additional information
-
in neuraminidase NanA deletion mutant, NanB can partially support the growth of pneumococci on glycoconjugates
additional information
in neuraminidase NanA deletion mutant, NanB can partially support the growth of pneumococci on glycoconjugates
additional information
subcloning of a 56500 Da domain that retains full enzymatic activity
additional information
-
subcloning of a 56500 Da domain that retains full enzymatic activity
additional information
-
introduction of 7 surface mutations does not alter the enzymes' activities but facilitate crystallization
additional information
-
engineering of an enzymatically deficient mutant trans-sialidase containing the catalytic domain without the immunodominant shed acute phase antigen repeats SAPA. Mice vaccinated with the mutant trans-sialidase are highly protected against Trypanosoma cruzi infection
additional information
-
construction of highly infectious laryngotracheitis virus expressing H5 hemagglutinin and N1 neuraminidase for ocular immunization of chickens
additional information
-
fusion of gene encoding the neuraminidase N1 head domain residues 63-449 with the Saccharomyces cerevisiae alpha-factor secretion signal and expression in Pichia pastoris. Recombinant product is a soluble protein with similar kinetic characteristics as wild-type
additional information
-
construction of highly infectious laryngotracheitis virus expressing H5 hemagglutinin and N1 neuraminidase for ocular immunization of chickens
-
additional information
-
subcloning of carbohydrate-binding module CBM40 of sialidase, showing high affinity for sialic acid and specificity to alpha(2,3), alpha(2,6), and alpha(2,8)-linked sialosides. Creation of polypeptides containing up to four CBM40 modules in tandem show increased affinities compared with the single module molecule. Variation in linker length has little effect on affinity
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.